

# EAU Guidelines on Urinary Incontinence in Adults

F.C. Burkhard (Chair), J.L.H.R. Bosch, F. Cruz, G.E. Lemack,  
A.K. Nambiar, N. Thiruchelvam, A. Tubaro  
Guidelines Associates: D. Ambühl, D.A. Bedretdinova,  
F. Farag, R. Lombardo, M.P. Schneider

# TABLE OF CONTENTS

# PAGE

1.	INTRODUCTION	8
1.1	Aim and objectives	8
1.1.1	The elderly	8
1.2	Panel composition	8
1.3	Available publications	8
1.4	Publication history	9
1.4.1	Summary of changes.	9
2.	METHODS	11
2.1	Introduction	11
2.2	Review	11
2.3	Future goals	11
3.	DIAGNOSTIC EVALUATION	11
3.1	History and physical examination	11
3.2	Patient questionnaires	12
3.2.1	Questions	12
3.2.2	Evidence	12
3.2.3	Summary of evidence and recommendations for patient questionnaires	13
3.3	Voiding diaries	14
3.3.1	Question	14
3.3.2	Evidence	14
3.3.3	Summary of evidence and recommendations for voiding diaries	14
3.4	Urinalysis and urinary tract infection	14
3.4.1	Question	14
3.4.2	Evidence	14
3.4.3	Summary of evidence and recommendations for urinalysis	15
3.5	Post-void residual volume	15
3.5.1	Question	15
3.5.2	Evidence	15
3.5.3	Summary of evidence and recommendations for post-void residual	15
3.6	Urodynamics	15
3.6.1	Question	16
3.6.2	Evidence	16
3.6.2.1	Variability	16
3.6.2.2	Diagnostic accuracy	16
3.6.2.3	Question	16
3.6.2.4	Evidence	16
3.6.2.5	Question	16
3.6.2.6	Evidence	16
3.6.2.7	Question	17
3.6.2.8	Evidence	17
3.6.2.9	Question	17
3.6.2.10	Evidence	17
3.6.3	Summary of evidence and recommendations for urodynamics	17
3.6.4	Research priority	18
3.7	Pad testing	18
3.7.1	Questions	18
3.7.2	Evidence	18
3.7.3	Summary of evidence and recommendations for pad testing	18
3.7.4	Research priority	18
3.8	Imaging	18
3.8.1	Questions	19
3.8.2	Evidence	19
3.8.3	Summary of evidence and recommendations for imaging	19
3.8.4	Research priority	19

4.	DISEASE MANAGEMENT	20
4.1	Conservative management	20
4.1.1	Simple clinical interventions	20
4.1.1.1	Underlying disease/cognitive impairment	20
4.1.1.1.1	Question	20
4.1.1.1.2	Evidence	20
4.1.1.1.3	Summary of evidence and recommendations regarding associated conditions	20
4.1.1.2	Adjustment of other (non-incontinence) medication	20
4.1.1.2.1	Question	21
4.1.1.2.2	Evidence	21
4.1.1.2.3	Summary of evidence and recommendations for adjustment of other (non-incontinence) medication	21
4.1.1.3	Constipation	21
4.1.1.3.1	Question	21
4.1.1.3.2	Evidence	21
4.1.1.3.3	Summary of evidence and recommendations for constipation	21
4.1.1.3.4	Research priority	21
4.1.1.4	Containment	21
4.1.1.4.1	Question	22
4.1.1.4.2	Evidence	22
4.1.1.4.3	Question	22
4.1.1.4.4	Evidence	22
4.1.1.4.5	Question	22
4.1.1.4.6	Evidence	22
4.1.1.4.7	Question	22
4.1.1.4.8	Evidence	22
4.1.1.4.9	Summary of evidence and recommendations for containment	23
4.1.1.4.10	Research priority	23
4.1.2	Lifestyle interventions	23
4.1.2.1	Caffeine reduction	23
4.1.2.1.1	Question	23
4.1.2.1.2	Evidence	23
4.1.2.1.3	Summary of evidence for caffeine reduction	23
4.1.2.2	Physical exercise	23
4.1.2.2.1	Question	23
4.1.2.2.2	Evidence	24
4.1.2.2.2.1	The elderly	24
4.1.2.2.3	Summary of evidence for physical exercise	24
4.1.2.3	Fluid intake	24
4.1.2.3.1	Question	24
4.1.2.3.2	Evidence	24
4.1.2.3.3	Summary of evidence for fluid intake	24
4.1.2.4	Obesity and weight loss	24
4.1.2.4.1	Question	24
4.1.2.4.2	Evidence	24
4.1.2.4.3	Summary of evidence for obesity and weight loss	25
4.1.2.5	Smoking	25
4.1.2.5.1	Question	25
4.1.2.5.2	Evidence	25
4.1.2.5.3	Summary of evidence for smoking cessation	25
4.1.2.6	Recommendations for lifestyle interventions	25
4.1.2.7	Research priority	25
4.1.3	Behavioural and Physical therapies	25
4.1.3.1	Prompted voiding	26
4.1.3.2	Bladder Training	26
4.1.3.2.1	Questions	26
4.1.3.2.2	Evidence	26

	4.1.3.2.3	Summary of evidence for bladder training	26
4.1.3.3		Pelvic floor muscle training (PFMT)	26
	4.1.3.3.1	Question	27
	4.1.3.3.2	Evidence	27
	4.1.3.3.3	Efficacy of PFMT in SUI, UII and MUI in women	27
	4.1.3.3.4	PFMT in the elderly	27
	4.1.3.3.5	PFMT in men (post radical prostatectomy)	27
	4.1.3.3.6	Summary of evidence for pelvic floor muscle training	28
	4.1.3.3.7	Electrical stimulation	28
	4.1.3.3.8	Question	28
	4.1.3.3.9	Evidence	28
	4.1.3.3.10	Summary of evidence for electrical stimulation	29
4.1.3.4		Posterior tibial nerve stimulation	29
	4.1.3.4.1	Question	29
	4.1.3.4.2	Evidence	29
	4.1.3.4.3	Summary of evidence for posterior tibial nerve stimulation	29
	4.1.3.5	Recommendations for behavioural and physical therapies	29
4.1.4		Conservative therapy in mixed urinary incontinence	30
	4.1.4.1	Question	30
	4.1.4.2	Evidence	30
	4.1.4.3	Summary of evidence and recommendations for conservative therapy in mixed urinary incontinence	30
4.2		Pharmacological management	30
4.2.1		Antimuscarinic drugs	30
	4.2.1.1	Question	31
	4.2.1.2	Evidence	31
	4.2.1.2.1	Darifenacin	31
	4.2.1.2.2	Transcutaneous oxybutynin	31
4.2.2		Comparison of antimuscarinic agents	32
	4.2.2.1	Question	32
	4.2.2.2	Evidence	32
	4.2.2.3	Summary of evidence for antimuscarinic agents	32
4.2.3		Antimuscarinic drugs vs. conservative treatment	32
	4.2.3.1	Question	33
	4.2.3.2	Evidence	33
	4.2.3.3	Summary of evidence and recommendations for antimuscarinic drugs	33
4.2.4		Antimuscarinic agents: adherence and persistence	33
	4.2.4.1	Question	33
	4.2.4.2	Evidence	33
	4.2.4.3	Summary of evidence for adherence to antimuscarinic treatment	34
4.2.5		Mirabegron	34
	4.2.5.1	Summary of evidence and recommendations for mirabegron	35
4.2.6		Antimuscarinic and beta3 agonist agents, the elderly and cognition	35
	4.2.6.1	Question	35
	4.2.6.2	Evidence	35
	4.2.6.2.1	Oxybutynin	35
	4.2.6.2.2	Solifenacin	35
	4.2.6.2.3	Tolterodine	36
	4.2.6.2.4	Darifenacin	36
	4.2.6.2.5	Trospium chloride	36
	4.2.6.2.6	Fesoterodine	36
	4.2.6.2.7	Anti-incontinence drugs in the elderly	36
	4.2.6.2.8	Mirabegron	36
	4.2.6.2.9	Applicability of evidence to general elderly population	36
	4.2.6.2.10	Anticholinergic load	36
	4.2.6.2.11	Question	36
	4.2.6.2.12	Evidence	36

4.2.6.3	Summary of evidence and additional recommendations for use of antimuscarinic drugs in the elderly	37
4.2.6.4	Research priorities	37
4.2.7	Drugs for stress urinary incontinence	37
4.2.7.1	Questions	37
4.2.7.2	Evidence	37
4.2.7.3	Summary of evidence and recommendations on drugs for SUI	37
4.2.8	Oestrogen	38
4.2.8.1	Questions	38
4.2.8.2	Evidence	38
4.2.8.3	Summary of evidence and recommendations for oestrogen therapy	38
4.2.9	Desmopressin	39
4.2.9.1	Questions	39
4.2.9.2	Evidence	39
	4.2.9.2.1 Improvement of incontinence	39
	4.2.9.2.2 Monitoring for hyponatraemia	39
4.2.9.3	Summary of evidence and recommendations for desmopressin	39
4.2.10	Drug treatment in mixed urinary incontinence	39
4.2.10.1	Question	39
4.2.10.2	Evidence	39
4.2.10.3	Summary of evidence and recommendations for drug treatment in mixed urinary incontinence	40
4.3	Surgical management	40
4.3.1	Women with uncomplicated stress urinary incontinence	41
4.3.1.1	Mid-urethral slings	41
	4.3.1.1.1 Questions	41
	4.3.1.1.2 Evidence	41
4.3.1.2	Adjustability	43
	4.3.1.2.1 Questions	43
	4.3.1.2.2 Evidence	43
4.3.1.3	Single-incision slings	43
	4.3.1.3.1 Questions	43
	4.3.1.3.2 Evidence	43
	4.3.1.3.3 Summary of evidence for mid-urethral slings	44
4.3.1.4	Open and laparoscopic surgery for stress urinary incontinence	45
	4.3.1.4.1 Question	45
	4.3.1.4.2 Evidence	45
	4.3.1.4.3 Summary of evidence for open and laparoscopic surgery for stress urinary incontinence	46
4.3.1.5	Bulking agents	46
	4.3.1.5.1 Question	46
	4.3.1.5.2 Evidence	46
	4.3.1.5.3 Summary of evidence for bulking agents	47
4.3.1.6	Recommendations for women with uncomplicated stress urinary incontinence	47
4.3.2	Complicated stress urinary incontinence in women	47
4.3.2.1	Colposuspension or sling following failed surgery	47
	4.3.2.1.1 Question	48
	4.3.2.1.2 Evidence	48
	4.3.2.1.3 Summary of evidence for colposuspension or sling following failed surgery	48
4.3.2.2	External compression devices	49
	4.3.2.2.1 Questions	49
	4.3.2.2.2 Evidence	49
	4.3.2.2.3 Summary of evidence for external compression devices	49
4.3.2.3	Recommendations for complicated stress urinary incontinence	50
4.3.3	Women with both stress urinary incontinence and pelvic organ prolapse	50
4.3.3.1	Questions	50
4.3.3.2	Evidence	50

4.3.3.3	Summary of evidence for women with both stress urinary incontinence and pelvic organ prolapse	52
4.3.3.4	Recommendations for women with both stress urinary incontinence and pelvic organ prolapse	52
4.3.4	Urethral diverticulum	52
4.3.4.1	Question	52
4.3.4.2	Evidence	52
4.3.4.3	Question	52
4.3.4.4	Surgical treatment	52
4.3.4.5	Summary of evidence and recommendation for urethral diverticulum	53
4.3.5	Men with stress urinary incontinence	53
4.3.5.1	Drug therapy	53
4.3.5.1.1	Summary of evidence for drug therapy in men with stress urinary incontinence	53
4.3.5.2	Bulking agents in men	53
4.3.5.2.1	Question	53
4.3.5.2.2	Evidence	53
4.3.5.2.3	Summary of evidence for bulking agents in men	54
4.3.5.3	Fixed male sling	54
4.3.5.3.1	Question	54
4.3.5.3.2	Evidence	54
4.3.5.3.3	Summary of evidence for fixed male sling	54
4.3.5.4	Adjustable slings in males	55
4.3.5.4.1	Question	55
4.3.5.4.2	Evidence	55
4.3.5.4.3	Summary of evidence for adjustable slings in males	55
4.3.5.5	Compression devices in males	55
4.3.5.5.1	Question	55
4.3.5.5.2	Evidence	55
4.3.5.5.3	Summary of evidence for compression devices in males	56
4.3.5.6	Recommendations for men with stress urinary incontinence	56
4.3.6	Surgical interventions for refractory detrusor-overactivity	57
4.3.6.1	Bladder wall injection of botulinum toxin A	57
4.3.6.1.1	Question	57
4.3.6.1.2	Evidence	57
4.3.6.1.3	Summary of evidence and recommendations for bladder wall injection of botulinum toxin A	58
4.3.6.2	Sacral nerve stimulation (neuromodulation)	58
4.3.6.2.1	Question	58
4.3.6.2.2	Evidence	58
4.3.6.2.3	Summary of evidence and recommendation for sacral nerve stimulation	59
4.3.6.3	Cystoplasty/urinary diversion	59
4.3.6.3.1	Augmentation cystoplasty	59
4.3.6.3.2	Detrusor myectomy (bladder auto-augmentation)	60
4.3.6.3.3	Urinary diversion	60
4.3.6.3.4	Summary of evidence and recommendations for cystoplasty/urinary diversion	60
4.3.7	Surgery in patients with mixed urinary incontinence	61
4.3.7.1	Question	61
4.3.7.2	Evidence	61
4.3.7.3	Summary of evidence and recommendations for surgery in patients with mixed urinary incontinence	61
4.3.7.4	Research priorities	62
4.3.8	Surgery for urinary incontinence in the elderly	62
4.3.8.1	Summary of evidence and recommendation for surgery for urinary incontinence in the elderly	62

APPENDIX A: NON OBSTETRIC URINARY FISTULA	67
A.2 Introduction	67
A.3 Diagnosis of fistula	67
A.4 Management of vesicovaginal fistula	67
A.3.1 Conservative management	67
A.3.2 Surgical management	67
A.3.2.1 Surgical approaches	67
A.4 Management of radiation fistula	68
A.5 Management of ureteric fistula	68
A.6 Management of urethrovaginal fistula	68
A.6.1 Diagnosis	69
A.6.2 Surgical repair	69
A.6.2.1 Vaginal approach	69
A.6.2.2 Abdominal approach	69
A.7 Summary of evidence and recommendations for management of urethrovaginal fistula	69
5. REFERENCES	71
6. CONFLICT OF INTEREST	98
7. CITATION INFORMATION	99

# 1. INTRODUCTION

Urinary incontinence (UI) is an extremely common complaint in every part of the world. It causes a great deal of distress and embarrassment, as well as significant costs, to both individuals and societies. Estimates of prevalence vary according to the definition of incontinence and the population studied. However, there is universal agreement about the importance of the problem in terms of human suffering and economic cost.

## 1.1 Aim and objectives

These Guidelines from the European Association of Urology (EAU) Working Panel on Urinary Incontinence are written by a multidisciplinary group, primarily for urologists, and are likely to be referred to by other professional groups. They aim to provide sensible and practical evidence-based guidance on the clinical problem of UI rather than an exhaustive narrative review. Such a review is already available from the International Consultation on Incontinence [1], and so the EAU Guidelines do not describe the causation, basic science, epidemiology and psychology of UI. The focus of these Guidelines is entirely on assessment and treatment reflecting clinical practice. The Guidelines also do not consider patients with UI caused by neurological disease, or in children, as this is covered by complementary EAU Guidelines [2, 3].

The current Guidelines provide:

- A clear pathway (algorithm) for common clinical problems. This can provide the basis for thinking through a patient's management and also for planning and designing clinical services.
- A brief but authoritative summary of the current state of evidence on clinical topics, complete with references to the original sources.
- Clear guidance on what to do or not to do, in most clinical circumstances. This should be particularly helpful in those areas of practice for which there is little or no high-quality evidence.

In this edition the Panel has continued to focus, largely, on the management of a 'standard' patient. The Panel has referred in places to patients with 'complicated incontinence', by which we mean patients with associated morbidity, a history of previous pelvic surgery, surgery for UI, radiotherapy and women with associated genitourinary prolapse. An appendix is included on non-obstetric genitourinary fistulae. The subject of prevention of UI has not been addressed. A systematic review (SR) on nocturnal incontinence found no studies on the topic. The Panel are of the opinion that nocturnal incontinence should be considered in future research studies.

### 1.1.1 *The elderly*

The Panel decided to include a separate but complimentary set of recommendations referring to the elderly population within each section. Older people with UI deserve special consideration for a number of reasons. Physiological changes with natural ageing mean that all types of UI become more common with increasing age. Urinary incontinence commonly co-exists with other comorbid conditions, reduced mobility, and impaired cognition and may require specific interventions, such as assisted toileting.

For the elderly person expectations of assessment and treatment may need to be modified to fit in with specific circumstances, needs, and preferences, while also taking into account any loss of capacity for consent. When the urologist is dealing with a frail elderly patient with urinary incontinence, collaboration with other healthcare professionals such as elderly care physicians is recommended.

It must be emphasised that clinical guidelines present the best evidence available to the experts. However, following guideline recommendations will not necessarily result in the best outcome. Guidelines can never replace clinical expertise when making treatment decisions for individual patients, but rather help to focus decisions - also taking personal values and preferences/individual circumstances of patients into account. Guidelines are not mandates and do not purport to be a legal standard of care.

## 1.2 Panel composition

The EAU Urinary Incontinence Panel consists of a multidisciplinary group of experts, including urologists, a gynaecologist and a physiotherapist. All experts involved in the production of this document have submitted potential conflict of interest statements which can be viewed on the EAU website: <http://www.uroweb.org/guideline/urinary-incontinence>.

## 1.3 Available publications

A quick reference document (Pocket Guidelines) is available, both in print and as an app for iOS and Android devices. These are abridged versions which may require consultation together with the full text versions. Two scientific publications in the journal *European Urology* are also available [4, 5]. All documents are accessible through the EAU website: <http://www.uroweb.org/guideline/urinary-incontinence>.



## 1.4 Publication history

The EAU published the first Urinary Incontinence Guidelines in 2001. Section 4.3 Surgical Management has been completely updated in this 2018 publication.

### 1.4.1 Summary of changes.

Changed evidence summaries and recommendations can be found in sections:

#### 4.3.1.1.3 Summary of evidence for mid-urethral slings

Summary of evidence	LE
Mid-urethral synthetic sling inserted by either the transobturator or retropubic route provides equivalent patient-reported outcome at five years.	1a
Mid-urethral synthetic sling inserted by the retropubic routes has higher objective patient-reported cure rates at 8 years.	1b
Long-term analysis of TVT cohorts showed a sustained response up to 17 years.	2b
The transobturator route of insertion is associated with a higher risk of groin pain than the retropubic route.	1a
Long-term analysis showed no difference in terms of efficacy for the skin-to-vagina compared to vagina-to-skin directions up to nine years.	2a
The top-to-bottom direction in the retropubic approach is associated with a higher risk of post-operative voiding dysfunction.	1b
Incontinence surgery has similar outcomes in older patients ( $\geq 65$ years).	2a
Incontinence surgery may be safely performed in obese women, however, outcomes may be inferior.	2b
Improvement in sexual life is higher with single incision slings than with standard MUS.	1a

SUI = stress urinary incontinence; TVT = tension-free vaginal tape.

NB: Most evidence on single-incision slings is from studies using the tension-free vaginal tape secure (TVT-S) device and although this device is no longer available, many women still have the device in place.

#### 4.3.1.4.3 Summary of evidence for open and laparoscopic surgery for stress urinary incontinence

Summary of evidence	LE
Laparoscopic colposuspension has a shorter hospital stay and may be more cost-effective than open colposuspension.	1a

#### 4.3.1.5.3 Summary of evidence for bulking agents

Summary of evidence	LE
Peri-urethral injection of a bulking agent may provide short-term improvement and cure (twelve months), in women with SUI.	1b
Autologous fat and hyaluronic acid as bulking agents have a higher risk of adverse events.	1a
Peri-urethral route of injection of bulking agents may be associated with a higher risk of urinary retention compared to the transurethral route.	2b

SUI = stress urinary incontinence.

#### 4.2.5.2.13 Additional recommendations for antimuscarinic drugs in the elderly

Recommendations	Strength rating
Inform women about the higher risk of groin pain following a transobturator approach when compared to a retropubic approach.	Strong
Inform women that any vaginal surgery may have an impact on sexual function, which is generally positive.	Weak
Offer bulking agents to women with SUI who request a low-risk procedure with the understanding that repeat injections are likely and long-term durability is not established.	Strong

SUI = stress urinary incontinence.

#### 4.3.2.1.3 Summary of evidence for colposuspension or sling following failed surgery

Summary of evidence	LE
TVT and TOT have similar outcomes in patients with recurrent SUI.	1a
Burch colposuspension has similar patient reported or objective cure rates when compared to TVT.	1b

TOT = trans-obturator tape; TVT = tension-free vaginal tape.

#### 4.3.3.4 Recommendations for women with both stress urinary incontinence and pelvic organ prolapse

Recommendations for women requiring surgery for bothersome pelvic organ prolapse who have symptomatic or unmasked stress urinary incontinence	Strength rating
Inform women of the increased risk of adverse events with combined surgery compared to prolapse surgery alone, as well as the risk of UI progression if UI is untreated at the time of POP repair.	Strong

POP = pelvic organ prolapse; UI = urinary incontinence.

#### 4.3.5.1.1 Summary of evidence for drug therapy in men with stress urinary incontinence

Summary of evidence	LE
Duloxetine, either alone or combined with conservative treatment, can hasten recovery but does not improve continence rate following prostate surgery. However, it can be associated with significant, albeit often transient, side effects.	1b

#### 4.3.5.3.3 Summary of evidence for fixed male sling

Summary of evidence	LE
There is no evidence that intraoperative placement of an autologous sling during RARP improves return of continence at 6 months.	1b

RARP = robotic assisted radical prostatectomy.

#### 4.3.5.6 Recommendations for men with stress urinary incontinence

Recommendation	Strength rating
Offer duloxetine only to hasten recovery of continence after prostate surgery but inform the patient about the possible adverse events and that its use is off label for this indication in most European countries.	Weak

#### 4.3.6.2.3 Summary of evidence for sacral nerve stimulation

Recommendations	LE
Sacral nerve neuromodulation is not more effective than OnabotulinumA toxin 200 U injection at 6 months.	1b

#### 4.3.6.3.4 Recommendations for cystoplasty/urinary diversion

Recommendations	Strength rating
Offer augmentation cystoplasty to patients with UI who have failed all other treatment options.	Weak
Inform patients undergoing augmentation cystoplasty of the high risk of having to perform clean intermittent self-catheterisation (ensure they are willing and able to do so) and that they need lifelong surveillance.	Weak

UI = urinary incontinence.

## 2. METHODS

### 2.1 Introduction

For the 2018 Urinary Incontinence Guidelines, the literature has been assessed for Section 4.3 – Surgical Management. Databases searched included Medline, EMBASE, and the Cochrane Libraries, covering a time frame between January 2012 and March 15<sup>th</sup>, 2017. Four different PICOS were developed (Slings and tapes, Botox and SNS, Other procedures including Colposuspension and Major surgery), resulting in a total of 2,142 records identified which were retrieved and screened for relevance. Detailed search strategies are available online for each of these PICOS: <https://uroweb.org/guideline/urinary-incontinence/?type=appendices-publications>.

For the 2018 edition of the EAU Guidelines the Guidelines Office have transitioned to a modified GRADE methodology across all 20 guidelines [6, 7]. For each recommendation within the guidelines there is an accompanying online strength rating form which addresses a number of key elements namely:

1. the overall quality of the evidence which exists for the recommendation, references used in this text are graded according to a classification system modified from the Oxford Centre for Evidence-Based Medicine Levels of Evidence [8];
2. the magnitude of the effect (individual or combined effects);
3. the certainty of the results (precision, consistency, heterogeneity and other statistical or study related factors);
4. the balance between desirable and undesirable outcomes;
5. the impact of patient values and preferences on the intervention;
6. the certainty of those patient values and preferences.

These key elements are the basis which panels use to define the strength rating of each recommendation. The strength of each recommendation is represented by the words ‘strong’ or ‘weak’ [9]. The strength of each recommendation is determined by the balance between desirable and undesirable consequences of alternative management strategies, the quality of the evidence (including certainty of estimates), and nature and variability of patient values and preferences. The strength rating forms will be available online.

Additional information can be found in the general Methodology section of this print, and online at the EAU website; <http://www.uroweb.org/guideline/>.

A list of Associations endorsing the EAU Guidelines can also be viewed online at the above address.

### 2.2 Review

The Surgical Management section has been peer reviewed prior to publication in 2018. The remainder of the document was peer reviewed prior to publication in 2015. The decision for re-review is made based on the extent of the revision. A major revision resulting in significant changes to the clinical recommendations presented in the text will warrant re-review.

### 2.3 Future goals

- A systematic review on the topic of female nocturia is ongoing [10].

## 3. DIAGNOSTIC EVALUATION

### 3.1 History and physical examination

Taking a careful clinical history is fundamental to the clinical process. Despite the lack of formal evidence, there is universal agreement that taking a history should be the first step in the assessment of anyone with UI. The history should include details of the type, timing and severity of UI, associated voiding and other urinary symptoms. The history should allow UI to be categorised into stress urinary incontinence (SUI), urgency urinary incontinence (UUI) or mixed urinary incontinence (MUI). It should also identify patients who need rapid referral to an appropriate specialist. These include patients with associated pain, haematuria, a history of recurrent urinary tract infection (UTI), pelvic surgery (particularly prostate surgery) or radiotherapy, constant leakage suggesting a fistula, voiding difficulty or suspected neurological disease. In women, an obstetric and gynaecological history may help to understand the underlying cause and identify factors that may impact on treatment decisions. The patient should also be asked about other ill health and for the details of current medications, as these may impact on symptoms of UI.

Similarly, there is little evidence from clinical trials that carrying out a clinical examination improves care, but wide consensus suggests that it remains an essential part of assessment of people with UI. It should include abdominal examination, to detect an enlarged bladder or other abdominal mass, and perineal and digital examination of the rectum (prostate) and/or vagina. Examination of the perineum in women includes an assessment of oestrogen status and a careful assessment of any associated pelvic organ prolapse (POP). A cough test may reveal SUI if the bladder is sufficiently full while pelvic floor contraction together with urethral mobility can be assessed digitally.

### **3.2 Patient questionnaires**

This section includes symptom scores, symptom questionnaires, scales, indexes, patient-reported outcome measures (PROMs) and health-related quality of life (HRQoL) measures. The latter include generic or condition specific measures. Questionnaires should have been validated for the language in which they are being used, and, if used for outcome evaluation, must have been shown to be sensitive to change. The US Food and Drug Administration (FDA) published guidance for industry on patient-reported outcome instruments (questionnaires) in 2009 [11].

#### **3.2.1 Questions**

- In patients with UI, can the use of Questionnaires/PROMS differentiate between stress, urgency and mixed incontinence, and does this differentiation impact on quality of life (QoL) after treatment?
- In adults with UI, does assessment using either urinary symptom or QoL questionnaires improve treatment outcome for UI?
- In adults with UI, does assessment of the patient perspective (concerns or expectations) improve patient outcomes, regarding either urinary symptoms or QoL, compared to no patient-reported assessment?

#### **3.2.2 Evidence**

Although many studies have investigated the validity and reliability of urinary symptom questionnaires and PROMs most of these studies did not include adult patients diagnosed with UI. This limits the extent to which results and conclusions from these studies can be applied in adults with UI. Some questionnaires (QUID, 3IQ) have potential to discriminate UI types in women [12, 13]. In men ICIQ-UI-SF score does not differentiate UI types [14]. Some questionnaires are responsive to change and may be used to measure outcomes, though evidence on their sensitivity is inconsistent [15-17]. No evidence was found to indicate whether use of QoL or condition specific questionnaires have an impact on outcome of treatment.

Table 1 shows a summary of the ICUD review (2012) with recent additions. Criteria on which questionnaires are assessed include validity, reliability and responsiveness to change.

**Table 1: Summary of the ICUD review 2012\*.**

	<b>Category A (all 3 criteria fulfilled)*</b>	<b>Category B (2 criteria fulfilled)*</b>	<b>Category C (only 1 criterion fulfilled)*</b>
Symptom measures and health-related QOL measures	ICIQ-UI Short Form, ICIQFLUTS, ICIQ-MLUTS IIQ and IIQ-7, I-QOL (ICIQ-Uqol), ISS, KHQ, LIS (?-interview), N-QoL, OAB-q SF, OAB-q (ICIQOABqol), PFDI and PFDI-20, PFIQ and PFIQ-7, PRAFAB, UISS	Contilife, EPIQ, LUTS tool IOQ, YIPS	ABSST ISI, ISQ, UIHI, UIQ
Measure of patient satisfaction (patient's measure of treatment satisfaction)	BSW, OAB-S, OABSAT-q, TBS	PPQ	EPI, GPI, PSQ
Goal attainment scales		SAGA	
Screening tools (used to identify patients with UI)	B-SAQ, OAB-SS, OABV8, OAB-V3, QUID	ISQ, USP	3IQ, CLSS, MESA, PUF
<b>Patient symptom scale</b>			
Assessment of symptom bother and overall bother	PPBC, UDI or UDI-6, LUSQ, PGI-I and PGI-S	PFBQ, SSI and SII	PMSES, POSQ, UI-4
Assessment of the impact of urgency	IUSS, U-IIQ, UU Scale, U-UDI	PPIUS, SUIQ, UPScore, UPScale, UQ, USIQ-QOL, USIQ-S, USS	
Questionnaires to assess sexual function and urinary symptoms		FSFI, ICIQ-VS, PISQ, SQoL-F	SFQ
Treatment adherence Measures		MASRI	

\* For all abbreviations please see the Abbreviations list in the Appendix at the end of the full Guidelines.

\*\* Criteria on which questionnaires are assessed include validity, reliability and responsiveness to change.

To date, there is no one questionnaire that fulfils all requirements for assessment of people with UI. Clinicians must evaluate the tools which exist, for use alone or in combination, for assessment and monitoring of treatment outcome [18].

The questionnaires can be found on the following websites: [www.iciq.net](http://www.iciq.net), [www.proqolid.org](http://www.proqolid.org), [www.mapi-institute.com](http://www.mapi-institute.com), [www.pfizerpatientreportedoutcomes.com](http://www.pfizerpatientreportedoutcomes.com), [www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov).

### 3.2.3 Summary of evidence and recommendations for patient questionnaires

<b>Summary of evidence</b>	<b>LE</b>
Validated condition specific symptom scores assist in the screening for, and categorisation of, UI.	3
Validated symptom scores measure the severity of UI.	3
Both condition specific and general health status questionnaires measure current health status, and change following treatment.	3

<b>Recommendation</b>	<b>Strength rating</b>
Use a validated and appropriate questionnaire when standardised assessment is required (See Table 1, above).	Strong

UI = urinary incontinence.

### 3.3 Voiding diaries

Measurement of the frequency and severity of lower urinary tract symptoms (LUTS) is an important step in the evaluation and management of lower urinary tract (LUT) dysfunction, including UI. Voiding diaries are a semi-objective method of quantifying symptoms, such as frequency of UI episodes. They also quantify urodynamic variables, such as voided volume and 24-hour or nocturnal total urine volume. Voiding diaries are also known as micturition time charts, frequency/volume charts and bladder diaries.

Discrepancy between diary recordings and the patient rating of symptoms, e.g. frequency or UI, can be useful in patient counselling. In addition, voided volume measurement can be used to support diagnoses, such as overactive bladder (OAB) or polyuria. Diaries can also be used to monitor treatment response and are widely used in clinical trials. In patients with severe UI, a voiding diary is unlikely to accurately report 24-hour urine output and so voided volume may be lower than total bladder capacity.

#### 3.3.1 Question

- In adults with UI, what is the reliability, diagnostic accuracy and predictive value of a voiding diary compared to patient history or symptom score?

#### 3.3.2 Evidence

Two articles have suggested a consensus has been reached in the terminology used in voiding [19, 20]. However, the terms micturition diary, frequency voiding chart and voiding diary, have been used interchangeably for many years and include information on fluid intake, times of voiding, voided volumes, incontinence episodes, pad usage, degree of urgency and degree of UI recorded for at least 24 hours. When reviewing the evidence all possible terminology has been included.

Two studies have demonstrated the reproducibility of voiding diaries in both men and women [21, 22]. Further studies have demonstrated variability of diary data within a 24-hour period and compared voided volumes recorded in diaries with those recorded by uroflowmetry [23, 24]. Another study found that keeping a voiding diary had a therapeutic benefit [25].

A number of observational studies have demonstrated a close correlation between data obtained from voiding diaries and standard symptom evaluation [26-29].

#### 3.3.3 Summary of evidence and recommendations for voiding diaries

Summary of evidence	LE
Voiding diaries of three to seven days duration are a reliable tool for the objective measurement of mean voided volume, day time and night time frequency, and incontinence episode frequency.	2b
Voiding diaries are sensitive to change and are a reliable measure of outcome.	2b

Recommendations	Strength rating
Ask patients with UI to complete a voiding diary when standardised assessment is needed.	Strong
Use a diary duration of at least three days.	Strong

UI = urinary incontinence.

### 3.4 Urinalysis and urinary tract infection

Reagent strip ('dipstick') urinalysis may indicate UTI, proteinuria, haematuria or glycosuria requiring further assessment. Refer to the Urological Infections Guidelines for diagnosis and treatment of UTI [30].

#### 3.4.1 Question

- In adults with UI, what is the diagnostic accuracy of urinalysis to detect UTI?
- In adults with UI does treatment of UTI or asymptomatic bacteriuria cure or improve UI compared to no treatment?

#### 3.4.2 Evidence

Urinalysis negative for nitrite and leucocyte esterase reliably excludes UTI in people with UI [31] and should be included, with urine culture when necessary, in the evaluation of all patients with UI. Urinary incontinence may occur during symptomatic UTI [32] and existing UI may worsen during UTI [33]. The rate and severity of UI was unchanged after eradication of asymptomatic bacteriuria in nursing home residents [34].

### 3.4.3 Summary of evidence and recommendations for urinalysis

Summary of evidence	LE
Urinalysis negative for nitrite and leucocyte esterase reliably excludes UTI.	1
Urinary incontinence may be a symptom during UTI.	3
The presence of a symptomatic UTI worsens symptoms of UI.	3
Elderly nursing home patients with UI do not benefit from treatment of asymptomatic bacteriuria.	2

Recommendations	Strength rating
Perform urinalysis as a part of the initial assessment of a patient with UI.	Strong
If a symptomatic UTI is present with UI, reassess the patient after treatment.	Strong
Do not routinely treat asymptomatic bacteriuria in elderly patients to improve UI.	Strong

UI = urinary incontinence; UTI = urinary tract infection.

## 3.5 Post-void residual volume

Post-void residual (PVR) volume is the amount of urine that remains in the bladder after voiding. It indicates poor voiding efficiency, which may result from a number of contributing factors. It is important because it may worsen symptoms and, more rarely, may be associated with UTI, upper urinary tract (UUT) dilatation and renal insufficiency. Both bladder outlet obstruction and detrusor underactivity contribute to the development of PVR. Post-void residual can be measured by catheterisation or ultrasound (US). The prevalence of PVR in patients with UI is uncertain, partly because of the lack of a standard definition of an abnormal PVR volume.

### 3.5.1 Question

In adults with UI, what are the benefits of measuring PVR?

### 3.5.2 Evidence

Most studies investigating PVR have not included patients with UI. Although some studies have included women with UI and men and women with LUTS, they have also included children and adults with neurogenic UI. In general, the data on PVR can be applied with caution to adults with non-neurogenic UI. The results of studies investigating the best method of measuring PVR [35-40] have led to the consensus that US measurement of PVR is preferable to catheterisation.

In peri- and post-menopausal women without significant LUTS or pelvic organ symptoms, 95% of women had a PVR < 100 mL [41]. In women with UUI, a PVR > 100 mL was found in 10% of cases [42]. Other research has found that a high PVR is associated with pelvic organ prolapse (POP), voiding symptoms and an absence of SUI [41, 43-45].

In women with SUI, the mean PVR was 39 mL measured by catheterisation and 63 mL measured by US, with 16% of women having a PVR > 100 mL [42].

### 3.5.3 Summary of evidence and recommendations for post-void residual

Summary of evidence	LE
Lower urinary tract symptoms coexisting with UI are associated with a higher rate of PVR compared to asymptomatic subjects.	2

Recommendations	Strength rating
When measuring PVR, use US.	Strong
Measure PVR in patients with UI who have voiding symptoms.	Strong
Measure PVR when assessing patients with complicated UI.	Strong
Post-void residual should be monitored in patients receiving treatments that may cause or worsen voiding dysfunction, including surgery for SUI.	Strong

PVR = post void residual urine; SUI = stress urinary incontinence; UI = urinary incontinence; US = ultrasound.

## 3.6 Urodynamics

Urodynamic testing is widely used as an adjunct to clinical diagnosis, in the belief that it may help to provide or confirm diagnosis, predict treatment outcome, or facilitate discussion during counselling. For all these reasons,



urodynamics is often performed prior to invasive treatment for UI. These Guidelines will focus on invasive tests, including multichannel cystometry, ambulatory monitoring and video-urodynamics, and different tests of urethral function, such as urethral pressure profilometry, Valsalva leak point pressure estimation, and retrograde urethral resistance measurement.

### 3.6.1 **Question**

In adults with UI, what is the reproducibility, diagnostic accuracy and predictive value of urodynamic testing?

### 3.6.2 **Evidence**

#### 3.6.2.1 **Variability**

In common with most physiological tests there is variability in urodynamics results. A number of small studies, assessing same-session repeatability of urodynamic testing, present contradictory findings [46, 47]. Measurement of urethral closure pressure (MUCP) correlates poorly with incontinence severity [48] and there is conflicting evidence about its reproducibility [49, 50]. One method of recording MUCP cannot be compared meaningfully to another [51].

Valsalva leak point pressures are not standardised and there is minimal evidence about reproducibility. Valsalva leak point pressure did not reliably assess incontinence severity in a cohort of women selected for surgical treatment of SUI [52]. The predictive value of the tests, regarding the outcome of treatment, remains unclear. No studies on the reproducibility of ambulatory monitoring were found.

#### 3.6.2.2 **Diagnostic accuracy**

The diagnostic accuracy of urodynamics is assessed in terms of its correlation with clinical diagnosis of UI and incontinence severity. The problem is that clinical diagnosis and urodynamic findings often do not correlate [53, 54], and normal healthy people may have urodynamic abnormalities.

The diagnostic accuracy of urethral pressure profilometry [48] and 'urethral retro-resistance' is generally poor [55]. Urethral reflectometry may have greater diagnostic accuracy but its clinical role remains unclear [56].

Ambulatory urodynamics may detect unexpected physiological variance from normal more often than conventional cystometry, but the clinical relevance of this is uncertain [57, 58].

#### 3.6.2.3 **Question**

Does urodynamics influence the outcome of conservative therapy?

#### 3.6.2.4 **Evidence**

A Cochrane review of seven randomised control trials (RCTs) showed that use of urodynamic tests increased the likelihood of prescribing drugs or avoiding surgery. However, there was no evidence that this influence on decision making altered the clinical outcome of treatment [59]. Subanalysis of an RCT comparing fesoterodine to placebo [60, 61] showed no predictive value for treatment response, by the urodynamic diagnosis of detrusor overactivity (DO).

#### 3.6.2.5 **Question**

Does urodynamics influence the outcome of surgery for urinary incontinence?

#### 3.6.2.6 **Evidence**

A high-quality RCT (n = 630) compared office evaluation alone to office evaluation and urodynamics in women with clinical demonstrable SUI about to undergo surgery for SUI. Whilst urodynamics changed the clinical diagnosis in 56% of women [62], there was no difference in levels of UI or any secondary outcome at twelve months follow-up after surgery [63]. Another similar study closed with only 59 women included due to recruitment problems, found that the omission of urodynamics was not inferior in the pre-operative work up of SUI [64]. This study was then redesigned so that patients in whom urodynamics were discordant with clinical assessment (n = 109) were randomly allocated to receive either immediate surgery or individually tailored therapy based on urodynamics. In this trial, performing immediate surgery, irrespective of the result of urodynamics, did not result in inferior outcomes [65].

In observational studies there is no consistent correlation between the result of urethral function tests and subsequent success or failure of SUI surgery [27-30]. The same is true for a secondary analysis of an RCT [66].



Augmentation cystoplasty is only performed in patients with a urodynamic diagnosis of DO, so no statement can be made about predictive value for this group [61].

The Panel recognise that it may be valuable to use urodynamic test results to select the optimum surgical procedure but, at the time of this review, there is inconsistent evidence regarding any predictive value that would support this approach.

### 3.6.2.7 Question

Does urodynamics help to predict complications of surgery for UI?

### 3.6.2.8 Evidence

There have been no RCTs designed to answer this question.

The presence of pre-operative DO has been associated with post-operative UUI, but did not predict overall treatment failure following mid-urethral sling [66] or following sling surgery or colposuspension.

Whilst low pre-operative flow rate has been shown to correlate with post-operative voiding dysfunction [67, 68], *post-hoc* analysis of two high-quality surgical trials showed that no pre-operative urodynamic parameter had the ability to predict post-operative voiding dysfunction in a selected population of women with low pre-operative PVR [69, 70].

### 3.6.2.9 Question

Does urodynamics influence the outcome of treatment for post-prostatectomy urinary incontinence in men?

### 3.6.2.10 Evidence

There are no RCTs examining the clinical usefulness of urodynamics in post-prostatectomy UI. Whilst urodynamics will distinguish causes of incontinence, its ability to predict outcome of surgery for incontinence for these men is uncertain [71, 72].

## 3.6.3 Summary of evidence and recommendations for urodynamics

Summary of evidence	LE
Most urodynamic parameters show variability within the same session and over time, and this limits their clinical usefulness.	3
Different techniques of measuring urethral function may have good test-retest reliability, but do not consistently correlate to other urodynamic tests or to the severity of UI.	3
There is limited evidence that ambulatory urodynamics is more sensitive than conventional urodynamics for diagnosing SUI or DO.	2
There may be inconsistency between history and urodynamic results.	3
Preliminary urodynamics can influence the choice of treatment for UI, but does not affect the outcome of conservative therapy or drug therapy for SUI.	1a
Pre-operative urodynamics in women with uncomplicated, clinically demonstrable, SUI does not improve the outcome of surgery for SUI.	1b
There is no consistent correlation between the result of urethral function tests and subsequent success or failure of SUI surgery.	3
There is no consistent evidence that pre-operative DO is associated with surgical failure of MUS in women.	3
The presence of pre-operative DO may be associated with persistence of urgency post-operatively.	3
There is no evidence that urodynamics predicts the outcomes of treatment for post-prostatectomy incontinence in men.	4

Recommendations (NB: Concerning only neurologically intact adults with UI)	Strength rating
When performing urodynamics in patients with UI adhere to 'Good Urodynamic Practice' standards as described by the International Continence Society [73]: <ul style="list-style-type: none"> <li>• attempt to replicate the patient's symptoms;</li> <li>• check recordings for quality control;</li> <li>• interpret results in the context of the clinical problem;</li> <li>• remember there may be physiological variability within the same individual.</li> </ul>	Strong
Do not routinely carry out urodynamics when offering treatment for uncomplicated SUI.	Strong

Perform urodynamics if the findings may change the choice of invasive treatment.	Weak
Do not use urethral pressure profilometry or leak point pressure to grade severity of incontinence.	Strong

DO = detrusor overactivity; MUS = mid-urethral sling; SUI = stress urinary incontinence; UI = urinary incontinence.

### 3.6.4 **Research priority**

Does any individual urodynamic test, or combination of tests, influence the choice of treatments or prediction of treatment outcome for UI?

## 3.7 **Pad testing**

Measurement of urine loss using an absorbent pad worn over a set period of time or during a protocol of physical exercise can be used to quantify the presence and severity of UI, as well as a patient's response to treatment.

### 3.7.1 **Questions**

- In adults with UI, what is the reliability, diagnostic accuracy and predictive value of pad testing?
- In adults with UI, is one type of pad test better than another?

### 3.7.2 **Evidence**

The clinical usefulness of pad tests for people with UI has been assessed in two SRs [74, 75]. A one-hour pad test using a standardised exercise protocol and a diagnostic threshold of 1.4 g shows good specificity but lower sensitivity for symptoms of SUI and MUI. A 24-hour pad test using a threshold of 4.4 g is more reproducible but is difficult to standardise with variation according to activity level [76]. Pad test with a specific short graded exercise protocol also has diagnostic value but a negative test should be repeated or the degree of provocation increased [77]. The usefulness of pad tests in quantifying severity and predicting outcome of treatment is uncertain [74, 78] although early post-operative testing may predict future continence in men after prostatectomy [79]. Pad test is responsive to change following successful treatment [80]. There is no evidence that one type of pad test is superior to another.

### 3.7.3 **Summary of evidence and recommendations for pad testing**

Summary of evidence	LE
A pad test can diagnose UI accurately.	2
Standardisation of bladder volume and degree of provocation improves reproducibility.	2
Twenty-four hours is sufficient duration for home-based testing balancing diagnostic accuracy and adherence.	2
Change in leaked urine volume on pad tests can be used to measure treatment outcome.	2

Recommendations	Strength rating
Use a pad test of standardised duration and activity protocol.	Strong
Use a pad test when quantification of UI is required.	Weak

UI = urinary incontinence.

### 3.7.4 **Research priority**

- Do the results of pad testing influence the choice of treatments or the prediction of the outcome of treatment for UI?
- Does the amount of physical activity influence the outcome of 24-hour pad testing leading to overestimation of the severity of UI?

## 3.8 **Imaging**

Imaging improves our understanding of the anatomical and functional abnormalities that may cause UI. In clinical research, imaging is used to understand the relationship between anatomy and function, between conditions of the central nervous system (CNS) or of the LUT and UI, and to investigate the relationship between LUT and pelvic floor imaging and treatment outcome.

Ultrasound and magnetic resonance imaging (MRI) have largely replaced X-ray imaging. Ultrasound is preferred to MRI because of its ability to produce three-dimensional and four-dimensional (dynamic) images at lower cost and wider availability. Studies on LUT imaging in patients with UI often include an evaluation of surgical outcomes, making design and conduct of these trials challenging.

**3.8.1 Questions**

In adults with UI:

- What is the reliability and accuracy of imaging in the diagnosis of UI?
- Do the results of imaging influence the choice of treatment for UI?
- Do the results of imaging help predict outcome of treatment for UI?
- Do the results of imaging help evaluate outcome of treatments for UI?

**3.8.2 Evidence**

Many studies have evaluated the imaging of bladder neck mobility by US and MRI, and concluded that UI cannot be identified by a particular pattern of urethrovesical movements [81]. In addition, the generalised increase in urethral mobility after childbirth does not appear to be associated with *de novo* SUI [82].

There is a general consensus that MRI provides good global pelvic floor assessment, including pelvic organ prolapse (POP), defecatory function and integrity of the pelvic floor support [83]. However, there is a large variation in MRI interpretation between observers [84] and little evidence to support its clinical usefulness in the management of UI. Studies have assessed the use of imaging to assess the mechanism of mid-urethral sling (MUS) insertion for SUI. One study suggested that MUS placement decreased mobility of the mid-urethra but not mobility of the bladder neck [85]. Following MUS, a wider gap between symphysis and sling (assessed by imaging) has been shown to correlate with a lower chance of cure of SUI [86].

Several imaging studies have investigated the relationship between sphincter volume and function in women [87] and between sphincter volume and surgery outcome, in men and women [88, 89]. In patients undergoing radical prostatectomy, longer membranous urethra before and after surgery was associated with a higher rate of continence [90]. However, no imaging test has been shown to predict the outcome of treatment for UI. Imaging of the pelvic floor can identify *levator ani* detachment and hiatus size, although there is little evidence of a relationship to clinical benefit after treatment of UI.

*Detrusor wall thickness*

As OAB has been linked to DO, it has been hypothesised that frequent detrusor contractions may increase detrusor/bladder wall thickness (DWT/BWT). However, there is no evidence that BWT/DWT imaging improves management of OAB in practice. No consensus exists as to the relationship between OAB and increased BWT/DWT [91].

**3.8.3 Summary of evidence and recommendations for imaging**

Summary of evidence	LE
Imaging can reliably be used to measure bladder neck and urethral mobility, although there is no evidence of clinical benefit for patients with UI.	2b
There is no consistent evidence that bladder (detrusor) wall thickness measurement is useful in the management of UI.	3

Recommendation	Strength rating
Do not routinely carry out imaging of the upper or lower urinary tract as part of the assessment of UI.	Strong

*UI = urinary incontinence.*

**3.8.4 Research priority**

More research is needed into the relationship between sling position, as determined by imaging, and surgical outcome.

## 4. DISEASE MANAGEMENT

### 4.1 Conservative management

In clinical practice, it is the convention that non-surgical therapies are tried first because they usually carry the least risk of harm. They are often used in combination which makes it difficult to determine which components are effective. Containment devices play an important role, especially for individuals who prefer to avoid the risks of interventional treatments, or in whom active treatment is impossible for any reason.

#### 4.1.1 Simple clinical interventions

##### 4.1.1.1 Underlying disease/cognitive impairment

Urinary incontinence, especially in the elderly, has been associated with multiple comorbid conditions including:

- cardiac failure;
- chronic renal failure;
- diabetes;
- chronic obstructive pulmonary disease;
- neurological disease including stroke and multiple sclerosis;
- general cognitive impairment;
- sleep disturbances, e.g. sleep apnoea;
- depression;
- metabolic syndrome.

It is possible that improvement of associated disease may reduce the severity of urinary symptoms. However, this is often difficult to assess as patients frequently suffer from more than one condition. In addition, interventions may be combined and individualised, making it impossible to decide which alteration in an underlying disease has affected a patient's UI.

##### 4.1.1.1.1 Question

In adults with UI, does improving an associated condition improve UI compared to no correction of that condition?

##### 4.1.1.1.2 Evidence

There is compelling evidence that there is a higher prevalence of UI in women with type 2 diabetes. One study showed no correlation between earlier intensive treatment of type 1 diabetes mellitus and the prevalence of UI in later life vs. conventional treatment [92].

##### 4.1.1.1.3 Summary of evidence and recommendations regarding associated conditions

Summary of evidence	LE
There is a lack of evidence that improving any associated condition improves UI, with the exception of weight loss (see section 4.1.2.4 Obesity and weight loss).	3

Recommendation	Strength rating
Patients with UI who have associated conditions, should have appropriate treatment for those conditions in line with good medical practice.	Strong

UI = urinary incontinence.

##### 4.1.1.2 Adjustment of other (non-incontinence) medication

Although UI is listed as an adverse effect of many drugs in drug compendia, this mainly results from uncontrolled individual patient reports and post-marketing surveillance. Few controlled studies have used the occurrence of UI as a primary outcome, or were powered to assess the occurrence of statistically significant UI, or worsening rates against placebo. In most cases, it is therefore not possible to be sure that a drug causes UI.

In patients with existing UI, particularly the elderly, it may be difficult or impossible to distinguish between the effects of medication, comorbidity or ageing on UI. Although changing drug regimens for underlying disease may be considered as a possible early intervention for UI, there is very little evidence of benefit [53]. There is also a risk that stopping or altering medication may result in more harm than benefit.

#### 4.1.1.2.1 Question

In adults with UI, does adjustment of other (non-incontinence) medication improve UI compared to no change in treatment?

#### 4.1.1.2.2 Evidence

Structured literature review failed to identify any studies addressing whether adjustment of specific medications could alter existing symptoms of UI. Also, there is little evidence relating to the occurrence or worsening of UI in relation to prescription of any specific drugs.

#### 4.1.1.2.3 Summary of evidence and recommendations for adjustment of other (non-incontinence) medication

Summary of evidence	LE
There is very little evidence that alteration of non-incontinence medication can cure or improve symptoms of UI.	3

Recommendations	Strength rating
Take a history of current medication use from all patients with UI.	Strong
Review any new medication associated with the development or worsening of UI.	Weak

UI = urinary incontinence.

#### 4.1.1.3 Constipation

Several studies have shown strong associations between constipation and UI. Constipation can be improved by behavioural, physical and medical treatments.

##### 4.1.1.3.1 Question

Does treatment for constipation improve UI?

##### 4.1.1.3.2 Evidence

Two, large, cross-sectional population-based studies [93, 94] and two longitudinal studies [95, 96] showed that constipation was a risk factor for LUTS. An observational study comparing women with UI and women with POP to controls found that a history of constipation was associated with both prolapse and UI [97]. One RCT found that a multimodal intervention in elderly patients, involving assisted toileting, fluid intake, etc., reduced the occurrence of UI and constipation, while behavioural therapy appeared to improve both [98].

In conclusion, constipation appears to be associated with UI. However, there is no evidence to show whether or not treating constipation improves UI, although both constipation and UI appear to be improved by certain behavioural interventions.

##### 4.1.1.3.3 Summary of evidence and recommendations for constipation

Summary of evidence	LE
There is a consistent association between a history of constipation and the development of UI and POP.	3
There is no consistent evidence in adults that treatment of constipation alone improves UI.	4

Recommendation	Strength rating
Adults with UI who also suffer from constipation should be given advice about bowel management in line with good medical practice.	Strong

POP = pelvic organ prolapse; UI = urinary incontinence.

##### 4.1.1.3.4 Research priority

Does the normalisation of bowel habit improve UI in patients who are constipated?

#### 4.1.1.4 Containment

Containment is important for people with UI when active treatment does not cure the problem, or when it is not available or not possible. Some individuals may prefer containment rather than undergo active treatment with

its associated risks. This includes the use of absorbent pads, urinary catheters, external collection devices, penile clamps for men and intravaginal devices for women. Studies of catheter use are not specific to patients with non-neurogenic UI. Detailed literature summaries can be found in the current ICUD monograph [1] and in European Association of Urological Nurses guidance documents [99-101]. A useful resource for health care professionals and patients can be found at: [www.continenceproductadvisor.org](http://www.continenceproductadvisor.org).

#### 4.1.1.4.1 Question

For adults with UI, is one type of containment device better than another?

#### 4.1.1.4.2 Evidence

One RCT involving elderly women in care comparing management with pads to indwelling urethral catheter found no difference in dependency level or skin integrity score at six months [102]. Use of an external sheath was compared with indwelling catheterisation over 30 days in an RCT involving elderly men resident in hospital [103]; there were no differences in bacteriuria or symptomatic UTI but the sheath was more comfortable. A short-term (two weeks) crossover RCT in men with UI found that disease specific QoL was better when using an external sheath and more men preferred it, compared to pads [104].

#### 4.1.1.4.3 Question

For men or women with UI, is one type of pad better than another?

#### 4.1.1.4.4 Evidence

A SR of six RCTs comparing different types of pads found that pads filled with superabsorbent material were better than standard pads, whilst evidence that disposable pads were better than washable pads was inconsistent [105]. For men with light UI, a randomised crossover trial found that a leaf-shaped type of pad was preferred to rectangular pads [106]. A series of three crossover RCTs examined performance of different pad designs for differing populations [107]. For women with light UI, disposable insert pads (within washable pouch pants) were most effective. In adults with moderate/severe incontinence, disposable pull-up pants were more effective for women, whilst for men disposable diapers were more effective during the day and washable diapers at night.

#### 4.1.1.4.5 Question

For men or women with UI, is one type of catheter or external collection device better than another?

#### 4.1.1.4.6 Evidence

A Cochrane review summarised three RCTs comparing different types of long-term indwelling catheters and found no evidence that one catheter material or type of catheter was superior to another [108]. A SR of non-randomised studies found no differences in UTI outcome or UUT changes between use of suprapubic or urethral catheter drainage; however, patients with suprapubic catheters were less likely to have urethral complications [109]. For people using intermittent catheterisation, a Cochrane review found no evidence that one type of catheter or regimen of catheterisation was better than another [110]. However, there is recent evidence from a narrative review suggesting that in certain populations using single-use catheters may reduce urethral trauma and UTI [111]. A Cochrane review summarising five trials comparing washout policies in adults with indwelling urinary catheters found inconsistent evidence of benefit [112].

A further Cochrane review summarising eight trials testing whether antibiotic prophylaxis was beneficial for adults using intermittent or indwelling catheterisation found it reduced incidence of symptomatic UTI but possible harms were not assessed [113].

#### 4.1.1.4.7 Question

For men and women with UI, are external pressure devices more effective than standard treatment and is one device better than another?

#### 4.1.1.4.8 Evidence

A crossover RCT in twelve men with post-prostatectomy incontinence found a hinge-type penile clamp to be more effective than circular clamps for control of UI and that the hinge-type penile clamp was preferred by participants, although it reduced penile blood flow [114].

A Cochrane review summarised seven trials comparing mechanical devices in women with UI finding limited evidence that SUI was reduced by intravaginal devices, no evidence on the effectiveness of intra-urethral devices, and that there was no difference in control of UI between intravaginal and intra-urethral devices [115].

There was no difference in outcome at twelve months in women with SUI between vaginal pessary alone; pelvic floor muscle training (PFMT) alone; and vaginal pessary + PFMT, although vaginal pessary was inferior to PFMT at three months for both from UI.

#### 4.1.1.4.9 Summary of evidence and recommendations for containment

Summary of evidence	LE
Pads are effective in containing urine.	1b
Hinge-type penile clamps are more effective than circular clamps to control SUI in men.	2a
Vaginal devices may improve SUI in women in selective groups.	2a

Recommendations	Strength rating
Ensure that adults with UI and/or their carers are informed regarding available treatment options before deciding on containment alone.	Strong
Offer incontinence pads and/or containment devices for management of UI.	Strong

SUI = stress urinary incontinence; UI = urinary incontinence.

#### 4.1.1.4.10 Research priority

To develop methods for assessing the best method of containment for individual adults with UI.

### 4.1.2 Lifestyle interventions

Examples of lifestyle factors that may be associated with incontinence include obesity, smoking, level of physical activity and diet. Modification of these factors may improve UI.

#### 4.1.2.1 Caffeine reduction

Many drinks contain caffeine, particularly tea, coffee and cola. Anecdotal evidence of urinary symptoms being aggravated by excessive caffeine intake has focused attention on whether caffeine reduction may improve UI. However, a cross-sectional population survey found no statistical association between caffeine intake and UI [116]. Lack of knowledge about the caffeine content of different drinks has made the role of caffeine reduction in alleviating UI difficult to assess.

##### 4.1.2.1.1 Question

In adults with UI, does caffeine reduction improve UI or QoL compared to no caffeine reduction?

##### 4.1.2.1.2 Evidence

Four studies were found on the effect of caffeine reduction on UI [117-120]. They were of moderate quality and the results were inconsistent. The studies were mainly in women, so results can only be cautiously generalised to men [118, 119]. One RCT showed that reducing caffeine intake as an adjunct to behavioural therapy resulted in reduced urgency but not reduced UI compared to behavioural therapy alone [118]. Another RCT found that reducing caffeine had no benefit for UI [119]. A further interventional study in the elderly showed borderline significance for the benefit of reducing caffeine intake on UI [120]. In a large prospective cohort study there was no evidence that caffeine reduction reduced the risk of progression of UI over two years [121].

##### 4.1.2.1.3 Summary of evidence for caffeine reduction

Summary of evidence	LE
Reduction of caffeine intake does not improve UI.	2
Reduction in caffeine intake may improve symptoms of urgency and frequency.	2

UI = urinary incontinence.

#### 4.1.2.2 Physical exercise

Regular physical activity may strengthen the pelvic floor musculature and possibly decrease the risk of developing UI, especially SUI. However, it is also possible that heavy physical exercise may aggravate UI.

##### 4.1.2.2.1 Question

Does physical exercise cause, improve or exacerbate UI in adults?



#### 4.1.2.2.2 Evidence

The association between exercise and UI is unclear. Four studies [116, 122-124] in differing populations concluded that strenuous physical exercise increases the risk of SUI during periods of physical activity. There is also consistent evidence that physically active females and elite athletes experience higher levels of SUI than control populations [125-130]. On the other hand, the presence of UI may prevent women from taking exercise [131]. There is no evidence that strenuous exercise predisposes athletes to the development of SUI later in life [132]. Lower levels of UI have been observed in cohorts of women who undertake moderate exercise, but it remains unclear whether taking exercise can prevent development of UI [133, 134].

##### 4.1.2.2.2.1 The elderly

Three RCTs in the elderly confirmed that exercise, as a component of a multidimensional regime including PFMT and weight loss, was effective in improving UI in women. It is not clear which component of such a scheme is most important [98, 135, 136].

##### 4.1.2.2.3 Summary of evidence for physical exercise

Summary of evidence	LE
Female athletes may experience UI during intense physical activity but not during common activities.	3
Strenuous physical activity does not predispose for women to UI later in life.	3
Moderate exercise is associated with lower rates of UI in middle-aged or older women.	2b

UI = urinary incontinence.

#### 4.1.2.3 Fluid intake

Modification of fluid intake, particularly restriction, is a strategy commonly used by people with UI to relieve symptoms. Advice on fluid intake given by healthcare professionals should be based on 24-hour fluid intake and urine output measurements. From a general health point of view, it should be advised that fluid intake should be sufficient to avoid thirst and that low or high 24-hour urine output should be investigated.

##### 4.1.2.3.1 Question

In adults with UI, what is the effect of modifying fluid intake compared to not modifying fluid intake on symptoms and QoL?

##### 4.1.2.3.2 Evidence

The few RCTs [119, 137, 138] provide inconsistent evidence. In most studies, the instructions for fluid intake were individualised and it is difficult to assess participant adherence to protocol. All available studies were in women. An RCT [138] showed that a reduction in fluid intake by 25% improved symptoms in patients with OAB but not UI. Personalised fluid advice compared to generic advice made no difference to continence outcomes in people receiving antimuscarinics for OAB, according to an RCT comparing drug therapy alone to drug therapy with behavioural advice [139].

##### 4.1.2.3.3 Summary of evidence for fluid intake

Summary of evidence	LE
There is conflicting evidence on whether fluid modification improves UI.	2

UI = urinary incontinence.

#### 4.1.2.4 Obesity and weight loss

Being overweight or obese has been identified as a risk factor for UI in many epidemiological studies [140, 141]. There is evidence that the prevalence of both UUI and SUI increases proportionately with rising body mass index [142]. The proportion of patients who undergo surgery for incontinence who are overweight or obese is higher than that of the general population [143].

##### 4.1.2.4.1 Question

In adults with UI, does weight loss lead to an improvement in symptoms of UI or QoL?

##### 4.1.2.4.2 Evidence

All the available evidence relates to women. Three SRs plus two large RCTs concluded that weight loss was beneficial in improving UI [140, 141, 144]. Five further RCTs reported a similar beneficial effect on incontinence



following surgical weight reduction programmes [145-149]. Two large studies in women with diabetes, for whom weight loss was the main lifestyle intervention, showed UI did not improve but there was a lower subsequent incidence of UI among those who lost weight [145, 150]. There have been other cohort studies and case-control studies suggesting similar effects, including surgery for the morbidly obese [151-155].

#### 4.1.2.4.3 Summary of evidence for obesity and weight loss

Summary of evidence	LE
Obesity is a risk factor for UI in women.	1b
Non-surgical weight loss in overweight and obese women improves UI.	1a
Surgical weight loss improves UI in obese women.	1b
Weight loss in obese women improves UI.	1b
Weight loss in obese adults with diabetes mellitus reduces the risk of developing UI.	1b

UI = urinary incontinence.

#### 4.1.2.5 Smoking

Smoking cessation is now a generalised public health measure and has been shown to be weakly associated with improving urgency frequency and UI [116, 156].

##### 4.1.2.5.1 Question

In adults with UI, does smoking cessation improve patient outcomes regarding either urinary symptoms or QoL compared to continued smoking?

##### 4.1.2.5.2 Evidence

The effect of smoking cessation on UI was described as uncertain in a NIHR review [157].

##### 4.1.2.5.3 Summary of evidence for smoking cessation

Summary of evidence	LE
There is no evidence that smoking cessation will improve the symptoms of UI.	4

UI = urinary incontinence.

#### 4.1.2.6 Recommendations for lifestyle interventions

Recommendations	Strength rating
Encourage overweight and obese adults with UI to lose weight and maintain weight loss.	Strong
Advise adults with UI that reducing caffeine intake may improve symptoms of urgency and frequency but not incontinence.	Strong
Review type and amount of fluid intake in patients with UI.	Weak
Provide smoking cessation strategies to patients with UI who smoke.	Strong

UI = urinary incontinence.

#### 4.1.2.7 Research priority

Which lifestyle modifications are effective for the cure or sustained improvement of UI?

#### 4.1.3 Behavioural and Physical therapies

Terminology relating to behavioural and physical therapies remains confusing because of the wide variety of ways in which treatment regimens and combinations of treatments have been delivered in different studies [158]. The terms are used to encompass all treatments which require a form of self-motivated personal retraining by the patient and also include techniques which are used to augment this effect.

Approaches include bladder training (BT) and PFMT, but terms such as bladder drill, bladder discipline and bladder re-education and behaviour modification are also used. Almost always in clinical practice, these will be introduced as part of a package of care including lifestyle changes, patient education and possibly some cognitive therapy as well. The extent to which individual therapists motivate, supervise and monitor these interventions is likely to vary but it is recognised that these influences are important components of the whole treatment package.

#### 4.1.3.1 Prompted voiding

The term 'prompted voiding' implies that carers, rather than the patient, initiate the decision to void and this applies largely to an assisted care setting.

Two SRs (nine RCTs) [159, 160] confirmed a positive effect on continence outcomes for prompted voiding in comparison to standard care [160]. Timed voiding is defined as fixed, pre-determined, time intervals between toileting, applicable for those with or without cognitive impairment. A Cochrane review of timed voiding reviewed two RCTs, finding inconsistent improvement in continence compared with standard care in cognitively impaired adults [161].

#### 4.1.3.2 Bladder Training

A programme of patient education along with a scheduled voiding regimen with gradually adjusted voiding intervals. Specific goals are to correct faulty habit patterns of frequent urination, improve control over bladder urgency, prolong voiding intervals, increase bladder capacity, reduce incontinent episodes and restore patient confidence in controlling bladder function. The ideal form or intensity of a BT programme for UI is unclear. It is also unclear whether or not BT can prevent the development of UI.

##### 4.1.3.2.1 Questions

In adults with UI:

- Is BT better than no treatment for cure or improvement of UI?
- Is BT better than other conservative treatments for cure or improvement of UI?
- Does BT, as an adjunct to other conservative treatments, cure or improve UI?
- Are the benefits of BT durable in the longer term?
- Are there any patient groups for whom BT is more effective?

##### 4.1.3.2.2 Evidence

There have been three SRs on the effect of BT compared to standard care [53, 157, 162] confirming that BT is more effective than no treatment in improving UUI. The addition of BT to anticholinergic therapy did not improve UI compared to antimuscarinics alone but it did improve frequency and nocturia [163].

This review identified seven RCTs in which BT was compared to drug therapy alone and showed only a benefit for oxybutynin in cure and improvement of UI [163].

Bladder training alone is inferior to a high-intensity programme of PFMT to improve SUI in elderly women [164]. Bladder training is better than intravaginal pessaries to control SUI, although the improvement may only be short term. Whatever the method of training used, any benefit of BT on UI is likely to be of short duration unless the BT programme is practised repeatedly. No adverse events have been reported with BT. Biofeedback combined with BT increased continence rates and improved MUI in two RCTs [162].

##### 4.1.3.2.3 Summary of evidence for bladder training

Summary of evidence	LE
Bladder training is effective for improvement of UI in women.	1b
The effectiveness of BT diminishes after the treatment has ceased.	2
The comparative benefit of BT and drugs for the improvement of UUI remains uncertain.	2
The combination of BT with antimuscarinic drugs does not result in greater improvement of UI but may improve frequency and nocturia.	1b
Bladder training is better than pessary alone.	1b
Prompted voiding, either alone or as part of a behavioural modification programme, improves continence in elderly, care-dependent people.	1b

*BT = bladder training; UI = urinary incontinence; UUI = urgency urinary incontinence.*

*For recommendations see section 4.1.3.5.*

#### 4.1.3.3 Pelvic floor muscle training (PFMT)

Pelvic floor muscle training is used to improve function of the pelvic floor, improving urethral stability. There is some evidence that improving pelvic floor function may inhibit bladder contraction in patients with OAB [165]. Pelvic floor muscle training may be used to prevent UI, e.g. in childbearing women before birth, in men about

to undergo radical prostatectomy, or as part of a planned recovery programme after childbirth or surgery. Most often, PFMT is used to treat existing UI, and may be augmented with biofeedback (using visual, tactile or auditory stimuli), surface electrical stimulation (ES) or vaginal cones.

#### 4.1.3.3.1 Question

In adult men and women suffering from UI, does treatment with PFMT, given either alone or augmented with biofeedback, ES or vaginal cones, improve or cure UI or improve QoL, compared to no treatment, sham treatment or other conservative treatments, e.g. bladder training, ES or vaginal cones?

#### 4.1.3.3.2 Evidence

In a recent UK Health Technology Appraisal (HTA), the role of PFMT in the care of women with SUI was analysed in a direct comparison of treatments using a mixed treatment comparison model, which compared different ‘packages’ of care [157]. This extensive meta-analysis reviewed data from 37 interventions and 68 direct comparisons, while the mixed treatment comparisons examined combinations of fourteen different types of intervention from 55 separate trials. The mixed treatment comparison used both indirect and direct comparisons and may provide more accurate estimates of effect. Where relevant, the Health Technology Appraisal has influenced the evidence and recommendations in these Guidelines. The Agency for Healthcare Research and Quality (AHRQ) review of nonsurgical treatment of UI in adult women also included indirect comparison methods as well as conventional meta-analysis [162].

#### 4.1.3.3.3 Efficacy of PFMT in SUI, UUI and MUI in women

This question has been addressed by several SRs [157, 162, 166], all report inconsistency between studies because of poor reporting of technique and different outcome measures. Meta-analysis showed that PFMT was effective for cure or improvement of incontinence, and improvement in QoL. The effect applies in women with SUI, UUI and MUI though the effect in MUI is lower than in women with pure SUI. A Cochrane review comparing different approaches to delivery of PFMT (21 RCTs) concluded that increased intensity of delivery of the therapy improves response and that there is no consistent difference between group therapy and individualised treatment sessions [167]. No other consistent differences between techniques were found.

With regard to the durability of PFMT, another RCT reported fifteen-year follow-up outcomes of an earlier RCT, showing that long-term adherence to treatment was poor and half of patients had progressed to surgery [168]. Numerous SRs have addressed the question of whether the effects of PFMT and BT are additive [157, 162, 169]. These reviews are confounded by differences in patient selection and have arrived at conflicting conclusions leaving uncertainty about the extent to which one treatment may augment the other. Similarly, there remains uncertainty about the additional value of biofeedback with SRs reaching differing conclusions [162, 169].

Comparison of PFMT to other treatments was extensively reviewed by both AHRQ and the 2010 UK HTA [157, 162], which considered additional non-randomised data as part of a mixed treatment comparison. The UK HTA resulted in a number of different findings from those based solely on direct comparisons. In conclusion, the HTA, using a revised methodology, supporting the general principle that greater efficacy was achieved by adding together different types of treatment and by increasing intensity.

#### *Efficacy of PFMT in childbearing women*

Two SRs [170, 171] reviewed RCTs in pregnant or postpartum women, which included PFMT in one arm of the trial. Treatment of UI with PFMT in the postpartum period increased the chances of continence at 12 months’ postpartum.

#### 4.1.3.3.4 PFMT in the elderly

The effect of PFMT in women with SUI does not seem to decrease with increased age: in trials with older women with SUI it appeared both primary and secondary outcome measures were comparable to those in trials focused on younger women [135, 164, 172].

#### 4.1.3.3.5 PFMT in men (post radical prostatectomy)

A 2015 Cochrane review concluded that there was no overall benefit at twelve months post-surgery for men who received post-operative PFMT for the treatment of post-prostatectomy urinary incontinence (PPI) and that the benefits of conservative treatment of PPI remain uncertain [173]. A meta-analysis within this review showed that a greater proportion of men were dry from between three and twelve months suggesting that PFMT may speed recovery of continence. A subsequent study adds to this evidence [174].

Two additional RCTs have shown that written instructions alone offer similar levels of improvement to supervised PFMT [175, 176]. One RCT found that PFMT was helpful in men who had been incontinent for at least one year after prostatectomy, and who had had no previous therapy [177].

One RCT compared PFMT to no treatment in men undergoing trans-urethral resection of the prostate (TURP). There was no demonstrable difference in the incidence of post-operative incontinence up to twelve months [178].

#### 4.1.3.3.6 Summary of evidence for pelvic floor muscle training

Summary of evidence	LE
<b>Pelvic floor muscle training (PFMT) for women with UI</b>	
Pelvic floor muscle training is better than no treatment for improving UI and QoL in women with SUI and MUI.	1
Higher-intensity, supervised treatment regimes, and the addition of biofeedback, confer greater benefit in women receiving PFMT.	1
Short-term benefits of intensive PFMT are not maintained at fifteen-year follow-up.	2
Pelvic floor muscle training commencing in the early postpartum period improves UI in women for up to twelve months.	1
<b>Pelvic floor muscle training for post-prostatectomy UI</b>	
Pelvic floor muscle training appears to speed the recovery of continence following radical prostatectomy.	1b
Pelvic floor muscle training does not cure UI in men post radical prostatectomy or transurethral prostatectomy.	1b
There is conflicting evidence on whether the addition of bladder training, ES or biofeedback increases the effectiveness of PFMT alone.	2
Pre-operative PFMT does not confer additional benefit to men undergoing radical prostatectomy.	1b

ES = electrical stimulation; MUI = mixed urinary incontinence; PFMT = pelvic floor muscle training;

QoL=quality of life; SUI = stress urinary incontinence; UI = urinary incontinence.

For recommendations see section 4.1.3.5.

#### 4.1.3.3.7 Electrical stimulation

The details and methods of delivery of ES vary considerably. Electrical stimulation of the pelvic floor can also be combined with other forms of conservative therapy, e.g. PFMT and biofeedback. Electrical stimulation is often used to assist women who cannot initiate contractions to identify their pelvic floor muscles. Electrical stimulation is also used in patients with OAB and UUI, for detrusor inhibition. It has been suggested that ES probably targets the pelvic floor directly in SUI and the detrusor muscle or pelvic floor muscle or afferent innervation in UUI.

#### 4.1.3.3.8 Question

In adults with UI, does treatment with ES improve or cure symptoms of UI or QoL compared to no/sham treatment or antimuscarinics?

#### 4.1.3.3.9 Evidence

Most evidence on ES refers to women with SUI. The topic has been included in two HTAs [157, 162] and three SRs [53, 179, 180]. The reviews include analysis of fifteen trials and use different comparison methods, but differ in their assessment of whether ES is more effective than sham stimulation and whether ES adds to the benefit of PFMT alone. Studies were considered to be of generally low quality, with a variety of stimulation parameters, treatment regimens and outcome parameters [173].

A subanalysis in a SR on one small low quality RCT in which ES had been compared to oxybutynin and PFMT in patients with UI, showed no difference in incontinence outcomes [181].

A Cochrane review of ES in men with UI (six RCTs) concluded that there was some evidence that ES enhanced the effect of PFMT in the short-term but not after six months. Electrical Stimulation was also more effective than sham stimulation at six, but not twelve months. There were, however, more adverse effects (pain or discomfort) with ES [182].

Electromagnetic stimulation has been promoted as treatment for UI but weak evidence of the short-term and long-term effects has been found in SRs [183, 184].

#### 4.1.3.3.10 Summary of evidence for electrical stimulation

Summary of evidence	LE
In adults with UI, ES may improve UI compared to sham treatment and antimuscarinics.	2
Electrical stimulation may add benefit to PFMT in the short-term.	2

ES = electrical stimulation, PFMT = pelvic floor muscle training; UI = urinary incontinence.

For recommendations see section 4.1.3.5.

#### 4.1.3.4 Posterior tibial nerve stimulation

Electrical stimulation of the posterior tibial nerve (PTNS) delivers electrical stimuli to the sacral micturition centre via the S2-S4 sacral nerve plexus. Stimulation is done percutaneously with a fine, 34-G, needle, inserted just above the medial aspect of the ankle (P-PTNS). Transcutaneous stimulation is also available (T-PTNS). Treatment cycles typically consist of twelve weekly treatments of 30 minutes.

##### 4.1.3.4.1 Question

In adults suffering from UUI, what is the clinical effectiveness of PTNS compared to sham treatment or alternative treatment such as antimuscarinic drugs?

##### 4.1.3.4.2 Evidence

###### P-PTNS

The reviewed studies included two twelve-week RCTs of PTNS against sham treatment [185, 186], one comparing PTNS to tolterodine, and a three-year extension trial utilising a maintenance protocol in patients with UUI [187, 188]. The results of studies of PTNS in women with refractory UUI are consistent. Considered together, these results suggest that PTNS improves UUI in women who did not have adequate improvement or could not tolerate anti-muscarinic therapy. However, there is no evidence that PTNS cures UUI in women. In addition, PTNS is no more effective than tolterodine for improvement of UUI in women. In men there is insufficient evidence to reach a conclusion about efficacy.

###### T-PTNS

A small RCT compared transcutaneous PTNS plus standard treatment (PFMT and BT) with PFMT and BT alone in older women [189]. Women in the T-TPNS group were more likely to achieve improvement at the end of therapy.

#### 4.1.3.4.3 Summary of evidence for posterior tibial nerve stimulation

Summary of evidence	LE
Percutaneous posterior tibial nerve stimulation appears effective for improvement of UUI in women who have had no benefit from antimuscarinic medication.	2b
A maintenance programme of P-PTNS has been shown to be effective up to three years.	1b
Percutaneous Posterior tibial nerve stimulation has comparable effectiveness to tolterodine for improvement of UUI in women.	1b
No serious adverse events have been reported for P-PTNS in UUI.	3
There is limited evidence for effectiveness of T-PTNS.	2a
There is no evidence that P-PTNS cures UI.	2b

P-PTNS = Percutaneous posterior tibial nerve stimulation; T-PTNS = transcutaneous posterior tibial nerve stimulation; UI=urinary incontinence; UUI=urge urinary incontinence.

#### 4.1.3.5 Recommendations for behavioural and physical therapies

Recommendations	Strength rating
Offer prompted voiding for adults with UI who are cognitively impaired.	Strong
Offer bladder training as a first-line therapy to adults with UUI or MUI.	Strong
Offer supervised intensive PFMT, lasting at least 3 months, as a first-line therapy to all women with SUI or MUI (including the elderly and post-natal).	Strong

Offer instruction on PFMT to men undergoing radical prostatectomy to speed recovery from UI.	Strong
Ensure that PFMT programmes are as intensive as possible.	Strong
Do not offer ES with surface electrodes (skin, vaginal, anal) alone for the treatment of stress UI.	Strong
Do not offer magnetic stimulation for the treatment of UI or overactive bladder in adult women.	Strong
Consider PTNS as an option for improvement of UUI in women who have not benefited from antimuscarinic medication.	Strong

ES = electrical stimulation; MUI = mixed urinary incontinence; PFMT = pelvic floor muscle training; PTNS = percutaneous tibial nerve stimulation; SUI = stress urinary incontinence; UI = urinary incontinence; UUI = urge urinary incontinence.

#### 4.1.4 Conservative therapy in mixed urinary incontinence

About one-third of women with UI have MUI with symptoms of both SUI and UUI, and this becomes more common with increasing age. In terms of evidence base, many studies include patients with MUI, but it is rare for these studies to provide a separate analysis of patients with MUI.

##### 4.1.4.1 Question

In adults with MUI, is the outcome of conservative therapy different to that obtained with the same treatment in patients with either pure SUI or pure UUI?

##### 4.1.4.2 Evidence

No specific SRs were found that addressed the above question. However, a Cochrane report on PFMT [166] concluded that training was less likely to result in a cure in patients with MUI than in patients with pure SUI, though it is not clear from the report how this conclusion was reached.

A small RCT (n = 71) compared delivery of PFMT, with or without an instructive audiotape. It showed equal efficacy for different types of UI [190].

Following a RCT of PFMT, a review of 88 women available for follow-up at five years found that outcomes were less satisfactory in women with MUI than in women with pure SUI [191].

##### 4.1.4.3 Summary of evidence and recommendations for conservative therapy in mixed urinary incontinence

Summary of evidence	LE
Pelvic floor muscle training appears less effective for MUI than for SUI alone.	2
Electrical stimulation is equally effective for MUI and SUI.	1b

Recommendation	Strength rating
Treat the most bothersome symptom first in patients with MUI.	Weak

MUI = mixed urinary incontinence; SUI = stress urinary incontinence.

## 4.2 Pharmacological management

### 4.2.1 Antimuscarinic drugs

Antimuscarinic (anticholinergic) drugs are currently the mainstay of treatment for UUI. They differ in their pharmacological profiles, e.g. muscarinic receptor affinity and other modes of action, in their pharmacokinetic properties, e.g. lipid solubility and half-life, and in their formulation.

The evaluation of cure or improvement of UI is made harder by the lack of a standard definition of improvement and the failure to use cure as a primary outcome. In general, SRs note that the overall treatment effect of drugs is usually small but larger than placebo.

Dry mouth is the commonest side effect, though constipation, blurred vision, fatigue and cognitive dysfunction may occur [162].

The immediate release (IR) formulation of oxybutynin is the archetype drug in the treatment of UUI. Oxybutynin IR provides maximum dosage flexibility, including an off-label 'on-demand' use. Immediate-release drugs have a greater risk of side effects than extended release (ER) formulations because of differing pharmacokinetics. A transdermal delivery system (TDS) and gel developed for oxybutynin gives a further alternative formulation.



#### 4.2.1.1 Question

In adults with UUI, are antimuscarinic drugs better than placebo for improvement or cure of UUI and for the risk of adverse effects?

#### 4.2.1.2 Evidence

Seven SRs of individual antimuscarinic drugs vs. placebo were reviewed for this section [162, 192-197] as well as studies published since these reviews up until April 2016. Most studies included patients with a mean age of 55-60 years. Both female and male subjects were included in different studies but results cannot be generalised across sexes. Only short-term rates for improvement or cure of UUI are reported. The evidence reviewed was consistent, indicating that ER and IR formulations of antimuscarinics offer clinically significant short-term cure and improvement rates for UUI compared to placebo. On balance, IR formulations tend to be associated with more side effects compared to ER formulations [196].

Cure of UI was deemed to be the most important outcome measure. Risk of adverse events was best represented by withdrawal from a trial because of adverse events, although this does not reflect practice. Table 2 shows a summary of the findings from a SRs [162]. In summary, every drug where cure of UI was available shows superiority compared to placebo in achieving UI, but the absolute size of effect is small. There is limited evidence that patients who do not respond to a first-line antimuscarinic treatment may respond to a higher dose or a different antimuscarinic agent [198, 199].

**Table 2: Summary of cure rates and discontinuation rates of antimuscarinic drugs from RCTs which reported these outcomes [162]**

Drug	No. of studies	Patients	Relative risk (95% CI) (of curing UI)	Number needed to treat (95% CI) (to achieve one cure of UI)
<b>Cure of incontinence</b>				
Fesoterodine	2	2,465	1.3 (1.1-1.5)	8 (5-17)
Oxybutynin (includes IR)	4	992	1.7 (1.3-2.1)	9 (6-16)
Propiverine (includes IR)	2	691	1.4 (1.2-1.7)	6 (4-12)
Solifenacin	5	6,304	1.5 (1.4-1.6)	9 (6-17)
Tolterodine (includes IR)	4	3,404	1.2 (1.1-1.4)	12 (8-25)
Trospium (includes IR)	4	2,677	1.7 (1.5-2.0)	9 (7-12)
<b>Discontinuation due to adverse events</b>				
			<b>Relative Risk (95% CI) (of discontinuation)</b>	<b>NNT (95% CI) (of one discontinuation)</b>
Darifenacin	7	3,138	1.2 (0.8-1.8)	
Fesoterodine	4	4,433	2.0 (1.3-3.1)	33 (18-102)
Oxybutynin (includes IR)	5	1,483	1.7 (1.1-2.5)	16 (8-86)
Propiverine (includes IR)	2	1,401	2.6 (1.4-5)	29 (16-77)
Solifenacin	7	9,080	1.3 (1.1-1.7)	78 (39-823)
Tolterodine (includes IR)	10	4,466	1.0 (0.6-1.7)	
Trospium (includes IR)	6	3,936	1.5 (1.1-1.9)	56 (30-228)

CI = confidence interval; NNT = number to treat; UI = urinary incontinence.

##### 4.2.1.2.1 Darifenacin

The cure rates for darifenacin were not included in the AHRQ review. Continence rates were 29-33% for darifenacin compared to 17-18% for placebo [162].

##### 4.2.1.2.2 Transcutaneous oxybutynin

Transdermal oxybutynin has shown a significant improvement in the number of incontinence episodes and micturitions per day vs. placebo and other oral formulations but continence was not reported as an outcome [162].

Oxybutynin topical gel was superior to placebo for improvement of UUI with a higher proportion of participants being cured [162, 200].

#### 4.2.2 Comparison of antimuscarinic agents

Head-to-head comparison trials of the efficacy and side effects of different antimuscarinic agents are of interest for decision making in practice.

##### 4.2.2.1 Question

In adults with UUI, does one type of antimuscarinic drug result in a greater likelihood of cure or improvement in UUI, and/or a greater improvement in QoL, and/or a lesser likelihood of adverse effects compared to an alternative antimuscarinic drug?

##### 4.2.2.2 Evidence

There are over 40 RCTs and eight SRs [162, 181, 192, 194, 197, 201-203]. Nearly all the primary studies were industry sponsored. Upward dose titration is often included in the protocol for the experimental arm, but not for the comparator arm.

In general, these studies have been designed for regulatory approval. They have short treatment durations (twelve weeks) and a primary outcome of a change in OAB symptoms rather than a cure of, or an improvement in, UUI, which were generally analysed as secondary outcomes. The clinical utility of these trials in real life practice is questionable. Most trials were of low or moderate quality [194]. The 2012 AHRQ review included a specific section addressing comparisons of antimuscarinic drugs (Table 2).

##### Fesoterodine

Results of an RCT of fesoterodine 4 vs. 8 mg suggested a larger therapeutic effect on UUI with the higher dose but with more adverse events [198].

No antimuscarinic agent improved QoL more than another agent [194]. Dry mouth is the most prevalent adverse effect. Good evidence indicates that, in general, higher doses of any drug are likely to be associated with higher rates of adverse events. Also, ER formulations of short-acting drugs and longer-acting drugs are generally associated with lower rates of dry mouth than IR preparations [194, 201]. Oxybutynin IR showed higher rates of dry mouth than tolterodine IR and trospium IR, but lower rates of dry mouth than darifenacin, 15 mg daily [194, 201]. Overall, oxybutynin ER has higher rates of dry mouth than tolterodine ER, although the incidence of moderate or severe dry mouth were similar. Transdermal oxybutynin had a lower rate of dry mouth than oxybutynin IR and tolterodine ER, but had an overall higher rate of withdrawal due to an adverse skin reaction [194]. Solifenacin, 10 mg daily, had higher rates of dry mouth than tolterodine ER [194]. Fesoterodine, 8 mg daily, had a higher rate of dry mouth than tolterodine, 4 mg daily [204-206]. In general, similar discontinuation rates were observed, irrespective of differences in the occurrence of dry mouth (doses have been given were the evidence relates to a specific dose level typically from trials with a dose escalation element).

##### 4.2.2.3 Summary of evidence for antimuscarinic agents

Summary of evidence	LE
There is limited evidence that one antimuscarinic drug is superior to an alternative antimuscarinic drug for cure or improvement of UUI.	1b
Higher doses of antimuscarinic drugs are more effective to cure or improve UUI, but with a higher risk of side effects.	1b
Once daily (extended release) formulations are associated with lower rates of adverse events compared to immediate release ones, although similar discontinuation rates are reported in clinical trials.	1b
Dose escalation of antimuscarinic drugs may be appropriate in selected patients to improve treatment effect although higher rates of adverse events can be expected.	1b
Transdermal oxybutynin (patch) is associated with lower rates of dry mouth than oral antimuscarinic drugs, but has a high rate of withdrawal due to skin reaction.	1b

UUI=urge urinary incontinence.

#### 4.2.3 Antimuscarinic drugs vs. conservative treatment

The choice of drug vs. conservative treatment of UUI is an important question.



#### 4.2.3.1 Question

In adults with UUI, does one type of antimuscarinic drug result in a greater likelihood of cure or improvement in UUI and/or greater improvement in QoL, and/or lesser likelihood of adverse effects compared to conservative treatment?

#### 4.2.3.2 Evidence

More than 100 RCTs and high-quality reviews are available [163, 181, 194, 195, 207, 208]. Most of these studies were independent. A US HTA [181] found that trials were of a low- or moderate-quality. The main focus of the review was to compare the different drugs used to treat UUI. In one study, multicomponent behavioural modification produced significantly greater reductions in incontinence episodes compared to oxybutynin and higher patient satisfaction for behavioural vs. drug treatment. In men with storage LUTS no difference in efficacy was found between oxybutynin and behavioural therapy [209].

The combination of BT and solifenacin in women with OAB conferred no additional benefit in terms of continence [210]. A recent Cochrane review on the benefit of adding PFMT to other active treatments of UI in women showed insufficient evidence of any benefit in adding PFMT to drug treatment [211].

One RCT [212] reported a similar improvement in subjective parameters with either transcutaneous electrical nerve stimulation (T-PTNS) or oxybutynin. One study compared tolterodine ER to transvaginal/anal ES without differences in UI outcomes [213].

#### 4.2.3.3 Summary of evidence and recommendations for antimuscarinic drugs

Summary of evidence	LE
There is no consistent evidence to show superiority of drug therapy over conservative therapy for treatment of UUI.	1b
Behavioural treatment has higher patient satisfaction than drug treatment.	1b
There is insufficient evidence as to the benefit of adding PFMT to drug treatment for UUI.	1b

Recommendations	Strength rating
Offer antimuscarinic drugs for adults with UUI who failed conservative treatment.	Strong
Consider extended release formulations of antimuscarinics drugs, whenever possible.	Strong
If an antimuscarinic treatment proves ineffective, consider dose escalation or offering an alternative antimuscarinic formulation, or mirabegron, or a combination.	Strong
Encourage early review (of efficacy and side effects) of patients on antimuscarinic medication for UUI.	Strong

PFMT = pelvic floor muscle training; UUI = urgency urinary incontinence.

#### 4.2.4 Antimuscarinic agents: adherence and persistence

Most studies on antimuscarinic medication are short term (twelve weeks). Adherence in clinical trials is considered to be much higher than in clinical practice [214].

##### 4.2.4.1 Question

Do patients with UUI adhere to antimuscarinic drug treatment and persist with prescribed treatment in clinical practice?

##### 4.2.4.2 Evidence

This topic has been reviewed for the development of these Guidelines [215]. Two open-label extensions of RCTs of fesoterodine 8 mg showed adherence rates at two years of 49-84% [216, 217]. The main drugs studied were oxybutynin and tolterodine IR and ER. Non-persistence rates were high for tolterodine at twelve months, and particularly high (68-95%) for oxybutynin.

Five articles reported 'median days to discontinuation' as between < 30 days and 50 days [218-222]. In a military health system where free medication was provided, the median time to discontinuation extended to 273 days [219].

Data on adherence/persistence from open-label extension populations are questionable as these patients are self-selected to be compliant. A Longitudinal Disease Analyser database study has indicated an increasing discontinuation rate from 74.8% at one year to 87% at three years [223].

Several of the RCT trials tried to identify the factors associated with low/lower, adherence or persistence of antimuscarinics. These were identified as:

- low level of efficacy (41.3%);
- adverse events (22.4%);
- cost (18.7%), higher adherence rates were observed when drugs were provided at no cost to the patient [219].

Other reasons for poor adherence included:

- IR vs. ER formulations;
- age (lower persistence among younger adults);
- unrealistic expectations of treatment;
- gender distribution (better adherence/persistence in female patients);
- ethnic group (African-Americans and other ethnic minorities are more likely to discontinue or switch treatment).

In addition, the data source influenced the adherence figures.

#### 4.2.4.3 Summary of evidence for adherence to antimuscarinic treatment

Summary of evidence	LE
Adherence to antimuscarinic treatment is low and decreases over time because of lack of efficacy, adverse events and/or cost.	2
Most patients will stop antimuscarinic agents within the first three months.	2

#### 4.2.5 Mirabegron

Mirabegron is the first clinically available beta3 agonist, available from 2013. Beta3 adrenoceptors are the predominant beta receptors expressed in the smooth muscle cells of the detrusor and their stimulation is thought to induce detrusor relaxation.

Mirabegron has undergone evaluation in industry-sponsored phase 2 and phase 3 trials [224-227]. Three SRs assessing the clinical effectiveness of mirabegron [224, 225, 228] reported that mirabegron at doses of 25, 50 and 100 mg, results in significantly greater reduction in incontinence episodes, urgency episodes and micturition frequency/24 hours than placebo, with no difference in the rate of common adverse events [224]. The placebo dry rates in most of these trials are between 35-40%, and 43 and 50% for mirabegron. In all trials the statistically significant difference is consistent only for improvement but not for cure of UI. Similar improvement in frequency of incontinence episodes and micturitions/24 hours was found in people who had previously tried and those who had not previously tried antimuscarinic agents. One SR showed that mirabegron is similarly efficacious as most antimuscarinics in reducing UUI episodes [229].

The most common treatment adverse events in the mirabegron groups were hypertension (7.3%), nasopharyngitis (3.4%) and UTI (3%), with the overall rate similar to placebo [224, 227, 230].

In a twelve-month, active-controlled RCT of mirabegron 50/100 mg vs. tolterodine ER 4 mg, the improvement in efficacy seen at twelve weeks was sustained at twelve-month evaluation in all groups. The reported dry rates at twelve months were 43%, 45% and 45% for mirabegron 50 mg, 100 mg and tolterodine 4 mg respectively [230]. *Post-hoc* analyses of RCTs showed that clinical improvement observed in parameters of OAB severity translates to an improvement in HRQoL and efficacy is maintained in patients with more severe degree of UI [231, 232].

No risk of QTc prolongation on electrocardiogram [233] and raised intraocular pressure [234] were observed up to 100 mg dose; however, patients with uncontrolled hypertension or cardiac arrhythmia were excluded from these trials. There is no significant difference in rate of side effects at different doses of mirabegron [230]. Data from a large Canadian Private Drug Plan database suggest a higher adherence rate for mirabegron compared to antimuscarinics [235]. Patients on certain concurrent medications (i.e. metoprolol) should be counselled that, due to common metabolism pathways, their medication dosage may need to be adjusted. In the case of patients taking metoprolol, blood pressure should be monitored after starting mirabegron and, if necessary, metoprolol dosing changed.

Evaluation of urodynamic parameters in men with combined bladder outlet obstruction (BOO) and OAB concluded that mirabegron (50 or 100 mg) did not adversely affect voiding urodynamic parameters compared to placebo [236].

Equivalent adherence was observed for tolterodine and mirabegron at twelve months (5.5% and 3.6%), although the incidence of dry mouth was significantly higher in the tolterodine group [230]. In mirabegron treated patients, improvement in objective outcome measures correlates directly with clinically relevant PROMs (OAB-q and PPBC) [231, 237].

An RCT in patients who had inadequate response to solifenacin monotherapy 5 mg, demonstrated that combination treatment with mirabegron 50 mg had a higher chance of achieving clinically meaningful improvement in UI as compared to dose escalation of solifenacin [238].

#### 4.2.5.1 Summary of evidence and recommendations for mirabegron

Summary of evidence	LE
Mirabegron is better than placebo and as efficacious as antimuscarinics for improvement of UUI symptoms.	1a
Adverse event rates with mirabegron are similar to placebo.	1a
Patients inadequately treated with solifenacin 5 mg may benefit more from the addition of mirabegron than dose escalation of solifenacin.	1b

Recommendation	Strength rating
Offer antimuscarinic drugs or mirabegron to adults with UUI who failed conservative treatment.	Strong

UUI = urgency urinary incontinence.

#### 4.2.6 Antimuscarinic and beta3 agonist agents, the elderly and cognition

Trials have been conducted in elderly people with UI. Considerations in this patient group include the multifactorial aetiology of UI in the elderly, comorbidities such as cognitive impairment, the effect of co-medications and the risk of adverse events.

The effects of antimuscarinic agents on cognition have been studied in more detail.

##### 4.2.6.1 Question

What is the comparative efficacy, and risk of adverse effects, particularly the cognitive impact, of treatment with antimuscarinic medication in elderly men and women with UUI?

##### 4.2.6.2 Evidence

Two SRs focusing on elderly patients are available [239, 240]. A community-based cohort study found a high incidence of cognitive dysfunction [241]. Other SRs have included sections on the efficacy and safety of antimuscarinics in elderly patients [162, 194]. A SR in 2012 found inconclusive evidence as to the impact of antimuscarinics on cognition [242].

Two recent longitudinal cohort studies in patients using drugs with antimuscarinic effect showed a deterioration in cognitive function, alteration in CNS metabolism and an association with brain atrophy [243, 244]. In general, the long-term impact of antimuscarinic agents specifically approved for OAB treatment on specific patient cohorts is poorly understood [245-248].

##### 4.2.6.2.1 Oxybutynin

There is evidence that oxybutynin IR may cause/worsen cognitive dysfunction in adults [245, 247, 249-253]. Recent evidence has emerged from a prospective cohort study showing cumulative cognitive deterioration associated with prolonged use of antimuscarinic medication including oxybutynin [243].

More rapid functional deterioration might result from the combined use of cholinesterase inhibitors with antimuscarinic agents in elderly patients with cognitive dysfunction [254].

##### 4.2.6.2.2 Solifenacin

One pooled analysis [255] has shown that solifenacin does not increase cognitive impairment in the elderly. No age-related differences in the pharmacokinetics of solifenacin in different age groups was found, although more frequent adverse events in subjects over 80 years of age were observed. No cognitive effect on healthy elderly volunteers was shown [253]. In a subanalysis of a large trial, solifenacin 5-10 mg improved symptoms and QoL in people  $\geq 75$  years who had not responded to tolterodine [256]. In patients with mild cognitive impairment,  $\geq 65$  years, solifenacin showed no difference in efficacy between age groups and a lower incidence of most side effects compared to oxybutynin IR [252, 257].

#### 4.2.6.2.3 Tolterodine

No change in efficacy or side effects related to age have been reported, although a higher discontinuation rate was found for both tolterodine and placebo in elderly patients [245]. Two RCTs in the elderly found a similar efficacy and side effect profile to younger patients [258-261]. *Post-hoc* analysis has shown little effect on cognition. One non-randomised comparison showed lower rates of depression in elderly participants treated with tolterodine ER compared to oxybutynin IR [262].

#### 4.2.6.2.4 Darifenacin

Two RCTs in the elderly population (one in patients with UI and the other in volunteers) concluded that darifenacin was effective with no risk of cognitive change, measured as memory scanning tests, compared to placebo [263, 264]. Another study on darifenacin and oxybutynin ER in elderly subjects concluded that the two agents had a similar efficacy, but that cognitive function was more often affected in the oxybutynin ER arm [247].

#### 4.2.6.2.5 Trospium chloride

Trospium does not appear to cross the blood brain barrier in significant amounts in healthy individuals due to its molecular characteristics (quaternary amine structure and hydrophilic properties). Two (EEG) studies in healthy volunteers showed no effect from trospium whilst tolterodine caused occasional changes and oxybutynin caused consistent changes [265, 266]. No evidence as to the comparative efficacy and side effect profiles of trospium in different age groups is available. However, there is some evidence that trospium does not impair cognitive function [248, 267] and that it is effective compared to placebo in the elderly [268].

#### 4.2.6.2.6 Fesoterodine

Pooled analyses of the RCTs of fesoterodine confirmed the efficacy of the 8 mg but not the 4 mg dose in over 75-year olds [216]. Adherence was lower in the over-75 year-old group but the effect on mental status was not reported [206, 216, 269]. A more recent RCT showed efficacy of fesoterodine in the vulnerable elderly with no differences in cognitive function at twelve weeks [270].

#### 4.2.6.2.7 Anti-incontinence drugs in the elderly

RCTs comparing duloxetine and placebo included women up to 85 years, but no age stratification of the results is available [195, 271, 272].

#### 4.2.6.2.8 Mirabegron

Analysis of pooled data from three RCTs showed efficacy and safety of mirabegron in elderly patients [273].

#### 4.2.6.2.9 Applicability of evidence to general elderly population

It is not clear how much the data from pooled analyses and subgroup analyses from large RCTs can be extrapolated to a general ageing population. Community-based studies of the prevalence of antimuscarinic side effects may be the most helpful [241]. When starting anticholinergics in elderly patients, mental function should be assessed objectively and monitored [274]. No consensus exists as to the best mental function test to detect changes in cognition [254, 275].

#### 4.2.6.2.10 Anticholinergic load

A number of medications have anticholinergic effects and their cumulative effects on cognition should be considered [276].

#### 4.2.6.2.11 Question

In older people suffering from UI, what is the effect of anticholinergic burden (defined by anticholinergic cognitive burden scale) on cognitive function?

#### 4.2.6.2.12 Evidence

No studies were identified specifically in older people with UI, but evidence was available from observational cohort studies relating to the risk in a general population of older people. Lists of drugs with anticholinergic properties are available from two sources [276, 277].

Two SRs of largely retrospective cohort studies showed a consistent association between long-term anticholinergic use and cognitive dysfunction [278, 279].

Longitudinal studies in older people over two to four years have found increased rate of decline in cognitive function for patients on anticholinergics or drugs with anticholinergic effects [243, 244, 280, 281].

#### 4.2.6.3 Summary of evidence and additional recommendations for use of antimuscarinic drugs in the elderly

Summary of evidence	LE
Antimuscarinic drugs are effective in elderly patients.	1b
Mirabegron has been shown to be efficacious and safe in elderly patients.	1b
In older people, the cognitive impact of drugs which have anticholinergic effects is cumulative and increases with length of exposure.	2
Oxybutynin may worsen cognitive function in elderly patients.	2
Solifenacin, darifenacin, fesoterodine and trospium have been shown not to cause cognitive dysfunction in elderly people in short-term studies.	1b

Recommendations	Strength rating
Long-term antimuscarinic treatment should be used with caution in elderly patients especially those who are at risk of, or have, cognitive dysfunction.	Strong

#### 4.2.6.4 Research priorities

- All drug trials should report cure rates for UI based on a bladder diary.
- What is the relative incidence of cognitive side effects of antimuscarinic drugs?

#### 4.2.7 Drugs for stress urinary incontinence

Duloxetine inhibits the presynaptic re-uptake of neurotransmitters, serotonin (5-HT) and norepinephrine (NE). In the sacral spinal cord, an increased concentration of 5-HT and NE in the synaptic cleft increases stimulation of 5-HT and NE receptors on the pudendal motor neurones, which in turn increases the resting tone and contraction strength of the urethral striated sphincter.

##### 4.2.7.1 Questions

- In adults with SUI, does duloxetine cure or improve UI and/or improve QoL compared to no treatment?
- In adults with SUI, does duloxetine result in a greater cure or improvement of UI, or a greater improvement in QoL, or a lesser likelihood of adverse effects, compared to any other intervention?

##### 4.2.7.2 Evidence

Duloxetine was evaluated as a treatment for female SUI or MUI in three SRs [195, 271, 272].

Improvement in UI compared to placebo was observed with no clear differences between SUI and MUI. One study reported cure for UI in about 10% of patients. An improvement in I-QoL was not found in the study using I-QoL as a primary endpoint. In a further study comparing duloxetine, 80 mg daily, with PFMT alone, PFMT + duloxetine, and placebo [282], duloxetine reduced leakage compared to PFMT or no treatment.

Global improvement and QoL were better for combined therapy than no treatment. There was no significant difference between PFMT and no treatment.

Two open-label studies with a follow-up of one year or more evaluated the long-term effect of duloxetine in controlling SUI; however, both had high discontinuation rates [283, 284].

All studies had a high patient withdrawal rate, which was caused by a lack of efficacy and high incidence of adverse events, including nausea and vomiting (40% or more of patients), dry mouth, constipation, dizziness, insomnia, somnolence and fatigue, amongst other causes [283, 284].

A SR showed significant efficacy for duloxetine compared to placebo in women with UI but with increased risk of adverse events [272].

#### 4.2.7.3 Summary of evidence and recommendations on drugs for SUI

Summary of evidence	LE
Duloxetine, 40 mg twice daily improves SUI in women.	1a
Duloxetine causes significant gastrointestinal and central nervous system side effects leading to a high rate of treatment discontinuation, although these symptoms are limited to the first weeks of treatment.	1a

Recommendations	Strength rating
Offer Duloxetine in selected patients with symptoms of SUI when surgery is not indicated.	Strong
Duloxetine should be initiated and withdrawn using dose titration because of high risk of adverse event.	Strong

SUI = stress urinary incontinence.

#### 4.2.8 Oestrogen

Oestrogenic drugs including conjugated equine oestrogens, oestradiol, tibolone and raloxifene, are used as hormone replacement therapy (HRT) for women with natural or therapeutic menopause.

Oestrogen treatment for UI has been tested using oral, transdermal and vaginal routes of administration. Available evidence suggests that vaginal oestrogen treatment with oestradiol and oestriol is not associated with the increased risk of thromboembolism, endometrial hypertrophy, and breast cancer seen with systemic administration [285-287]. Vaginal (local) treatment is primarily used to treat symptoms of vaginal atrophy in postmenopausal women.

##### 4.2.8.1 Questions

- In women with UI, does vaginal (local) oestrogen cure or improve UI compared to no treatment or other active treatment?
- In women with UI, does oral (systemic) oestrogen cure or improve UI compared to no treatment?

##### 4.2.8.2 Evidence

###### Vaginal oestrogens

A Cochrane SR looked at the use of oestrogen therapy in postmenopausal women [285] given local oestrogen therapy. There is also a more recent narrative review of oestrogen therapy in urogenital diseases [288]. The Cochrane review (search date cut off June 2012) found that vaginal oestrogen treatment improved symptoms of UI in the short term [285]. The review found small, low quality trials comparing vaginal oestrogen treatment with phenylpropanolamine, PFMT, ES and its use as an adjunct to surgery for SUI. Local oestrogen was less likely to improve UI than PFMT but no differences in UI outcomes were observed for the other comparisons. A single trial of local oestrogen therapy comparing a ring device to pessaries found no difference in UI outcomes although more women preferred the ring device. No adverse effects of vaginal administration of oestradiol for vulvovaginal atrophy over two years was seen in one trial [289].

Vaginal oestrogen therapy can be given as conjugated equine oestrogen, oestriol or oestradiol in vaginal pessaries, vaginal rings or creams. The ideal treatment duration and the long-term effects are uncertain. A standardised review of local oestrogen showed improvement of UI over placebo with vaginal rings favoured subjectively over pessaries; no significant difference between vaginal and oral oestrogen treatments was found [290].

One RCT in postmenopausal women showed benefit in adding intravaginal oestriol to vaginal ES and PFMT [291].

###### Systemic oestrogens

Studies of HRT with non-urogenital primary outcomes have looked for change in urinary continence in secondary analyses. Large trials using conjugated equine oestrogens showed a higher rate of development or worsening of UI compared to placebo [292-295]. In a single RCT, use of raloxifene was not associated with development or worsening of UI [296]. Three small RCTs using oral oestriol or oestradiol as HRT for vulvovaginal atrophy suggested that UI symptoms were improved although the evidence was unclear [53, 297, 298].

##### 4.2.8.3 Summary of evidence and recommendations for oestrogen therapy

Summary of evidence	LE
Vaginal oestrogen therapy improves UI for post-menopausal women in the short term.	1a
Neoadjuvant or adjuvant use of local oestrogens are ineffective as an adjunct to surgery for UI.	2
Systemic hormone replacement therapy using conjugate equine oestrogens in previously continent women increases the risk of developing UI and worsens pre-existing UI.	1a



Recommendations	Strength rating
Offer long-term vaginal oestrogen therapy to post-menopausal women with UI and symptoms of vulvo-vaginal atrophy.	Strong
In women with a history of breast cancer, the treating oncologist should be consulted.	Weak
For women taking oral conjugated equine oestrogen as hormone replacement therapy who develop or experience worsening UI, discuss alternative hormone replacement therapies.	Strong
Advise women who are taking systemic oestradiol who suffer from UI that stopping the oestradiol is unlikely to improve their incontinence.	Strong

UI = urinary incontinence.

#### 4.2.9 **Desmopressin**

Desmopressin is a synthetic analogue of vasopressin (also known as antidiuretic hormone). It can be taken orally, nasally or by injection. Desmopressin is most commonly used to treat diabetes insipidus and, when used at night, to treat nocturnal enuresis.

##### 4.2.9.1 *Questions*

- In adults with UI, does desmopressin cure or improve UI and/or improve QoL compared to no treatment?
- In adults with UI, does desmopressin result in a lesser likelihood of adverse effects, compared to any other intervention?

##### 4.2.9.2 *Evidence*

###### 4.2.9.2.1 Improvement of incontinence

Few studies have examined the use of desmopressin exclusively for the treatment of UI. No evidence was found that demonstrated any effect of desmopressin on nocturnal incontinence, though evidence does exist for it reducing nocturnal polyuria, particularly in children [299]. One RCT compared desmopressin to placebo with daytime UI as an outcome measure, with improved continence shown during the first four hours after taking desmopressin in women [300]. There is no evidence reporting desmopressin cure rates for UI and no evidence that compares desmopressin with other non-drug treatments for UI.

###### 4.2.9.2.2 Monitoring for hyponatraemia

The use of desmopressin carries a risk of developing hyponatraemia (please refer to the EAU Guidelines on Male LUTS [30]).

##### 4.2.9.3 *Summary of evidence and recommendations for desmopressin*

Summary of evidence	LE
The risk of UI is reduced within four hours of taking oral desmopressin, but not after four hours.	1b
Continuous use of desmopressin does not improve or cure UI.	1b
Regular use of desmopressin may lead to hyponatraemia.	3

Recommendations	Strength rating
Consider offering desmopressin to patients requiring occasional short-term relief from daytime UI and inform them that this drug is not licensed for this indication.	Strong
Monitor plasma sodium levels in patients on desmopressin.	Strong
Do not use desmopressin for long-term control of UI.	Strong

UI = urinary incontinence.

#### 4.2.10 **Drug treatment in mixed urinary incontinence**

##### 4.2.10.1 *Question*

In adults with MUI, is the outcome of a drug treatment different to that for the same treatment in patients with either pure SUI or UUI?

##### 4.2.10.2 *Evidence*

Many RCTs include patients with MUI with predominant symptoms of either SUI or UUI but few report outcomes separately for those with MUI compared to pure SUI or UUI groups.

##### *Tolterodine*

In an RCT of 854 women with MUI, tolterodine ER was effective for improvement of UUI, but not SUI suggesting that the efficacy of tolterodine for UUI was not altered by the presence of SUI [301]. In another

study (n = 1380) tolterodine was equally effective in reducing urgency and UUI symptoms, regardless of whether there was associated SUI [302]. Similar results were found for solifenacin [303, 304].

#### Duloxetine

In one RCT of duloxetine vs. placebo in 588 women, subjects were stratified into either stress-predominant, urgency-predominant or balanced MUI groups. Duloxetine was effective for improvement of incontinence and QoL in all subgroups [305].

Duloxetine was found to have equal efficacy for SUI and MUI in an RCT (n = 553) following secondary analysis of respective subpopulations [306].

#### 4.2.10.3 Summary of evidence and recommendations for drug treatment in mixed urinary incontinence

Summary of evidence	LE
Limited evidence suggests that antimuscarinic drugs are effective for improvement of the UUI component in patients with MUI.	2
Duloxetine is effective for improvement of both SUI and UUI in patients with MUI.	1b

Recommendations	Strength rating
Treat the most bothersome symptom first in patients with MUI.	Weak
Offer antimuscarinic drugs or beta3 agonists to patients with urgency-predominant MUI.	Strong
Consider offering duloxetine for patients with MUI unresponsive to other conservative treatments and who are not seeking cure.	Strong

MUI = mixed urinary incontinence; SUI=stress urinary incontinence; UUI=urge urinary incontinence.

### 4.3 Surgical management

In line with the recommendations from the UK National Institute for Healthcare and Clinical Excellence (NICE) [53] the Panel agreed that surgeons and centres performing surgery should:

- be trained in the field of incontinence and for each surgical procedure they perform/offer;
- not be trained by someone who is not surgically qualified;
- perform sufficient numbers of a procedure to maintain expertise of him/herself and the surgical team;
- be able to offer alternative surgical treatments;
- be able to deal with the complications of surgery;
- provide suitable arrangements for long-term follow-up.

This section considers surgical options for:

- Women with uncomplicated SUI: This means no history of previous surgery, no neurogenic LUT dysfunction, no bothersome genitourinary prolapse, and women not considering further pregnancy.
- Women with complicated SUI: Neurogenic LUT dysfunction is reviewed in the EAU Guidelines on Neuro-Urology [2].
- Associated genitourinary prolapse has been included in these Guidelines in terms of treating incontinence, but no attempt has been made to comment on treatment of prolapse itself.
- Men with SUI: mainly men with post-prostatectomy incontinence without neurological disease affecting the LUT.
- Patients with refractory DO and low compliance bladders.

Although the outcome of surgical procedures should be considered in terms of cure, it is also important to consider any associated complications, adverse events and costs. The outcome parameters used to evaluate surgery for SUI have included:

- continence rate and number of incontinence episodes;
- patient-reported outcome measures;
- general and procedure-specific complications;
- generic, specific (UI) and correlated (sexual and bowel) QoL.

In this context it has to be taken into account that a number of products may no longer be available and therefore the recommendations may not be transferable to current devices. The Panel makes a strong recommendation that new devices are only used as part of a structured research programme and their outcomes monitored in a registry.



### 4.3.1 **Women with uncomplicated stress urinary incontinence**

#### 4.3.1.1 *Mid-urethral slings*

Early clinical studies identified that non-autologous slings should be made from monofilament, non-absorbable material, typically polypropylene, and constructed as a 1-2 cm wide mesh with a relatively large pore size (macroporous). Mid-urethral slings are now the most frequently used surgical intervention in Europe for women with SUI.

#### *Safety of mid-urethral slings*

A population-based study performed in Scotland on over 16,000 women operated on for SUI showed a similar rate of complications between mesh and non-mesh surgery confirming the safety of mesh procedure for UI [307]. However, a recent study of over 92,000 patients followed in the National Health Service (UK) showed a significant (9.8%) rate of complications using a more broad definition and following patients for a longer period of time. These findings suggest that, as with any SUI surgery, mid-urethral sling (MUS) surgery can be associated with complications and proper informed consent is mandatory.

#### 4.3.1.1.1 Questions

In women with SUI, what is the effectiveness in curing SUI and adverse effects for:

- mid-urethral synthetic sling insertion compared to Burch colposuspension?
- one method of insertion of a MUS compared to another method?
- one direction of insertion of a MUS compared to another direction of insertion?
- colposuspension compared to autologous fascial sling.

#### 4.3.1.1.2 Evidence

For the purpose of these Guidelines, a new meta-analysis was performed.

A Cochrane review of open retropubic colposuspension in the treatment on UI was published in 2016 [308]. Overall, colposuspension is associated with a continence rate of 85-90% at 1 to 5 years post-operatively and about 70% of patients can expect to be dry after five years. Comparison of colposuspension vs. MUS showed non difference in subjective or objective evaluation of incontinence rates at any time point (one to five years and five years and more time points). A subanalysis of autologous fascial slings showed better effectiveness compared to colposuspension at one to five years follow-up. In a RCT of Burch colposuspension vs. autologous fascial slings, continence rates decreased substantially over time in both arms. At five years, continence rate of colposuspension was 24.1% compared to 30.8% for fascial slings, satisfaction remained higher in the sling group (83% vs. 73%) and was related to the continence status [309]. Adverse events rates were similar for the two treatment groups with Burch 10% and sling 9% although post-operative obstruction was found exclusively in the sling group.

In general, open retropubic colposuspension does not seem to be associated with higher morbidity and complications compared to MUS. Pelvic organ prolapse is more common after colposuspension and voiding dysfunction occurs more often after MUS [308].

#### *Transobturator route vs. retropubic route*

A Cochrane meta-analysis of mid-urethral sling procedures for SUI in women was performed in 2017 spanning January 1947 to June 2014 [310]. Moderate quality evidence from 55 studies showed variable, but comparable, subjective cure rates between retropubic and transobturator slings (62-98% in the transobturator arms and 71-97% in the retropubic arms) in the short term (up to one year). No difference in the objective cure rate in the short term was found. A lower number of studies provide medium (one to five years) and long-term (over five years) follow-up with no difference in the subjective cure rates in the mid- and long-term. In the long term, a subjective cure rate of 43-92% in the transobturator group and of 51-88% in the retropubic group was found.

Although the adverse event rates are low, the retropubic approach was associated with a higher rate of bladder perforation (4.5% vs. 0.6%) and voiding dysfunction; vascular and visceral injury, mean operative time, operative blood loss and hospital stay were lower in the transobturator groups.

Transobturator surgery was associated with a lower risk of voiding dysfunction but groin pain was more frequent (6.4% vs. 0.6%). The opposite occurred for suprapubic pain (0.8% in the transobturator and 2.9% in the retropubic groups, respectively). The overall vaginal erosion risk was low and comparable in both groups (2.1% in retropubic and 2.4% in transobturator surgery). Re-do surgery for UI was more common in the transobturator group (RR = 8.79, 95% CI: 3.36-23) however the data is limited and of low quality

In retropubic surgery, the bottom-to-top route was 10% more efficacious than top-to-bottom in terms of subjective cure and it was associated with less voiding dysfunction, bladder perforations and vaginal erosion.

Analysis of the TOMUS trial (a randomised equivalence trial of retropubic vs. transobturator MUS for the treatment of SUI in women) confirms equivalence of objective cure rates at 12 but not at 24 months (77.3% and 72.3% objective cure rate for retropubic and transobturator surgery). Subjective cure rates are inconclusive for equivalence. Patient satisfaction (86.3% vs. 88.1%), frequency of *de novo* UUI (0% vs. 0.3%) and mesh exposure (4.4% vs. 2.7%) did not differ significantly between the retropubic and transobturator groups. Subjective and objective treatment success continues to decrease over time and equivalence of the retropubic and the transobturator routes cannot be confirmed at 24 and 60 months with retropubic demonstrating a slight benefit, however satisfaction remained high in both arms [311]. The cumulative rate of serious adverse events was nearly twice as high in the retropubic group compared with the transobturator group at 24 months, but they occurred much less often in the second year of follow-up [312].

An economic evaluation of retropubic vs. transobturator tapes suggests that the latter may be cost-effective and cost-saving compared to the standard tension-free vaginal tape (TVT) approach over a five years period [313].

Ten years data are available from a RCT of TVT, xenograft and autologous fascial slings. Dry rates were 31.7%, 50.8% and 15.7% at ten years, for TVT, autologous and Pelvicol™ fascial slings, respectively, down from 55%, 48% and 22% measured at one year follow-up. Re-operation rates at ten years were 3.2% in the TVT group, none in the autologous fascial sling arm and 13.1% in the Pelvicol group [314]. Satisfaction rates were 69.3%, 70.1%, 52.6% for TVT, autologous and Pelvicol fascial slings, respectively.

Long-term results of a RCT comparing TVT vs. inside-out trans-obturator tape (TOT) showed a 79.3% and a 69.4% objective cure rate at 95 months, however patient-reported cure rates were 74.1% and 61.3%, respectively. The long-term complication rates for TVT and TVT-O were 43.1% and 27.4% respectively ( $p=0.07$ ). [315].

#### *Surgery in obese women*

There is no agreement as to the outcome of incontinence surgery in obese women. Secondary analysis of a RCT on retropubic and transobturator tapes in the treatment of women with SUI suggests that obese women experience inferior outcome compared to non-obese women. Stratification of patients according to BMI ( $< 30$  and  $\geq 30$ ) shows significant difference in objective dry rates (negative pad test) at one (85.6% vs. 67.8%) and five years (87.4% vs. 65.9%) and subjective cure (absence of SUI symptoms) at one (85.8% vs. 70.7%) and five years (76.7% vs. 53.6%, respectively). Between one and five years, 6.7% and 16.3% of patients initially dry (negative pad test) after surgery developed a positive pad test, respectively [316, 317].

Conversely, short-term outcome of single-incision MiniArc sling showed comparable objective cure rates (negative cough stress test) at two years (86% and 81% in non-obese and obese women, respectively); similar improvement of the Urinary Distress Inventory 6 and Incontinence Impact questionnaire 7 was observed in non-obese and obese women [318].

#### *Long-term outcome of MUS ( $\geq 5$ years)*

Long-term follow-up of MUS is rarely available from RCTs and more often from cohort studies. Evaluation of the long-term (nine years) outcome of the E-TOT study using postal questionnaires showed a 71.6% patient-reported success rate (very/much improved) on the Patient's Global Impression of Improvement (PGI-I) scale. The nine-years success rates are lower than observed in the first year (80%) but comparable with the three-year follow-up (73.1%). Overall, 8% of patients had re-do surgery, tape extrusion/erosion rate was 4.5%, and groin pain/discomfort was reported in 4.32%, with only 1.4% requiring treatment [319].

Long-term efficacy of transobturator mid-urethral slings was confirmed by the ten-year follow-up of a large patient cohort with 92% cure rate (160 of 168 implanted patients were available for evaluation). *De novo* OAB developed in 14% of patients at ten years. History of failure of previous anti-incontinence procedures was the only predictor of recurrence of SUI (hazard ratio: 5.34; 95% CI: 2.61–11.9;  $p = 0.009$ ) [320].

Long-term follow-up of patients treated with TVT showed a sustained response with 95.3%, 97.6%, 97.0% and 87.2% of patients being cured or improved at 5, 7, 11 and 17 years, respectively [321].

Another long-term cohort study of retropubic tension-free vaginal tape showed a 89.9% objective cure rate, a 76.1% subjective cure rate at ten years. Overall, 82.6% of patients reported to be highly satisfied with the surgery [322].

#### *Insertion using a skin-to-vagina direction vs. a vagina-to-skin direction*

A Cochrane review of MUS operations for female SUI showed no difference in the short and medium-term

subjective cure rates in medial-to-lateral vs. lateral-to-medial approaches based on moderate quality evidence [310]. Voiding dysfunction seems to be more frequent in the medial-to-lateral group but this approach is associated with a lower frequency of vaginal perforations (RR 0.25, 95% CI: 0.12-0.53; 3 trials). Because of the low quality of the evidence it is unclear whether the lower frequency of vaginal perforations of the medial-to-lateral approach is responsible for the observed lower rate of vaginal tape erosions.

A meta-analysis of RCTs demonstrated no significant difference in efficacy between lateral-to-medial vs. medial-to-lateral approaches, but vaginal perforations were less frequent in the medial-to-lateral group (2.6% vs. 11.8%, OR: 0.21,  $p = 0.0002$ ) [323].

The five-year data of a prospective, non-randomised study of the two techniques showed a very high objective success rate (82.6 vs. 82.5%, respectively) with no difference between the two approaches [324].

In a secondary analysis of the E-TOT study (a study of transobturator tension-free vaginal tapes in the treatment of women with urodynamic MUI), no difference in the patient-reported success rates was found between the inside-out and the outside-in groups (63.2% and 65.5%, respectively; OR 1.11, 95% CI: 0.33-3.70,  $P > 0.999$ ) at 9 years follow-up [325].

#### 4.3.1.2 Adjustability

##### 4.3.1.2.1 Questions

- In women with SUI, does an adjustable sling cure SUI and improve QoL or does it cause adverse outcome(s)?
- How does an adjustable sling compare with other surgical treatments for SUI?

##### 4.3.1.2.2 Evidence

There are no RCTs investigating outcome of adjustable sling insertion for women with SUI. There are limited data from cohort studies on adjustable tension slings with variable selection criteria and outcome definitions. Few studies include sufficient numbers of patients or have a long enough follow-up to provide useful evidence. The available devices have differing designs, making it difficult to draw general conclusions about adjustable slings as a class of procedure.

#### 4.3.1.3 Single-incision slings

##### 4.3.1.3.1 Questions

- In women with SUI, do single-incision slings cure UI or improve QoL, or cause adverse outcomes?
- How does a single-incision sling compare to other surgical treatments for SUI?

##### 4.3.1.3.2 Evidence

Although there have been many studies published on single-incision devices, it should be noted that there are significant differences in technical design between devices and it may be misleading to make general statements about them as a class of operations. It should also be noted that some devices have been withdrawn from the market (e.g. TVT Secur<sup>®</sup>, Minitape, MiniArc<sup>®</sup>), and yet evidence relating to these may be included in current meta-analyses. There was evidence to suggest single-incision slings are quicker to perform and cause less post-operative thigh pain, but there was no difference in the rate of chronic pain. There was insufficient evidence for direct comparisons between single-incision slings, and reach any conclusions about differences.

The most recent meta-analyses [326, 327] and a re-analysis of the Cochrane review data by the Panel (excluding TVT Secur<sup>®</sup> data) have demonstrated that there was no difference in efficacy between available single-incision devices and conventional mid-urethral slings at one year. However, not all single-incision devices have been subjected to RCT evaluation and it may be unsafe to assume that they are collectively technically similar devices.

#### *Generalisability of evidence to adult women with SUI*

Analysis of the population studied in trials included in this meta-analysis suggests that the evidence is generalisable to women who have predominantly SUI, and no other clinically severe LUT dysfunction. The evidence is not adequate to guide choice of surgical treatment for those women with MUI, severe POP, or a history of previous surgery for SUI. The results of the EAU Panel meta-analysis [328] were consistent with those of the Cochrane SR [329], except that in the EAU Panel meta-analysis the objective cure rates appeared slightly higher for retropubic (88%) compared to transobturator insertion (84%). The EAU Panel finding is consistent with an additional SR and meta-analysis [330] and the difference may result from the Panel's decision to only consider trial data with at least twelve months of follow-up.

### Sexual function after mid-urethral tape surgery

A SR of the effect of female sexual function following mid-urethral slings suggested contradictory results, overall more papers show an improvement, or no change, in sexual function because of a reduction in coital incontinence, anxiety and avoidance of sex. Dyspareunia was the most common cause of worsening of sexual life [331].

A meta-analysis of outcome measures in trials of sling procedures suggests that single-incision slings are associated with a significantly higher improvement in sexual life compared to standard mid-urethral procedures [332].

### SUI surgery in the elderly

An RCT of 537 women comparing retropubic to transobturator tape, showed that increasing age was an independent risk factor for failure of surgery over the age of 50 [333]. An RCT assessing risk factors for the failure of TVT vs. transobturator tension-free vaginal tape (TVT-O) in 162 women found that age is a specific risk factor (adjusted OR 1.7 per decade) for recurrence at one year [334]. In a sub-analysis of a trial cohort of 655 women at 2 years' follow-up, it was shown that elderly women were more likely to have a positive stress test at follow-up (OR 3.7, 95% CI: 1.7-7.97), are less likely to report objective or subjective improvement in stress and urgency UI, and are more likely to undergo re-treatment for SUI (OR 3.9, 95% CI: 1.3-11.48). There was no difference in time to post-operative normal voiding [335].

Another RCT comparing immediate TVT vs. no surgery (delayed TVT) in older women, confirmed efficacy of surgery in terms of QoL and satisfaction, but with complications in the surgical arm [336].

A cohort study evaluating 181 women undergoing TVT-O surgery, found that women over 70 years had similar outcomes when compared to women under 70 years old in terms of cure rates (92.5% vs. 88.3%  $p = 0.40$ ), voiding dysfunction, vaginal erosion and groin pain at a median follow-up of 24 months [337].

A SR of the efficacy of treatments of UI in older patients suggests that MUS are successful in older patients ( $\geq 65$  years) with 5.2-17.6% reporting persistent SUI after surgery. No difference in the frequency of *de novo* UUI, persistent UUI and persistent SUI was found in older patients [338].

#### 4.3.1.3.3 Summary of evidence for mid-urethral slings

Summary of evidence	LE
The retropubic MUS provides equivalent patient-reported subjective and objective cure of SUI, compared with colposuspension.	1a
Mid-urethral synthetic slings inserted by either the transobturator or retropubic route provide equivalent patient-reported outcome at five years.	1a
Mid-urethral synthetic slings inserted by the retropubic routes has higher objective patient-reported cure rates at 8 years.	1b
Long-term analyses of MUS cohorts showed a sustained response beyond ten years.	2b
The retropubic route of insertion is associated with a higher intra-operative risk of bladder perforation and a higher rate of voiding dysfunction than the transobturator route.	1a
The transobturator route of insertion is associated with a higher risk of groin pain than the retropubic route.	1a
Long-term analysis showed no difference in terms of efficacy for the skin-to-vagina compared to vagina-to-skin directions up to nine years.	2a
The top-to-bottom direction in the retropubic approach is associated with a higher risk of post-operative voiding dysfunction.	1b
Adjustable mid-urethral synthetic sling devices may be effective for cure or improvement of SUI in women.	3
There is no evidence that adjustable slings are superior to standard MUS.	4
The comparative efficacy of single-incision slings against conventional MUS is uncertain.	1b
Operation times for insertion of single-incision MUS are shorter than for standard retropubic slings.	1b
Blood loss and immediate post-operative pain are lower for insertion of single-incision slings compared with conventional mid-urethral slings.	1b
There is no evidence that other adverse outcomes from surgery are more or less likely with single-incision slings than with conventional MUS.	1b
Incontinence surgery has similar outcomes in older patients ( $\geq 65$ years).	2a

The risk of failure from surgical repair of SUI, or suffering adverse events, appears to increase with age.	2
There is no evidence that any surgical procedure has greater efficacy or safety in older women than another procedure.	4
Incontinence surgery may be safely performed in obese women, however, outcomes may be inferior.	2b
In women undergoing surgery for SUI, coital incontinence is likely to improve.	3
Overall, sexual function is unlikely to deteriorate following SUI surgery.	2a
Improvement in sexual life is higher with single incision slings than with standard MUS.	1a

*MUS = mid-urethral sling; SUI = stress urinary incontinence; TVT = tension-free vaginal tape.*

*NB: Most evidence on single-incision slings is from studies using the tension-free vaginal tape secure (TVT-S) device and although this device is no longer available, many women still have the device in place.*

#### 4.3.1.4 Open and laparoscopic surgery for stress urinary incontinence

Open colposuspension was previously considered the most appropriate surgical intervention for SUI, and was used as the comparator in RCTs of newer, less invasive, surgical techniques. These include laparoscopic techniques, which have enabled colposuspension to be performed with a minimally invasive approach.

##### 4.3.1.4.1 Question

In women with SUI, what is the effectiveness of open and laparoscopic surgery, compared to other surgical procedures, measured in terms of cure or improvement of incontinence or QoL, or the risk of adverse events?

##### 4.3.1.4.2 Evidence

Four SRs were found, which covered the subject of open surgery for SUI, including 46 RCTs [2, 339-341]. Risk of re-operation for Burch colposuspension is estimated to 6% within 5 years [342] and 10.8% (95% CI: 9.3–12.3) within 9 years [343].

##### *Open colposuspension*

The Cochrane review [308] included 55 trials in which 5,417 women had open colposuspension. In most of these trials, open colposuspension was used as the comparator to an experimental procedure. Consequently, for this review we have only considered the absolute effect of colposuspension, but have not reviewed all of these comparisons. No additional trials have been reported since this review.

Within the first year, complete continence rates of approximately 85-90% were achieved for open colposuspension, while failure rates for UI were 17% up to five years and 21% over five years. The re-operation rate for UI was 2%. Colposuspension was associated with a higher rate of development, at five years, of enterocele/vault/cervical prolapse (42%) and rectocele (49%) compared to TVT (23% and 32%, respectively) but with a lower risk of voiding dysfunction compared to sling surgery. The rate of cystocele was similar in colposuspension (37%) and with TVT (41%). The Cochrane review concluded that open colposuspension is an effective treatment for SUI and 70% of women can expect to be dry at five years after surgery.

##### *Autologous fascial sling*

The Cochrane review [340, 344] described 26 RCTs, including 2,284 women undergoing autologous sling procedure in comparison to other operations [345].

There were seven trials of autologous fascial sling vs. colposuspension. Except for one very high-quality study [52] showing superiority of fascial sling, most of the studies were of variable quality, with a few very small studies and short follow-up. The meta-analysis showed that fascial sling and colposuspension had a similar cure rate at one year. Colposuspension had a lower risk of voiding difficulty and UTIs, but a higher risk of bladder perforation.

In twelve trials of autologous fascial sling vs. mid-urethral synthetic slings, the procedures showed similar efficacy. However, use of the synthetic sling resulted in shorter operating times and lower rates of complications, including voiding difficulty. Six trials compared autologous fascial slings with other materials of different origins, with results favouring traditional autologous fascial slings. *Post-hoc* analysis of an RCT comparing the autologous fascial sling to Burch colposuspension showed inferior outcomes for women who suffered pre-operative urgency [335].



### Laparoscopic colposuspension

The Cochrane review reported on twelve trials comparing laparoscopic colposuspension to open colposuspension. Although these procedures had a similar subjective cure rate, there was limited evidence suggesting the objective outcomes were less good for laparoscopic colposuspension. However, laparoscopic colposuspension had a lower risk of complications and shorter duration of hospital stay and may be slightly more cost-effective when compared with open colposuspension after 24 months follow-up.

In eight RCTs comparing laparoscopic colposuspension to MUS, the subjective cure rates were similar, while the objective cure rate favoured the mid-urethral sling at eighteen months. Complication rates were similar for the two procedures and operating times were shorter for the MUS. Comparisons of colposuspension to mid-urethral sling are covered in section 4.3.1.1.

Single-port laparoscopic Burch can be an alternative treatment for scarless surgery, though data confirming efficacy is limited [346].

#### 4.3.1.4.3 Summary of evidence for open and laparoscopic surgery for stress urinary incontinence

Summary of evidence	LE
Autologous fascial sling is more effective than colposuspension for improvement of SUI.	1b
Autologous fascial sling has a higher risk of operative complications than open colposuspension, particularly voiding dysfunction and post-operative UTI.	1b
Colposuspension is associated with a higher long-term risk of POP than MUS.	1a
Laparoscopic colposuspension has a shorter hospital stay and may be more cost-effective than open colposuspension.	1a

POP = pelvic organ prolapse; SUI = stress urinary incontinence ; UTI = urinary tract infection.

#### 4.3.1.5 Bulking agents

The concept of this procedure originates from the idea that intra or periurethral injection of an agent able to solidify under the submucosa or around the urethra, respectively, will form artificial cushions which increase the resistance to urine flow and facilitate continence.

##### 4.3.1.5.1 Question

In women with SUI, does injection of a urethral bulking agent cure SUI or improve QoL, or cause adverse outcomes?

##### 4.3.1.5.2 Evidence

A Cochrane review identified 14 randomised or quasi-randomised controlled trials of treatment for urinary incontinence in which at least one management arm involved periurethral or transurethral injection therapy [347]. Following this review, five additional reviews investigated the effect of injectables for the treatment of female SUI [348-352] but one review included results from RCTs only [352], independently of the injected material. Altogether, 1,814 patients were included from fourteen trials of seven different types of intraurethral injection: glutaraldehyde cross-linked collagen (Contigent<sup>®</sup>), a porcine dermal implant (Permacol<sup>®</sup>), solid silicone elastomer (Macroplastique<sup>®</sup>), autologous fat, pyrolytic carbon (Durasphere<sup>®</sup>), calcium hydroxylapatite (Coaptite<sup>®</sup>), hydrogel (Bulkamid<sup>®</sup>) and dextran polymer (Zuidex<sup>®</sup>). The heterogeneity of the populations, the variety of materials used and the lack of long-term follow-up limit guidance of practice. Most of the studies show a tendency for a short-term improvement in urinary incontinence, with the exception of a RCT which could not find difference between saline and fat injection [353]. The short-term analysis from the RCT does not give information about the effect of repeated injections.

A recent SR of 26 studies with 12 months follow-up showed objective success rates using urodynamics, 24-h pad tests, cough tests and voiding diaries ranging from 25.4% to 73.3%. A SR of 23 studies using Macroplastique<sup>®</sup> including 958 patients showed 75% improvement and 43% dry patients at less than 6 months but 64% improvements and 36% cures at more than 18 months [349]. A review of 514 elderly women with SUI treated with various agents showed a reduced pad weight in 73% at one year follow-up independently of the material injected [354]. Proximal urethral injection showed better outcome than mid-urethral injections [355]. Intra-urethral injections or peri-urethral injections produce similar outcomes, although the latter is associated with a higher risk of temporary urinary retention [347]. One study treated patients who had received radiotherapy with injection of Bulkamid<sup>®</sup> and reported around 25% cure at short term follow-up [356].

Bulking agent injection is safe, the most frequent adverse event being UTI. However, autologous fat or hyaluronic acid should not be used due to the risk of fatal embolism and local abscess formation, respectively [347, 352].

#### *Comparison with open surgery*

Two RCTs compared collagen injection to conventional surgery for SUI (autologous sling vs. silicon particles and collagen vs. other surgical procedures/bulking agents). The studies reported greater efficacy but higher complication rates for open surgery. In comparison, collagen injections showed inferior efficacy but equivalent levels of satisfaction and fewer serious complications [53, 357].

Another trial found that a peri-urethral route of injection can carry a higher risk of urinary retention compared to a transurethral injection [358]. A recent small RCT found no difference in efficacy between mid-urethral and bladder neck injection of collagen [359].

#### 4.3.1.5.3 Summary of evidence for bulking agents

Summary of evidence	LE
Peri-urethral injection of bulking agent may provide short-term improvement and cure (twelve months), in women with SUI.	1b
Bulking agents are less effective than colposuspension or autologous sling for cure of SUI.	1b
Autologous fat and hyaluronic acid as bulking agents have a higher risk of adverse events.	1a
Adverse effect rates are lower compared to open surgery.	2a
There is no evidence that one type of bulking agent is better than another type.	1b
The peri-urethral route of injection of bulking agents may be associated with a higher risk of urinary retention compared to the transurethral route.	2b

#### 4.3.1.6 Recommendations for women with uncomplicated stress urinary incontinence

Recommendations	Strength rating
Offer a MUS to women with uncomplicated SUI	Strong
Inform women of the unique complications associated with each individual procedure.	Strong
Inform women who are being offered a single-incision sling that long-term efficacy remains uncertain.	Strong
Inform women undergoing colposuspension that there is a longer duration of surgery, hospital stay and recovery, as well as a high risk of development of pelvic organ prolapse and voiding dysfunction post-operatively.	Strong
Inform older women with SUI about the increased risks associated with surgery, including the lower probability of success.	Weak
Inform women that any vaginal surgery may have an impact on sexual function, which is generally positive.	Weak
Only offer new devices, for which there is no level 1 evidence base, as part of a structured research programme.	Strong
Only offer adjustable MUS as a primary surgical treatment for SUI as part of a structured research programme.	Strong
Offer bulking agents to women with SUI who request a low-risk procedure with the understanding that repeat injections are likely and long-term durability is not established.	Strong

MUS = mid-urethral sling; SUI = stress urinary incontinence.

#### 4.3.2 Complicated stress urinary incontinence in women

This section will address surgical treatment for women who have had previous surgery for SUI, which has failed, or those women who have undergone previous radiotherapy affecting the vaginal or urethral tissues. Neurogenic LUT dysfunction is reviewed by the EAU Guidelines on Neuro-Urology [2]. Women with associated genitourinary prolapse are included in this edition (see section 4.3.3).

##### 4.3.2.1 Colposuspension or sling following failed surgery

There may be persistent or recurrent SUI, or the development of *de novo* UUI. This means that careful evaluation including urodynamics becomes an essential part of the work-up of these patients.



#### 4.3.2.1.1 Question

In women who have had failed surgery for SUI, what is the effectiveness of any second-line operation, compared to any other second-line operation, in terms of cure or improvement of UI, QoL or adverse events?

#### 4.3.2.1.2 Evidence

Most of the data on surgery for SUI refer to primary operations. Even when secondary procedures have been included, it is unusual for the outcomes in this subgroup to be separately reported. When they are, the numbers of patients is usually too small to allow meaningful comparisons.

The 4<sup>th</sup> International Consultation on Incontinence includes a review of this topic [1] up to 2008, and the subject has also been reviewed by Ashok [360] and Lovatsis *et al.* [361]. A further literature review has been carried out since that time by the Panel.

Cochrane reviews of individual operative techniques have not included separate evaluation of outcomes in women undergoing second-line surgery. However, there is a current protocol to address this issue [362]. Only one RCT was found (abstract only) comparing TVT to laparoscopic colposuspension in women with recurrent SUI. This small study found similar cure rates and adverse events in the short term for both procedures [363].

*Post-hoc* subgroup analysis of high-quality RCTs comparing one procedure to another have shown conflicting evidence of relative effectiveness [78, 335, 364, 365]. One large non-randomised comparative series suggested that cure rates after more than two previous operations were 0% for open colposuspension and 38% for fascial sling [366].

Several cohort studies have reported outcomes for TVT specifically for primary and secondary cases. Evidence on the effectiveness of second-line retropubic tapes conflicts with some series showing equivalent outcomes for primary and secondary cases [367, 368], whilst other research has shown inferior outcomes for secondary surgery [369, 370]. Other confounding variables make meaningful conclusions difficult.

Systematic review of older trials of open surgery for SUI suggest that the longer-term outcomes of redo open colposuspension may be poor compared to autologous fascial slings [371]. Successful results have been reported from mid-urethral slings after various types of primary surgery, while good outcomes are reported for both repeat TVT and for 'tightening' of TVT, but data are limited to small case series only.

Systematic meta-analysis of retropubic (TVT) vs. transobsturator (TOT) MUS in the treatment of recurrent SUI showed no difference in terms of patient-reported or objective cure/improvement after a mean follow-up of eighteen months. In one RCT no difference between Burch colposuspension and TVT could be observed in either patient-reported or objective cure/improvement rates [372].

A large cohort study (112 pts) of mid-urethral slings for recurrent SUI showed an overall subjective success rate (cured/improved) of 76.8% at 21 months with no significant differences between the retropubic and transobturator routes [373].

#### 4.3.2.1.3 Summary of evidence for colposuspension or sling following failed surgery for stress urinary incontinence

Summary of evidence	LE
There is conflicting evidence whether prior surgery for SUI or prolapse results in inferior outcomes from repeat operations for SUI.	2
Most procedures will be less effective when used as a second-line procedure.	2
In women who have had more than two procedures for SUI, the results of open colposuspension are inferior to autologous fascial sling.	2
Tension-free vaginal tape (TVT) and TOT have similar outcomes in patients with recurrent SUI.	1a
Burch colposuspension has similar patient-reported or objective cure rates when compared to TVT.	1b

SUI = stress urinary incontinence; TOT = trans-obturator tape; TVT = tension-free vaginal tape.

#### 4.3.2.2 External compression devices

External compression devices are still widely used in the treatment of recurrent SUI after the failure of previous surgery and if there is thought to be profound intrinsic failure of the sphincter mechanism, characterised by very low leak point pressures or low urethral closure pressures. This should be confirmed by urodynamic evaluation.

The two intracorporeal external urethral compression devices available are the adjustable compression therapy (ACT<sup>®</sup>) device and the artificial urinary sphincter (AUS). Using ultrasound or fluoroscopic guidance, the ACT<sup>®</sup> device is inserted by placement of two inflatable spherical balloons on either side of the bladder neck. The volume of each balloon can be adjusted through a subcutaneous port placed within the labia majora. More recently, an adjustable artificial urinary sphincter (Flowsecure<sup>™</sup>) has been introduced. It has the potential added benefit of 'conditional occlusion', enabling it to respond to rapid changes in intra-abdominal pressure.

##### 4.3.2.2.1 Questions

- In women with SUI, does insertion of an external compressive device cure SUI, improve QoL or cause adverse outcomes?
- How do external compression devices compare to other surgical treatments for SUI?

##### 4.3.2.2.2 Evidence

The major advantage of AUS over other anti-incontinence procedures is the perceived ability to be able to void normally [115]. However, voiding dysfunction is a known side effect, with a lack of data making it difficult to assess its importance. Because of significant differences in design between devices and in selection criteria between case series, results obtained with specific devices cannot be extrapolated generally to the use of adjustable devices. A recent consensus report has standardised the terminology used for reporting complications arising from implantation of materials into the pelvic floor region [20].

##### *Artificial urinary sphincter (AUS)*

A previous review of mechanical devices concluded that there was insufficient evidence to support the use of AUS in women [374].

There are a few case series in women, including four series (n = 611), with study populations ranging from 45 to 215 patients and follow-up ranging from one month to 25 years [375-378]. Case series have been confounded by varying selection criteria, especially the proportion of women who have neurological dysfunction or who have had previous surgery. Most patients achieved an improvement in SUI, with reported subjective cures in 59-88%. Common side effects included mechanical failure requiring revision (up to 42% at ten years) and explantation (5.9-15%). In a retrospective series of 215 women followed up for a mean of six years, the risk factors for failure were older age, previous Burch colposuspension and pelvic radiotherapy [378]. Peri-operative injury to the urethra, bladder or rectum was also a high-risk factor for explantation [376].

A newly introduced artificial sphincter using an adjustable balloon capacity through a self-sealing port, and stress responsive design, has been introduced to clinical use. A series of 100 patients reported 28% explantation at four years but the device has undergone redesign and more up-to-date evidence is awaited [379]. Early reports of laparoscopically implanted AUS do not have sufficient patient populations and/or sufficient follow-up to be able to draw any conclusions [380, 381].

##### *Adjustable compression device (ACT<sup>®</sup>)*

There are four case series (n = 349), with follow-up ranging from five to 84 months [382-385]. Reported outcome ranged from 47% objective cure to 100% subjective improvement. However, most patients required adjustment to achieve continence and 21% required explantation.

##### 4.3.2.2.3 Summary of evidence for external compression devices

Summary of evidence	LE
Implantation of an artificial sphincter can improve or cure incontinence in women with SUI caused by sphincter insufficiency.	3
Implantation of the adjustable compression therapy (ACT <sup>®</sup> ) device may improve complicated UI.	3
Complications, mechanical failure and device explantation often occur with both the artificial sphincter and the ACT <sup>®</sup> .	3
Explantation is more frequent in older women and among those who have had previous Burch colposuspension or pelvic radiotherapy.	3

### 4.3.2.3 Recommendations for complicated stress urinary incontinence

Recommendations	Strength rating
Management of complicated SUI should only be offered in expert** centres.	Weak
The choice of surgery for recurrent SUI should be based on careful evaluation of the individual patient including multichannel urodynamics and imaging as appropriate.	Weak
Inform women with recurrent SUI that the outcome of a surgical procedure, when used as a second-line treatment, is generally inferior to its use as a first-line treatment, both in terms of reduced efficacy and increased risk of complications.	Weak
Consider secondary synthetic sling, colposuspension or autologous sling as first options for women with complicated SUI.	Weak
Inform women receiving AUS or ACT® that although cure is possible, even in expert centres, there is a high risk of complications, mechanical failure or a need for explantation.	Weak

ACT® = Adjustable compression device; AUS = artificial urinary sphincter; SUI = stress urinary incontinence; UI = urinary incontinence.

\*\* Expert centres refers to the comments on surgeon volume in the introduction to the surgical chapter.

### 4.3.3 Women with both stress urinary incontinence and pelvic organ prolapse

There is a clear association between the presence of POP and SUI. Although the subject of prolapse is not part of the remit of these Guidelines, the extent to which it impacts on the management of SUI will be addressed. The aim is to assess the options available to women who require surgery for POP and who have associated UI (either symptomatic or after reduction of prolapse), and to assess the value of prophylactic anti-incontinence surgery in women with no evidence of UI.

#### 4.3.3.1 Questions

1. In women with POP and UI, does combined surgery for POP and SUI reduce the incidence of post-operative UI compared to POP surgery alone?
2. In continent women with POP, does combined surgery for POP and SUI reduce the incidence of post-operative *de novo* UI compared to POP surgery alone?
3. In women with POP and occult SUI, (i.e. seen only on prolapse reduction stress testing/urodynamics), does combined surgery for POP and SUI reduce the incidence of post-operative UI compared to POP surgery alone?
4. In women with POP and OAB, does surgery for POP improve OAB symptoms?
5. In adults with POP, what is the reliability, the diagnostic accuracy and predictive value of a prolapse reduction test to identify patients at risk from *de novo* SUI following prolapse repair?

#### 4.3.3.2 Evidence

A Cochrane review in 2013 included sixteen trials concerning bladder function after surgery for pelvic organ prolapse [386]. After prolapse surgery 434 of 2,125 women (20.4%) reported new subjective SUI, in sixteen trials. New voiding dysfunction was reported in 109 of 1,209 (9%) women, in twelve trials. A recent SR and meta-analysis assessing prolapse surgery with or without stress incontinence surgery found that combination surgery reduces the risk of post-operative SUI, but short-term voiding difficulties and adverse events were more frequent after combination with a MUS [387].

1. In women with POP does combined surgery for POP and SUI reduce the incidence of post operative UI compared to POP surgery alone?

In summary, it is difficult to generalise the results of trials using very different procedures to treat both POP and UI. It seems that with a combined procedure the rate of SUI post-operatively is lower. Studies using mid-urethral slings have generally shown more significant differences in UI outcomes with combined procedures than when other types of anti-incontinence procedure have been used. Individual patient characteristics may play the most important role in shaping treatment decisions. It must be taken into account that, although more women may be dry after combined surgery, the risks of repeat surgery, should it become necessary, may outweigh the potential benefits.

There are two well-designed RCTs relating to the prevalence of post-operative SUI in women (continent or incontinent) who underwent prolapse surgery with and without an anti-incontinence procedure. Both of these trials involved women with POP who did not complain of symptoms of SUI regardless of objective findings.

One trial compared abdominal sacrocolpopexy with and without Burch colposuspension [363], the other compared vaginal repair with and without a mid-urethral sling [364]. In both trials addition of anti-

incontinence surgery reduced the risk of SUI at twelve months. In one trial there was a higher rate of adverse events reported in the combined surgery group [364]. This was also the finding of the Cochrane review and meta-analysis.

The most recent RCT by van der Ploeg including 7 trials found that significantly more women in the combined therapy group reported the absence of post-operative SUI [387]. They concluded that women undergoing POP surgery should be counselled about the possibility of combination surgery. They should know that there is strong evidence that post-operative SUI is less frequent after combining prolapse and anti-incontinence surgery relative to prolapse surgery only. However, the number needed to treat to prevent one SUI is probably considerable. The rate of adverse events is likely to be higher with combined surgery. Further evaluation was undertaken according to subgroups (with or without UI prior to surgery).

#### Women with POP and SUI

Three trials addressed post-operative SUI in patients who had SUI pre-operatively. Borstad *et al.*, in a multicentre trial, randomised women with POP and SUI to have a TVT at the time of prolapse repair or three months later, if they still had SUI (n = 53). One year after surgery there was no difference between the groups regarding continence; however, 44% of the women without initial TVT never required surgery and 29% were dry [388].

In contrast, Costantini *et al.* followed-up women with POP and SUI randomised to abdominal POP repair with or without Burch colposuspension (after a median of 97 months), finding that additional SUI surgery did not improve outcome [389]. On the contrary, a higher number of patients had *de novo* storage symptoms when a Burch colposuspension was performed.

The most recent RCT by van der Ploeg *et al.* found that more women in the combined therapy group reported the absence of UI (62% vs. 30%) and SUI (78% vs. 39%) [390]. Seventeen percent of women undergoing POP surgery alone required an additional MUS. Severe complications were more common in the MUS group 16% vs. POP surgery only 6%.

#### 2. Women with POP asymptomatic for SUI

A pooled analysis of all studies (5) in continent women shows a reduction in both objective and subjective post-operative SUI after combined surgery with a reduced need for subsequent anti-incontinence surgery [387]. The number needed to treat (NNT) was six to prevent one woman developing *de novo* subjective SUI after POP repair, and 20 to prevent one woman undergoing an additional MUS.

#### 3. Women with POP and occult SUI

A recent RCT by van der Ploeg *et al.* found addressing occult incontinence found that women with occult SUI had a higher risk of reporting SUI after POP surgery than women without occult SUI [391]. Thirteen percent of women undergoing POP surgery alone needed an additional MUS. This is in line with the outcomes reported in the earlier SR. The NNT to prevent one woman with occult SUI from developing *de novo* subjective SUI after POP repair was three [387].

#### 4. Women with POP and OAB

There are three case series evaluating patients with concomitant OAB and pelvic organ prolapse which assess incontinence/OAB symptom scores post-surgical repair. Costantini *et al.* assessed the effect of posterior repair on OAB/DO and reported a 70-75% improvement rate in both parameters along with a 93% anatomic success rate [392]. Kummeling *et al.* assessed the effect of a modified laparoscopic sacrocolpopexy on urodynamic parameters and reported an improvement with no evidence to support a concomitant prophylactic colposuspension [393]. Lee *et al.* assessed the value of pre-operative urodynamic study and bladder outlet obstruction index (BOOI) in predicting the degree of OAB symptoms post anterior prolapse repair. They reported a significant correlation between low pre-operative BOOI and improvement in OAB symptom scores post-operative [394].

#### 5. Prolapse reduction stress test (PRST)

Data concerning PRST were made available from the CARE trial, where significant differences were noted in the detection of urodynamic stress incontinence with prolapse reduction among the various methods studied, ranging from 6% (pessary) to 30% (speculum). Manual, swab and forceps showed detection rates of 16%, 20% and 21%, respectively [395]. In the study by Duecy, about one third of women were diagnosed with occult SUI using a pessary while two thirds were diagnosed with manual reduction of the prolapse [396]. In a further study occult SUI was only detected by a pessary test in 19% of patients, not by urodynamics, history or clinical examination [397].

#### 4.3.3.3 Summary of evidence for women with both stress urinary incontinence and pelvic organ prolapse

Summary of evidence	LE
<b>Women with pelvic organ prolapse and urinary incontinence</b>	
Surgery for pelvic organ prolapse (POP) + SUI shows a higher rate of cure of UI in the short term than POP surgery alone.	1a
There is conflicting evidence on the relative long-term benefit of surgery for POP + SUI vs. POP surgery alone.	1a
Combined surgery for POP + SUI carries a higher risk of adverse events than POP surgery alone.	1a
<b>Continent women with pelvic organ prolapse</b>	
Are at risk of developing UI post-operatively.	1a
The addition of a prophylactic anti-incontinence procedure reduces the risk of post-operative UI.	1a
The addition of a prophylactic anti-incontinence procedure increases the risk of adverse events.	1a
<b>Women with pelvic organ prolapse and overactive bladder</b>	
There is some low-level inconsistent evidence to suggest that surgical repair of POP can improve symptoms of overactive bladder.	2

#### 4.3.3.4 Recommendations for women with both stress urinary incontinence and pelvic organ prolapse

Recommendations for women requiring surgery for bothersome pelvic organ prolapse who have symptomatic or unmasked SUI	Strength rating
Offer simultaneous surgery for pelvic organ prolapse and SUI.	Strong
Inform women of the increased risk of adverse events with combined surgery compared to prolapse surgery alone.	Strong
<b>Recommendations for women requiring surgery for bothersome pelvic organ prolapse who do not have symptomatic or unmasked SUI</b>	
Inform women that there is a risk of developing <i>de novo</i> SUI after prolapse surgery.	Strong
Warn women that the benefit of surgery for SUI may be outweighed by the increased risk of adverse events with combined surgery compared to prolapse surgery alone.	Strong

POP = pelvic organ prolapse; SUI = stress urinary incontinence; UI = urinary incontinence.

#### 4.3.4 Urethral diverticulum

A female urethral diverticulum is a sac-like protrusion made up by the entire urethral wall or only by the urethral mucosa situated between the periurethral tissues and the anterior vaginal wall. Urethral diverticula give rise to a variety of symptoms that include pain, urgency, frequency, recurrent UTIs, vaginal discharge, dyspareunia, voiding difficulties or urinary incontinence.

##### 4.3.4.1 Question

In a woman with the clinical suspicion of having a urethral diverticulum, what is the best test to confirm the diagnosis?

##### 4.3.4.2 Evidence

No robust diagnostic accuracy studies address this question. However, a case series of 27 patients concluded that endoluminal (vaginal or rectal) MRI has better diagnostic accuracy than voiding cystourethrography (VCUG) [398]. In a case series of 60 subjects Pathi, *et al.* reported that the sensitivity, specificity, positive predictive value and negative predictive value of MRI is 100%, 83%, 92% and 100%, respectively [399]. Dwarkasing *et al.* also reports 100% specificity and sensitivity of MRI in a case series of 60 patients [400]. However, in a case series of 41 patients, a study reported 25% discrepancy between MRI and surgical findings [401].

##### 4.3.4.3 Question

In a woman who has a bothersome urethral diverticulum, what is the relative effectiveness of available surgical treatments?

##### 4.3.4.4 Surgical treatment

No RCTs were found. Surgical removal is the most commonly reported treatment in contemporary case series. However, recurrence may occur; Han *et al.* found a recurrence rate of 33% in U-shaped and of 60% in circumferential diverticulum within one year [402], Ingber *et al.* found a 10.7% recurrence rate in 122 women

undergoing diverticulectomy, with a higher risk of recurrence in those with proximal or multiple diverticula or after previous pelvic surgery [403]. SUI may occur in up to 20% of women after diverticulectomy, requiring additional correction [404-407]. *De novo* SUI seems to be more common in proximal and in large size (> 30 mm) diverticula.

Diverticula may undergo neoplastic alterations (6%) including invasive adenocarcinomas [408].

#### 4.3.4.5 Summary of evidence and recommendation for urethral diverticulum

Summary of evidence	LE
Magnetic resonance imaging has good sensitivity and specificity for the diagnosis of urethral diverticula; however, there is a risk of misdiagnosis and missing potential intraluminal neoplastic change.	3
Surgical removal of symptomatic urethral diverticula provides good long-term results; however, women should be counselled of the risk of recurrence and <i>de novo</i> SUI.	3

Recommendations	Strength rating
Symptomatic urethral diverticula should be completely surgically removed.	Strong

*SUI = stress urinary incontinence.*

#### 4.3.5 Men with stress urinary incontinence

In men who fail conservative treatment (see chapter 4.1.3.3.5) other treatments can be considered.

##### 4.3.5.1 Drug therapy

Three RCTs suggest an earlier recovery of continence in men receiving duloxetine either alone [409], or in addition to PFMT, for post prostate surgery SUI [410, 411].

##### 4.3.5.1.1 Summary of evidence for drug therapy in men with stress urinary incontinence

Summary of evidence	LE
Duloxetine, either alone or combined with conservative treatment, can hasten recovery of continence but does not improve continence rate following prostate surgery, but can be associated with significant, albeit often transient, side effects.	1b

##### 4.3.5.2 Bulking agents in men

Injection of bulking agents has been used to try and improve the coaptation of a damaged sphincter zone. Initial reports showed limited efficacy in treating incontinence following radical prostatectomy [412, 413].

##### 4.3.5.2.1 Question

In men with post-prostatectomy incontinence or SUI, does injection of a urethral bulking agent cure SUI, improve QoL, or cause adverse outcomes?

##### 4.3.5.2.2 Evidence

Most studies are case series with small sample sizes. Small cohort studies showed a lack of benefit using a number of different materials [414, 415]. However, polyacrylamide hydrogel resulted in limited improvement in QoL without curing the UI [414]. A Cochrane review on the surgical treatment of post-prostatectomy incontinence found only one study that fulfilled the inclusion criteria [416]. A prospective, randomised study compared the AUS to silicone particles (Macroplastique™) in 45 patients. Eighty-two per cent of patients receiving an AUS were continent compared to 46% receiving silicone particles. In patients with severe incontinence, outcome was significantly worse after silicone bulking injection.



#### 4.3.5.2.3 Summary of evidence for bulking agents in men

Summary of evidence	LE
There is no evidence that bulking agents cure post-prostatectomy incontinence.	2a
There is weak evidence that bulking agents can offer temporary, short-term, improvement in QoL in men with post-prostatectomy incontinence.	3
There is no evidence that one bulking agent is superior to another.	3

QoL = quality of life

#### 4.3.5.3 Fixed male sling

In addition to external compression devices and bulking agents, slings have been introduced to treat post-prostatectomy incontinence. Fixed slings are positioned under the urethra and fixed by a retro-pubic or transobturator approach. The tension is adjusted during the surgery and cannot be re-adjusted post-operatively.

For the restoration of continence by these male slings, two concepts are now being proposed:

- continence restoration by urethral compression (InVance<sup>®</sup>, I-stop TOMS<sup>®</sup>);
- continence restoration by repositioning the bulb of urethra (AdVance<sup>®</sup>) [417].

In principle, the AUS can be used for all degrees of post-prostatectomy incontinence, while male slings are advocated for mild-to-moderate UI. However, the definitions of mild and moderate UI are not clear. The definition of cure, used in most studies, was no pad use or one security pad per 24 hours. Some authors used a stricter criterion of less than 2 g urine loss in a 24-hour pad test [418].

##### 4.3.5.3.1 Question

In men with post-prostatectomy SUI, does insertion of a fixed suburethral sling cure SUI, improve QoL, or cause adverse outcomes?

##### 4.3.5.3.2 Evidence

Concerning the surgical treatment of post-prostatectomy incontinence, three recent literature reviews are available [419-421]. There are a large number of uncontrolled case series concerning men implanted with several types of slings [422, 423].

For the repositioning sling (AdVance<sup>®</sup>), the benefit after a mean follow-up of three years has been published on 136 patients [424]. Earlier data were available from other cohort studies, totalling at least 614 patients with a mean follow-up of between three months and three years. Subjective cure rates for the device vary between 8.6% and 73.7%, with a mean of 49.5%. Pelvic radiotherapy was a negative prognostic factor [422]. Post-operative voiding dysfunction occurred in 5.7-1.3%, while erosions and chronic pain were uncommon (0-0.4%) [418, 424-426]. The overall failure rate was about 20%.

The previously available 'InVance<sup>®</sup>' device has now been removed from the market in some countries.

The strategy of intraoperative placement of an autologous vas deferens sling below the vesico-urethral anastomosis during robotic-assisted radical prostatectomy (RARP) has been explored with the intention to improve early return of continence. Two RCTs [427, 428] showed an advantage of sling vs. no sling at one month follow-up, and another study [429] showed an advantage of a 6-branch vs. a 2-branch sling at one month follow-up. However, a larger RCT [n = 195] showed that continence rate and near-continence rate were similar at six months with 66 vs. 65% and 88 vs. 87%, respectively [430].

##### 4.3.5.3.3 Summary of evidence for fixed male sling

Summary of evidence	LE
There is limited short-term evidence that fixed male slings cure or improve post-prostatectomy incontinence in patients with mild-to-moderate incontinence.	3
There is no evidence that intraoperative placement of an autologous sling during RARP improves return of continence at 6 months.	1b
Men with severe incontinence, previous radiotherapy or urethral stricture surgery may have less benefit from fixed male slings.	3
There is no evidence that one type of male sling is better than another.	3

RARP = robotic assisted radical prostatectomy.



#### 4.3.5.4 Adjustable slings in males

Adjustability in male sling surgery attempts to adjust the tension of the sling post-operatively. Three main systems have been used in men: the Remeex<sup>®</sup> system, the Argus<sup>®</sup> system and the ATOMS<sup>®</sup> system.

##### 4.3.5.4.1 Question

In men with post-prostatectomy incontinence or SUI, does insertion of an adjustable suburethral sling cure or improve SUI, improve QoL, or cause adverse outcomes?

##### 4.3.5.4.2 Evidence

There are no RCTs. Most studies consist of prospective or retrospective case series, with variable follow-up and different definitions of success. Some have been published only as conference abstracts. For the Remeex<sup>®</sup> system, only two abstracts, with conflicting findings, have been published. One study followed nineteen patients for nearly seven years and reported 70% success, with no explants, infections or erosions. The second study followed fourteen patients for 25 months. Only 36% of patients were satisfied and multiple re-adjustments were needed. Mechanical failure was reported in 21% [431].

##### *Argus<sup>®</sup> system*

Data on the Argus<sup>®</sup> system has been reported for 404 men, but only four series have reported on more than 50 patients [432, 433], with the longest follow-up being 2.4 years. Success rates varied between 17% and 91.6%, with a mean of 57.6% predominantly reporting a subjective cure. The number of implants requiring re-adjustment was reported as between 22.9% and 41.5% [433]. Infection of the device occurred in 5.4-8% [432]. Erosions were reported in 5-10% [434]. Urethral perforations occurred in 2.7-16% [432]. Pain at the implant site was usually only temporary, but chronic pain has been reported [432, 434]. These complications resulted in explantation rates of 10-15% [433].

The ATOMS<sup>®</sup> system consists of a mesh implant with an integrated adjustable cushion, which uses a titanium port left in the subcutaneous tissue of the lower abdomen or scrotum for adjustment of cushion volume. Initial reports show objective cure rates of 60.5% and improvement rates of 23.7% but with the need for up to nine post-operative adjustments [435, 436].

##### 4.3.5.4.3 Summary of evidence for adjustable slings in males

Summary of evidence	LE
There is limited evidence that adjustable male slings can cure or improve SUI in men.	3
There is limited evidence that early explantation rates are high.	3
There is no evidence that adjustability offers additional benefit over other types of sling.	3

SUI = stress urinary incontinence.

#### 4.3.5.5 Compression devices in males

External compression devices can be divided into two types: circumferential and non-circumferential compression of the urethral lumen [419]. The artificial urinary sphincter (AUS) is the standard treatment for moderate-to-severe male SUI. Most data available on the efficacy and adverse effects of AUS implantation are from older retrospective cohort studies with RCTs not performed due to the lack of a comparator. Men considering insertion of an AUS should understand that if the ability of an individual to operate the pump is uncertain, it may not be appropriate to implant an AUS. There are several recognised complications of AUS implantation, e.g. mechanical dysfunction, urethral constriction by fibrous tissue, erosion and infection. The non-circumferential compression devices consist of two balloons placed close to the vesico-urethral anastomotic site. The balloons can be filled and their volume can be adjusted post-operatively through an intra-scrotal port. Men who develop cognitive impairment or lose manual dexterity will have difficulty operating an AUS.

##### 4.3.5.5.1 Question

In men with post-prostatectomy SUI, does insertion of an external compression device cure SUI, improve QoL, or cause adverse outcomes?

##### 4.3.5.5.2 Evidence

##### *Artificial urinary sphincter*

Although the AUS is considered to be the standard treatment for men with SUI, there are three SRs [416, 421, 437] presenting limited evidence, of generally poor quality, except for one RCT comparing AUS with bulking

agents [412]. A continence rate of about 80% can be expected, while this may be lower in men who have undergone pelvic radiotherapy [419].

Trigo Rocha *et al.* published a prospective cohort study on 40 patients with a mean follow-up of 53 months, showing that from all urodynamic parameters only low bladder compliance had a negative impact on the outcome [438]. Another retrospective study showed that no urodynamic factors adversely altered the outcome of AUS implantation [439].

The transcorporeal technique of placement can be used for repeat surgery but evidence of effectiveness is lacking [440]. The dual-cuff placement was introduced to treat patients who remained incontinent with a single 4 cm cuff in place. However, it has not improved control of UI, while the availability of a 3.5 cm cuff may have eliminated the need for a dual cuff [441, 442]. Patients who experienced complete continence after AUS implantation had a higher erosion risk [443]. One small series reported results of AUS implantation after failure of previous AdVance® sling, showing no difference in efficacy between secondary and primary implantation [444].

#### *Non-circumferential compression device (ProAct®)*

There have been trials to treat post-prostatectomy SUI by insertion of a device consisting of balloons with adjustable volume external to the proximal bulbar urethra. A prospective cohort study (n = 128) described the functional outcome as 'good' in 68%, while 18% of the devices had to be explanted [445]. A subgroup of radiotherapy patients only had 46% success and a higher percentage of urethral erosions.

A quasi-randomised trial comparing a non-circumferential compression device (ProAct®) with bone-anchored male slings found that both types of device resulted in similar improvement of SUI (68% vs. 65%, respectively) [446]. Other prospective series have shown that adverse events were frequent, leading to an explantation rate of 11-58% [421, 447-450]. A questionnaire study showed that 50% of patients were still bothered significantly by persistent incontinence [451]. Other designs of artificial sphincter remain the subject of ongoing evaluation though they may have been introduced onto the market.

#### 4.3.5.5.3 Summary of evidence for compression devices in males

Summary of evidence	LE
There is evidence that primary AUS implantation is effective for cure of SUI in men.	2b
Long-term failure rate for AUS is high although device replacement can be performed.	3
There are conflicting data on whether previous pelvic radiotherapy affects the outcome of AUS implantation.	3
The usefulness of tandem-cuff placement is uncertain.	3
There is insufficient evidence to state whether one surgical approach for cuff placement is superior to another.	3
Very limited short-term evidence suggests that the non-circumferential compression device (ProACT®) is effective for treatment of post-prostatectomy SUI.	3
The non-circumferential compression device (ProACT®) is associated with a high failure and complication rate leading to frequent explantation.	3
The rate of explantation of the AUS because of infection or erosion remains high (up to 24% in some series).	3
Mechanical failure is common with the AUS.	3
Revision and re-implantation of AUS is possible after previous explantation or for mechanical failure.	3

AUS = artificial urinary sphincter; SUI = stress urinary incontinence.

#### 4.3.5.6 Recommendations for men with stress urinary incontinence

Recommendations	Strength rating
Offer duloxetine only to hasten recovery of continence after prostate surgery but inform the patient about the possible adverse events and that its use is off label for this indication in most European countries.	Weak
Only offer bulking agents to men with mild post-prostatectomy incontinence who desire temporary relief of incontinence symptoms.	Weak
Do not offer bulking agents to men with severe post-prostatectomy incontinence.	Weak
Offer fixed slings to men with mild-to-moderate* post-prostatectomy incontinence.	Weak

Warn men that severe incontinence, prior pelvic radiotherapy or urethral stricture surgery, may worsen the outcome of fixed male sling surgery.	Weak
Offer AUS to men with moderate-to-severe post-prostatectomy incontinence.	Weak
Implantation of AUS or ProACT <sup>®</sup> for men should only be offered in expert centres.	Weak
Warn men receiving AUS or ProACT <sup>®</sup> that, although cure can be achieved, even in expert centres, there is a high risk of complications, mechanical failure or a need for explantation.	Weak
Do not offer non-circumferential compression device (ProACT <sup>®</sup> ) to men who have had pelvic radiotherapy.	Weak

\* The terms “mild” and “moderate” post-prostatectomy incontinence remain undefined.  
ACT<sup>®</sup> = artificial compression device; AUS = artificial urinary sphincter.

#### 4.3.6 Surgical interventions for refractory detrusor-overactivity

##### 4.3.6.1 Bladder wall injection of botulinum toxin A

Onabotulinum toxin A (onabotA; BOTOX<sup>®</sup>) 100 U dissolved in 10 mL of saline and injected in 20 points of the bladder wall above the trigone (0.5 mL per injection site) is licenced in Europe to treat OAB with persistent or refractory UUI in adults of both genders, despite the small number of males included in the registration trials [452, 453]. Surgeons must realise that other doses of onabotA and other formulations of botulinum toxin A, abobotulinum toxin A and incobotulinum toxin A, are not licensed for use in UUI. Doses for onabotA are not transposable to the other brands of botulinum toxin A. The continued efficacy of repeat injections is the rule but discontinuation rate may be high. The most important adverse events related to onabotA 100 U injection detected in the regulatory trials were UTI and an increase in PVR that may require clean intermittent catheterisation [454].

##### 4.3.6.1.1 Question

In adults with UUI, is bladder wall injection of onabotA better than no treatment for cure or improvement?

##### 4.3.6.1.2 Evidence

Following a dose ranging study in which the 100 U of onabotA was established as the ideal dose, two phase III trials randomised (1:1) 1,105 OAB incontinent patients whose symptoms were not adequately managed with anticholinergics to receive bladder wall injections of onabotA (100 U) or saline. At baseline, the population had on average more than five episodes of UUI, around twelve micturitions per day and a small PVR. At week twelve, in patients treated with onabotA, UUI episodes/day were halved and the number of micturitions/day reduced by more than two. A total of 22.9% of the patients in the onabotA arm were fully dry, against 6.5% in the saline arm [455].

Quality of life was substantially improved in the onabotA arm, as shown by the more than 60% of positive responses in the Treatment Benefit Scale questionnaire at week twelve, which was double the positive responses in the saline arm. Cohort studies have shown the effectiveness of bladder wall injections of onabotA in the elderly and frail elderly [456], though the success rate might be lower and the PVR (> 150 mL) higher in this group.

The median time to request re-treatment in the pooled analysis of the two RCTs was 24 weeks [454, 455]. Follow-up over 3.5 years showed consistent or increasing duration of effect for each subsequent treatment, with a median of 7.5 months [457].

A recent RCT compared onabotA injection 100 U to solifenacin (with dose escalation or switch to trospium possible in the solifenacin group) and showed similar rates of improvement in UUI over the course of six months [458]. However, patients receiving onabotA were not only more likely to have cure of UUI (27% vs. 13%,  $p = 0.003$ ), but also had higher rates of urinary retention during the initial two months (5% vs. 0%) and of UTIs (33% vs. 13%). Patients taking antimuscarinics were more likely to have dry mouth.

Identification of DO in urodynamics does not influence the outcome of onabotulinum toxin A injections in patients with UUI [61].

#### 4.3.6.1.3 Summary of evidence and recommendations for bladder wall injection of botulinum toxin A

Summary of evidence	LE
A single treatment session of onabotulinum toxin A (100 U) injected in the bladder wall is more effective than placebo at curing and improving UUI and QoL.	1a
There is no evidence that repeated injections of onabotulinum toxin A have reduced efficacy.	3
There is a high risk of increased PVR when injecting elderly frail patients.	3
The risk of bacteriuria after onabotulinum toxin A (100 U) injection is high but the clinical significance of this remains uncertain.	1b
Onabotulinum toxin A (100 U) is superior to solifenacin for cure of UUI, but rates of improvement were equivalent.	1b

Recommendations	Strength rating
Offer bladder wall injections of onabotulinum toxin A (100 U) to patients with UUI refractory to conservative therapy (such as PFMT and/or drug treatment).	Strong
Warn patients of the limited duration of response, risk of UTI and the possible prolonged need to self-catheterise (ensure that they are willing and able to do so).	Strong

PFMT = pelvic floor muscle training PVR = post-void residual; QoL = quality of life;  
UUI = urgency urinary incontinence; UTI = urinary tract infection.

#### 4.3.6.2 Sacral nerve stimulation (neuromodulation)

In the first stage of a two-stage implantation, an electrode is placed percutaneously under fluoroscopic control in the sacral foramen alongside a sacral nerve, usually S3. In earlier techniques, a temporary wire electrode was used. More recently, a permanent tined electrode has been used for a longer test phase. Patients, in whom selected symptoms of UUI are reduced by more than 50% during the test phase, are candidates for the full implant, including the pulse generator, and reported results only apply to this sub population.

##### 4.3.6.2.1 Question

In adults suffering from refractory UUI, what is the clinical effectiveness of sacral nerve neuromodulation compared to alternative treatments?

##### 4.3.6.2.2 Evidence

All randomised studies suffer from the limitation that assessors and patients were not blinded to the treatment allocation since all recruited subjects had to respond to a test phase before randomisation. A Cochrane review of the literature until March 2008 [459] identified three RCTs that investigated sacral nerve stimulation in patients with refractory UUI.

One study compared implantation to controls who stayed on medical treatment and received delayed implantation at six months. Fifty percent of the immediately implanted group had > 90% improvement in UUI at six months compared to 1.6% of the control group [460]. The other RCT [461] achieved similar results, although these patients had already been included in the first report [460]. However, Weil *et al.* [461] showed that the effect on generic QoL measured by the SF-36, was unclear as it differed between the groups in only one of the eight dimensions.

The results of seventeen case series of patients with UUI, who were treated early in the experience with sacral nerve stimulation, were reviewed [462]. After a follow-up duration of between one and three years, approximately 50% of patients with UUI demonstrated > 90% reduction in UI, 25% demonstrated 50-90% improvement, and another 25% demonstrated < 50% improvement. Two case series describing the outcome of sacral nerve neuromodulation, with a mean or median follow-up of at least four years [463, 464] reported continued success (> 50% improvement on original symptoms) in patients available for follow-up. Cure rates for UUI were 15% [464]. A RCT comparing a strategy of onabotulinum toxinA injection of 200 U, repeated as required, against a strategy of test and permanent sacral nerve neuromodulation [465] (ROSETTA trial) showed lower cure rates with SNM: at six months, 20% in the onabotulinumtoxinA group and 4% in the sacral neuromodulation group had complete resolution of UUI ( $p < .001$ ). Forty-six percent in the onabotulinumtoxinA group and 26% in the sacral neuromodulation group had at least a 75% reduction in the number of episodes of UUI ( $p < .001$ ). This 4% cure rate is also lower than the 6 months cure rate in another RCT of sacral neuromodulation vs. standard medical therapy which reported a 39% continence rate in the sacral neuromodulation group at 6 months; however, the mean (SD) baseline leaks per day (2.4 [ $\pm$  1.7]) for the sacral

neuromodulation group in the study were lower than in the ROSETTA trial (5.3 [ $\pm$  2.7]), reflecting a less severe population [466].

Adverse events occurred in 50% of implanted cases, with surgical revision necessary in 33-41% [463, 464]. In a subanalysis of the RCT, the outcomes of UUI patients, with or without pre-implant DO, were compared. Similar success rates were found in patients with or without urodynamic DO [467].

#### 4.3.6.2.3 Summary of evidence and recommendation for sacral nerve stimulation

Summary of evidence	LE
Sacral nerve neuromodulation is more effective than continuation of failed conservative treatment for cure of UUI, but no sham controls have been used.	1b
Sacral nerve neuromodulation is not more effective than OnabotulinumA toxin 200 U injection at 6 months.	1b
In those patients who have been implanted, at long-term, 50% improvement of UUI is maintained in at least 50% of patients and 15% may remain cured.	3
The use of timed, permanent electrodes in a staged approach results in more patients receiving the final implant than occurs with temporary test stimulation.	4

Recommendations	Strength rating
Offer sacral nerve modulation to patients who have UUI refractory to antimuscarinic therapy.	Strong

*UUI = urgency urinary incontinence.*

#### 4.3.6.3 Cystoplasty/urinary diversion

##### 4.3.6.3.1 Augmentation cystoplasty

In augmentation cystoplasty (also known as clam cystoplasty), a detubularised segment of bowel is inserted into the bivalved bladder wall. The distal ileum is the bowel segment most often used but any bowel segment can be used if it has the appropriate mesenteric length. One study did not find any difference between bivalving the bladder in the sagittal or in the coronal plane [468, 469]. The procedure can be done, with equal success by open or robot techniques, although the robotic consumes considerably more operative time [470].

There are no RCTs comparing bladder augmentation to other treatments for patients with UUI. Most often, bladder augmentation is used to correct neurogenic DO or small-capacity, low-compliant, bladders caused by fibrosis, chronic infection such as tuberculosis, radiation or chronic inflammation from interstitial cystitis.

The largest case series of bladder augmentation in a mixed population of idiopathic and neurogenic UUI included 51 women [471]. At an average follow-up of 74.5 months, only 53% were continent and satisfied with the surgery, whereas 25% had occasional leaks and 18% continued to have disabling UUI. It seems that the results for patients with idiopathic DO (58%) appeared to be less satisfactory than for patients with neurogenic UUI (90%).

Adverse effects were common and have been summarised in a review over five to seventeen years of more than 267 cases, 61 of whom had non-neurogenic UUI [472]. In addition, many patients may require clean intermittent self-catheterisation to obtain adequate bladder emptying (Table 3). It is unclear if mucolytic agents will reduce mucus accumulation. The only RCT that was identified comparing various mucolytic agents did not find significant benefits with the use of N-acetylcysteine, aspirin, or ranitidine. In one small study (n = 40), the use of subcutaneous octreotide immediately before, and for 15 days after surgery was reported to yield significant reductions in mucus production, the need for bladder irrigation to clear blockages, and the mean duration of hospital stay [473].

Depending on the relative costs of Onabotulinum Toxin A and augmentation cytoplasty, the latter can be cost effective within five years if the complication rate is low and duration of effect of Onabotulinum Toxin A < 5 months [474].

**Table 3: Complications of bladder augmentation**

<b>Short-term complications</b>	<b>Affected patients (%)</b>
Bowel obstruction	2
Infection	1.5
Thromboembolism	1
Bleeding	0.75
Fistula	0.4
<b>Long-term complications</b>	<b>Affected patients (%)</b>
Clean intermittent self-catheterisation	38
Urinary tract infection	70% asymptomatic 20% symptomatic
Urinary tract stones	13
Metabolic disturbance	16
Deterioration in renal function	2
Bladder perforation	0.75
Change in bowel symptoms	25

#### 4.3.6.3.2 Detrusor myectomy (bladder auto-augmentation)

Detrusor myectomy aims to increase bladder capacity and reduce storage pressures by incising or excising a portion of the detrusor muscle, to create a bladder mucosal ‘bulge’ or pseudo-diverticulum. It was initially described as an alternative to bladder augmentation in children [475].

Two case series [476, 477] in adult patients with idiopathic and neurogenic bladder dysfunction, demonstrated poor long-term results caused by fibrosis of the pseudo-diverticulum. This technique is rarely, if ever, used nowadays.

#### 4.3.6.3.3 Urinary diversion

Urinary diversion remains a reconstructive option for patients with intractable incontinence after multiple pelvic procedures, radiotherapy or pelvic pathology leading to irreversible sphincteric incompetence or fistula formation. These patients may be offered irreversible urinary diversion surgery. Options include ileal conduit urinary diversion, orthotopic neobladder and heterotopic neobladder with Mitrofanoff continent catheterisable conduit. There is insufficient evidence to comment on which procedure leads to the most improved QoL.

A small study compared ileal with colonic conduits and concluded that there were no differences in the relative risks of UUT infection and uretero-intestinal stenosis. However, there are no studies that have specifically examined these techniques in the treatment of intractable UUI [468]. Therefore, careful consideration on which operation is undertaken will depend on patient factors and informed patient choice.

#### 4.3.6.3.4 Summary of evidence and recommendations for cystoplasty/urinary diversion

<b>Summary of evidence</b>	<b>LE</b>
There is limited evidence on the effectiveness of augmentation cystoplasty and urinary diversion in treatment of idiopathic DO.	3
Augmentation cystoplasty and urinary diversion are associated with high risks of short-term and long-term severe complications.	3
The need to perform clean intermittent self-catheterisation following augmentation cystoplasty is very common.	3
There is no evidence comparing the efficacy or adverse effects of augmentation cystoplasty with urinary diversion.	3
Detrusor myectomy is ineffective in adults with UI.	3



Recommendations	Strength rating
Offer augmentation cystoplasty to patients with UI who have failed all other treatment options.	Weak
Inform patients undergoing augmentation cystoplasty of the high risk of having to perform clean intermittent self-catheterisation (ensure they are willing and able to do so) and that they need lifelong surveillance.	Weak
Do not offer detrusor myectomy as a treatment for UI.	Weak
Only offer urinary diversion to patients who have failed less invasive therapies for the treatment of UI and who will accept a stoma and have been warned about the possible small risk of malignancy.	Weak

DO = detrusor overactivity; UI = urinary incontinence.

#### 4.3.7 **Surgery in patients with mixed urinary incontinence**

##### 4.3.7.1 *Question*

In adults with MUI, is the outcome of surgery different to that obtained with the same treatment in patients with either pure SUI or pure UUI?

##### 4.3.7.2 *Evidence*

Many RCTs include both patients with pure SUI or pure UUI and patients with MUI. However, very few RCTs report separate outcomes for MUI and pure UI groups.

*Post-hoc* analysis of the SISTER trial showed that in women undergoing either autologous fascial sling or Burch colposuspension, the outcomes were poorer for women with a concomitant complaint of pre-operative urgency [335]. A similar *post-hoc* review of another RCT comparing transobturator and retropubic mid-urethral slings showed that the greater the severity of pre-operative urgency, the more likely that treatment would fail [78]. However, an earlier study had found that surgery provided similar outcomes, whether or not urgency was present prior to surgery (this study included only a few patients with urodynamic DO). Another RCT with 93 patients with MUI showed a statistical improvement in continence and QOL in the group that had TVT and Botox rather than with either treatment alone [478].

Case series tend to show poorer results in patients with MUI compared with those with pure SUI. In a case series of 192 women undergoing mid-urethral sling insertion, overall satisfaction rates were lower for women with mixed symptoms and detrusor overactivity on pre-operative urodynamics compared to those with pure SUI and normal urodynamics (75% vs. 98%, respectively) [479]. A comparison of two parallel cohorts of patients undergoing surgery for SUI, with and without DO, found inferior outcomes in women with MUI [480].

One cohort of 450 women, showed that in urgency-predominant MUI, the success rate fell to 52% compared to 80% in stress-predominant MUI [481]. In a study with 1,113 women treated with transvaginal obturator tape, SUI was cured equally in stress-predominant MUI or urgency-predominant MUI. However, women with stress-predominant MUI were found to have significantly better overall outcomes than women with urgency predominant MUI [482].

In a prospective, multicentre, comparative trial, 42 women who had a TVT for mixed UI had a greater improvement in urgency and QOL scores than 90 women who had a TOT. There were no significant differences in the cure and satisfaction rates between the two groups [483].

Overall, the outcome for women with pre-existing urgency incontinence remains uncertain.

##### 4.3.7.3 *Summary of evidence and recommendations for surgery in patients with mixed urinary incontinence*

Summary of evidence	LE
Women with MUI are less likely to be cured of their UI by SUI surgery than women with SUI alone.	1b
The response of pre-existing urgency symptoms to SUI surgery is unpredictable.	3



Recommendations	Strength rating
Treat the most bothersome symptom first in patients with MUI.	Weak
Warn women that surgery for MUI is less likely to be successful than surgery for SUI alone.	Strong
Inform women with MUI that one single treatment may not cure UI; it may be necessary to treat other components of the incontinence problem as well as the most bothersome symptom.	Strong

MUI = mixed urinary incontinence; SUI = stress urinary incontinence; UI = urinary incontinence.

#### 4.3.7.4 Research priorities

Research trials should define accurately what is meant by 'mixed urinary incontinence'.

There is a need for well-designed trials comparing treatments in populations with MUI, and in which the type of MUI has been accurately defined.

#### 4.3.8 Surgery for urinary incontinence in the elderly

There are no RCTs comparing surgical treatment in older vs. younger women although subgroup analyses of some RCTs have included a comparison of older with younger cohorts.

A RCT of 537 women comparing retropubic to transobturator tapes, showed that cure rates decreased and failure increased with each decade over the age of 50 [333]. A RCT assessing risk factors for failure of TVT vs. TOT in 162 women found that age is a specific risk factor (adjusted OR 1.7 per decade) for recurrence at one year [334]. In a subanalysis of the SISTER trial cohort of 655 women at 2 years of follow-up, it was shown that elderly women were more likely to have a positive stress test at follow-up (OR 3.7, 95% CI: 1.7-7.97), are less likely to report objective or subjective improvement in stress and urgency UI, and are more likely to undergo re-treatment for SUI (OR 3.9, 95% CI: 1.3-11.48). There was no difference in time to normal post-operative voiding [335].

Another RCT compared immediate TVT vs. delayed TVT in older women, confirming significant efficacy for the women operated upon, but the cohort as a whole suffered higher complication rates, particularly bladder perforation (22%) and urinary retention (13%) [336].

A cohort study of 256 women undergoing inside-out TOT reported similar efficacy in older vs. younger women, but there was a higher risk of *de novo* urgency in older patients [330].

Cohort studies have shown the effectiveness of onabotulinum toxin A injections in the elderly and frail elderly [456, 484], although a comparison of cohort groups suggests that there is a lower success rate in the frail elderly and also a higher rate of increased PVR (> 150 mL) in this group.


##### 4.3.8.1 Summary of evidence and recommendation for surgery for urinary incontinence in the elderly

Summary of evidence	LE
Older women benefit from surgical treatment for incontinence.	1
The risk of failure from surgical repair of SUI, or of suffering adverse events, appears to increase with age.	2
There is no evidence that any surgical procedure has greater efficacy or safety in older women than another procedure.	4

Recommendations	Strength rating
Inform older women with UI about the increased risks associated with surgery (including onabotA injection), together with the lower probability of benefit.	Weak

SUI = stress urinary incontinence; UI = urinary incontinence.

Figure 1: Management and treatment of women presenting with urinary incontinence.



Continues on page 64.






Figure 2: Management and treatment of men presenting with urinary incontinence.



Continues on page 66.



# APPENDIX A: NON OBSTETRIC URINARY FISTULA

## A.2 Introduction

The evidence relating to diagnosis and treatment of urinary fistulae is generally poor and this review inevitably relies largely on numerous case series and other consensus statements. In particular, the epidemiology, aetiology, diagnosis, treatment and prevention of non-obstetric fistulae have been described in detail during the recent International Consultations on Incontinence [485, 486]. Most non-obstetric fistulae are iatrogenic in origin, with causes including pelvic surgery (particularly hysterectomy for benign or malignant conditions, caesarean section and obstetric injuries). The risks during pelvic surgery increase relative to the complexity of the resection, the extent of primary disease and when there has been prior radiotherapy (especially for recurrent disease). When a fistula occurs following radiotherapy for primary treatment, this may be an indication of tumour recurrence.

## A.3 Diagnosis of fistula

### *Clinical diagnosis*

Leakage of urine is the hallmark sign of a fistula. The leakage is usually painless, may be intermittent if it is position dependent, or may be constant. Unfortunately, intra-operative diagnosis of a GU or GI injury is made in only about half of the cases that result in fistula [487].

The diagnosis of vesicovaginal fistula (VVF) usually requires clinical assessment often in combination with appropriate imaging or laboratory studies. Direct visual inspection, cystoscopy, retrograde bladder filling with a coloured fluid or placement of a tampon into the vagina to identify staining may facilitate the diagnosis of a VVF. A double-dye test to differentiate between a ureterovaginal and VVF may be useful in some cases [488]. Testing the creatinine level in either the extravasated fluid or the accumulated ascites and comparing this to the serum creatinine level will confirm urinary leakage.

Contrast-enhanced CT with late excretory phase reliably diagnoses urinary fistulae and provides information about ureteric integrity and the presence of associated urinoma. Magnetic resonance imaging, in particular with T2 weighting, also provides optimal diagnostic information regarding fistulae and may be preferred for urinary - intestinal fistulae [489].

## A.4 Management of vesicovaginal fistula

### A.3.1 *Conservative management*

Before epithelialisation is complete an abnormal communication between viscera will tend to close spontaneously, provided that the natural outflow is unobstructed or if urine is diverted. Combining available data gives an overall spontaneous closure rate of 13% ± 23% [490], though this applies largely to small fistulae [486]. Hence, immediate management should be by urinary catheterisation or diversion.

### A.3.2 *Surgical management*

#### *Timing of surgery*

Findings from uncontrolled case series suggest no difference in success rates for early or delayed closure of VVF.

#### A.3.2.1 *Surgical approaches*

##### *Vaginal procedures*

There are two main types of closure techniques applied to the repair of urinary fistulae, the classical saucerisation/partial colpocleisis [491] and the more commonly used dissection and repair in layers or 'flapsplitting' technique [492]. There are no data comparing their outcomes.

##### *Abdominal procedures*

Repair by the abdominal route is indicated when high fistulae are fixed in the vault and are inaccessible through the vagina. A transvesical repair has the advantage of being entirely extraperitoneal. A simple transperitoneal repair is used less often although it is favoured by some using the laparoscopic approach. A combined transperitoneal and transvesical procedure is favoured by many urologists and is particularly useful for fistula repair following Caesarean section. There are no RCTs comparing abdominal and vaginal approaches. Results of secondary and subsequent repairs are not as good as primary repair [493].

A single RCT compared trimming of the fistula edge with no trimming [494]. There was no difference in success rates but failed repairs in trimmed cases ended up with larger recurrences than untrimmed cases, which were smaller.

### *Laparoscopic and Robotic*

Very small series (single figures) have been reported using these techniques, but whilst laparoscopic repair is feasible with and without robotic assistance, it is not possible to compare outcomes with alternative surgical approaches.

### *Tissue Interposition*

Tissue flaps are often added as an additional layer of repair during VVF surgery. Most commonly, such flaps are utilised in the setting of recurrence after a prior attempt at repair, for VVF related to previous radiotherapy (described later), ischemic or obstetrical fistulae, large fistulae, and finally those associated with a difficult or tenuous closure due to poor tissue quality. However, there is no high-level evidence that the use of such flaps improves outcomes for either complicated or uncomplicated VVF.

### *Post-operative management*

There is no high-level evidence to support any particular practice in post-operative management but most reported series used catheter drainage for at least ten days and longer periods in radiation-associated fistulae (up to three weeks).

## **A.4 Management of radiation fistula**

Modified surgical techniques are often required, and indeed, where the same techniques have been applied to both surgical and post-radiation fistulae, the results from the latter have been consistently poorer [495]. Due to the wide field abnormality surrounding many radiotherapy-associated fistulae, approaches include, on the one hand, permanent urinary and/or faecal diversion [496, 497] or alternatively preliminary urinary and faecal diversion, with later undiversion in selected cases following reconstruction. This may in some cases extend life perhaps inappropriately, and where life expectancy is deemed to be very short, ureteric occlusion might be more appropriate.

## **A.5 Management of ureteric fistula**

### *General principles*

Patients at higher risk of ureteric injury require experienced surgeons who can identify and protect the ureter and its blood supply to prevent injury and also recognise injury promptly when it occurs. Immediate repair of any intra-operative injury should be performed observing the principles of debridement, adequate blood supply and tension-free anastomosis with internal drainage using stents [490]. Delayed presentation of upper tract injury should be suspected in patients whose recovery after relevant abdominal or pelvic surgery is slower than expected, if there is any fluid leak, and if there is any unexpected dilatation of the pelvicalyceal system. Whilst there is no evidence to support the use of one surgical approach over another, there is consensus that repair should adhere to the standard principles of tissue repair and safe anastomosis, and be undertaken by an experienced team. Conservative management is possible with internal or external drainage, endoluminal management using nephrostomy and stenting where available, and early (< two weeks) or delayed (> three months) surgical repair when required [498]. Functional and anatomical imaging should be used to follow up patients after repair to guard against development of ureteric stricture and deterioration in renal function.

### *Ureterovaginal fistula*

Ureterovaginal fistula occurring in the early post-operative phase predominantly after hysterectomy is the most frequent presentation of UUT fistulae in urological practice. An RCT in 3,141 women undergoing open or laparoscopic gynaecological surgery found that prophylactic insertion of ureteric stents made no difference to the low risk (1%) of ureteric injury [499].

Endoscopic management is sometimes possible [500] by retrograde stenting, percutaneous nephrostomy and antegrade stenting if there is pelvicalyceal dilatation, or ureteroscopic realignment [501].

If endoluminal techniques fail or result in secondary stricture, the abdominal approach to repair is standard and may require end-to-end anastomosis, re-implantation into the bladder using psoas hitch or Boari flap, or replacement with bowel segments with or without reconfiguration.

## **A.6 Management of urethrovaginal fistula**

### *Aetiology*

Whilst they are rare, most urethrovaginal fistulae in adults have an iatrogenic aetiology. Causes include surgical treatment of stress incontinence with bulking agents or synthetic slings, surgery for urethral diverticulum and genital reconstruction in adults. Irradiation and even conservative treatment of prolapse with pessaries can lead to the formation of fistulae.



### A.6.1 **Diagnosis**

Clinical vaginal examination, including the three swab test, is often sufficient to diagnose the presence of a urethrovaginal fistula. Urethroscopy and cystoscopy can be performed to assess the extent and location of the fistulae. In cases of difficult diagnosis, voiding cystourethrography (VCUG) or ultrasound can be useful. 3D MRI or CT scan is becoming utilised more widely to clarify anatomy [502, 503].

### A.6.2 **Surgical repair**

Choice of surgery will depend on the size, localisation and aetiology of the fistula and the amount of tissue loss. Principles of reconstruction include identifying the fistula, creation of a plane between vaginal wall and urethra, watertight closure of urethral wall, eventual interposition of tissue, and closure of the vaginal wall.

#### A.6.2.1 *Vaginal approach*

Goodwin described in his series that a vaginal approach yielded a success rate of 70% at first attempt and 92% at second attempt, but that an abdominal approach only leads to a successful closure in 58% of cases. A vaginal approach required less operating time, had less blood loss and a shorter hospitalisation time.

Most authors describe surgical principles that are identical to those of vesicovaginal fistula repair: primary closure rates of 53-95.4% have been described. Pushkar *et al.* described a series of 71 women, treated for urethrovaginal fistula. 90.1% of fistulae were closed at the first vaginal intervention. Additionally, 7.4% were closed during a second vaginal intervention. Despite successful closure, stress incontinence developed in 52%. The stress incontinent patients were treated with synthetic or autologous slings and nearly 60% became dry and an additional 32% improved. Urethral obstruction occurred in 5.6% and was managed by urethral dilation or urethrotomy [504].

#### *Flaps and neourethra.*

The simplest flap is a vaginal advancement flap to cover the urethral suture line. Labial tissue can be harvested as a pedicled skin flap. This labial skin can be used as a patch to cover the urethral defect, but can also be used to create a tubular neo-urethra [505, 506]. The construction of a neo-urethra has mostly been described in traumatic aetiologies. In some cases a transpubic approach has been used [507]. The numbers of patients reported are small and there are no data on the long-term outcome of fistula closure and continence rates. The underlying bulbocavernosus tissue can be incorporated in the pedicled flap and probably offers a better vascularisation and more bulking to the repair. This could allow a safer placement of a sling afterwards, in those cases where bothersome stress incontinence would occur post-operatively [508, 509].

#### *Martius flap*

While in obstetrical fistula repair it was not found to have any benefit, in a large retrospective study in 440 women the labial bulbocavernosus muscle/fat flap by Martius is still considered by some to be an important adjunctive measure in the treatment of genitourinary fistulae where additional bulking with well vascularised tissue is needed [510]. The series of non-obstetrical aetiology are small and all of them are retrospective. There are no prospective data, nor randomised studies [511]. The indications for Martius flap in the repair of all types of fistulae remain unclear.

#### *Rectus muscle flap*

Rectus abdominis muscle flaps have been described by some authors [512, 513].

#### A.6.2.2 *Abdominal approach*

A retropubic retrourethral technique has been described by Koriatim [514]. This approach allows a urethrovaginal flap tube to be fashioned to form a continent neo-urethra.

## A.7 **Summary of evidence and recommendations for management of urethrovaginal fistula**

Summary of evidence	LE
Spontaneous closure of surgical fistulae does occur, although it is not possible to establish the rate with any certainty.	3
There is no evidence that the timing of repair makes a difference to the chances of successful closure of a fistula.	3
There is no high-quality evidence of differing success rates for repair of vesicovaginal fistulae by vaginal, abdominal, transvesical and transperitoneal approaches.	3

A period of continuous bladder drainage is crucial to successful fistula repair but there is no high-level evidence to support one regime over another.	3
A variety of interpositional grafts can be used in either abdominal or vaginal procedures, although there is little evidence to support their use in any specific setting.	3
<b>Post-radiation fistula</b>	
Successful repair of irradiated fistulae requires prior urinary diversion and the use of non-irradiated tissues to effect repair.	3
<b>Ureteric fistula</b>	
Prophylactic ureteric stent insertion does not reduce risk of ureteric injury during gynaecological surgery.	2
Antegrade endoluminal distal ureteric occlusion combined with nephrostomy tube diversion often palliates urinary leakage due to malignant fistula in the terminal phase.	4
<b>Urethrovaginal fistula</b>	
Urethrovaginal fistula repair may be complicated by stress incontinence, urethral stricture and urethral shortening necessitating long-term follow-up.	3

<b>Recommendations</b>	<b>Strength rating</b>
<b>General</b>	
Surgeons undertaking complex pelvic surgery should be competent at identifying, preserving and repairing the ureter.	Weak
Do not routinely use ureteric stents as prophylaxis against injury during routine gynaecological surgery.	Weak
Suspect ureteric injury or fistula in patients following pelvic surgery if a fluid leak or pelvic/cecal dilatation occurs post-operatively, or if drainage fluid contains high levels of creatinine.	Weak
Suspect uretero-arterial fistula in patients presenting with haematuria with a history of relevant surgery.	Weak
Use three dimensional imaging techniques to diagnose and localise urinary fistulae.	Weak
Manage upper urinary tract fistulae by conservative or endoluminal technique where such expertise and facilities exists.	Weak
<b>Surgical principles</b>	
Surgeons involved in fistula surgery should have appropriate training, skills, and experience to select an appropriate procedure for each patient.	Weak
Attention should be given as appropriate to skin care, nutrition, rehabilitation, counselling and support prior to, and following, fistula repair.	Weak
If a vesicovaginal fistula is diagnosed within six weeks of surgery, consider indwelling catheterisation for a period of up to twelve weeks after the causative event.	Weak
Tailor the timing of fistula repair to the individual patient and surgeon requirements once any oedema, inflammation, tissue necrosis, or infection, are resolved.	Weak
Where concurrent ureteric re-implantation or augmentation cystoplasty are required, the abdominal approach is necessary.	Weak
Ensure that the bladder is continuously drained following fistula repair until healing is confirmed (expert opinion suggests: 10-14 days for simple and/or postsurgical fistulae; 14-21 days for complex and/or post-radiation fistulae).	Weak
Where urinary and/or faecal diversions are required, avoid using irradiated tissue for repair.	Weak
Use interposition grafts when repair of radiation associated fistulae is undertaken.	Weak
In patients with intractable UI from radiation-associated fistula, where life expectancy is very short, consider performing ureteric occlusion.	Weak
Repair persistent ureterovaginal fistula by an abdominal approach using open, laparoscopic or robotic techniques according to availability and competence.	Weak
Consider palliation by nephrostomy tube diversion and endoluminal distal ureteric occlusion for patients with ureteric fistula associated with advanced pelvic cancer and poor performance status.	Weak
Urethrovaginal fistulae should preferably be repaired by a vaginal approach.	Weak

UI = urinary incontinence

## 5. REFERENCES

1. Abrams, P., *et al.* 5th International Consultation on Incontinence, Paris, February 2012.
2. Groen, J., *et al.* Summary of European Association of Urology (EAU) Guidelines on Neuro-Urology. *Eur Urol*, 2016. 69: 324.  
<https://www.ncbi.nlm.nih.gov/pubmed/26304502>
3. Tekgül, S., *et al.*, EAU Guidelines on Paediatric Urology, in EAU Guidelines, . 2018, EAU Guidelines Office: Arnhem, the Netherlands.  
<https://uroweb.org/guideline/paediatric-urology/>
4. Nambiar, A.K., *et al.* The Role of Urodynamics in the Evaluation of Urinary Incontinence: The European Association of Urology Recommendations in 2016. *Eur Urol*, 2017. 71: 501.  
<https://www.ncbi.nlm.nih.gov/pubmed/27726965>
5. Nambiar, A.K., *et al.* EAU Guidelines on Assessment and Nonsurgical Management of Urinary Incontinence. *Eur Urol*, 2018.  
<https://www.ncbi.nlm.nih.gov/pubmed/29398262>
6. Guyatt, G.H., *et al.* GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ*, 2008. 336: 924.  
<https://www.ncbi.nlm.nih.gov/pubmed/18436948>
7. Guyatt, G.H., *et al.* What is “quality of evidence” and why is it important to clinicians? *BMJ*, 2008. 336: 995.  
<https://www.ncbi.nlm.nih.gov/pubmed/18456631>
8. Phillips B, *et al.* Oxford Centre for Evidence-based Medicine – Levels of Evidence (March 2009). 2009.  
<https://www.cebm.net/2009/06/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/>
9. Guyatt, G.H., *et al.* Going from evidence to recommendations. *BMJ*, 2008. 336: 1049.  
<https://www.ncbi.nlm.nih.gov/pubmed/18467413>
10. Bedretdinova, D., *et al.* What is the most effective treatment for nocturia or nocturnal incontinence in terms of improving symptom severity and quality of life in women? 2015 p. PROSPERO 2017 CRD42017058997.  
[http://www.crd.york.ac.uk/PROSPERO/display\\_record.asp?ID=CRD42015027092](http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42015027092)
11. U.S. Department of Health and Human Services, F.a.D.A. Guidance for Industry - Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. 2009. 2016.  
<http://www.fda.gov/downloads/Drugs/Guidances/UCM193282.pdf>
12. Farrell, S.A., *et al.* Women’s ability to assess their urinary incontinence type using the QUID as an educational tool. *Int Urogynecol J*, 2013. 24: 759.  
<https://www.ncbi.nlm.nih.gov/pubmed/22940842>
13. Hess, R., *et al.* Long-term efficacy and safety of questionnaire-based initiation of urgency urinary incontinence treatment. *Am J Obstet Gynecol*, 2013. 209: 244 e1.  
<https://www.ncbi.nlm.nih.gov/pubmed/23659987>
14. Reis, R.B., *et al.* Lack of association between the ICIQ-SF questionnaire and the urodynamic diagnosis in men with post radical prostatectomy incontinence. *Acta Cir Bras*, 2013. 28 Suppl 1: 37.  
<https://www.ncbi.nlm.nih.gov/pubmed/23381822>
15. Chan, S.S., *et al.* Responsiveness of the Pelvic Floor Distress Inventory and Pelvic Floor Impact Questionnaire in women undergoing treatment for pelvic floor disorders. *Int Urogynecol J*, 2013. 24: 213.  
<https://www.ncbi.nlm.nih.gov/pubmed/22669425>
16. Kim, J., *et al.* 1576 Is there a relationship between incontinence impact questionnaire 7 score after surgery for stress urinary incontinence and patient-perceived satisfaction and improvement? *J Urol*. 189: e647. *J Urol*. 189: e647.  
[http://www.jurology.com/article/S0022-5347\(13\)03402-2/abstract](http://www.jurology.com/article/S0022-5347(13)03402-2/abstract)
17. Tran, M.G., *et al.* Patient reported outcome measures in male incontinence surgery. *Ann R Coll Surg Engl*, 2014. 96: 521.  
<https://www.ncbi.nlm.nih.gov/pubmed/25245731>
18. Shy, M., *et al.* Objective Evaluation of Overactive Bladder: Which Surveys Should I Use? *Curr Bladder Dysfunct Rep*, 2013. 8: 45.  
<https://www.ncbi.nlm.nih.gov/pubmed/23439804>
19. Abrams, P., *et al.* The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. *Neurourol Urodyn*, 2002. 21: 167.  
<https://www.ncbi.nlm.nih.gov/pubmed/11857671>

20. Haylen, B.T., *et al.* An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint terminology and classification of the complications related directly to the insertion of prostheses (meshes, implants, tapes) and grafts in female pelvic floor surgery. *Neurourol Urodyn*, 2011. 30: 2.  
<https://www.ncbi.nlm.nih.gov/pubmed/21181958>
21. Brown, J.S., *et al.* Measurement characteristics of a voiding diary for use by men and women with overactive bladder. *Urology*, 2003. 61: 802.  
<https://www.ncbi.nlm.nih.gov/pubmed/12670569>
22. Nygaard, I., *et al.* Reproducibility of the seven-day voiding diary in women with stress urinary incontinence. *Int Urogynecol J Pelvic Floor Dysfunct*, 2000. 11: 15.  
<https://www.ncbi.nlm.nih.gov/pubmed/10738929>
23. Ertberg, P., *et al.* A comparison of three methods to evaluate maximum bladder capacity: cystometry, uroflowmetry and a 24-h voiding diary in women with urinary incontinence. *Acta Obstet Gynecol Scand*, 2003. 82: 374.  
<https://www.ncbi.nlm.nih.gov/pubmed/12716323>
24. Fitzgerald, M.P., *et al.* Variability of 24-hour voiding diary variables among asymptomatic women. *J Urol*, 2003. 169: 207.  
<https://www.ncbi.nlm.nih.gov/pubmed/12478137>
25. Burgio, K.L., *et al.* Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial. *JAMA*, 1998. 280: 1995.  
<https://www.ncbi.nlm.nih.gov/pubmed/21224456>
26. Fayyad, A.M., *et al.* Urine production and bladder diary measurements in women with type 2 diabetes mellitus and their relation to lower urinary tract symptoms and voiding dysfunction. *Neurourol Urodyn*, 2010. 29: 354.  
<https://www.ncbi.nlm.nih.gov/pubmed/19760759>
27. Homma, Y., *et al.* Assessment of overactive bladder symptoms: comparison of 3-day bladder diary and the overactive bladder symptoms score. *Urology*, 2011. 77: 60.  
<https://www.ncbi.nlm.nih.gov/pubmed/20951412>
28. Stav, K., *et al.* Women overestimate daytime urinary frequency: the importance of the bladder diary. *J Urol*, 2009. 181: 2176.  
<https://www.ncbi.nlm.nih.gov/pubmed/19296975>
29. van Brummen, H.J., *et al.* The association between overactive bladder symptoms and objective parameters from bladder diary and filling cystometry. *Neurourol Urodyn*, 2004. 23: 38.  
<https://www.ncbi.nlm.nih.gov/pubmed/14694455>
30. Gravas, S., *et al.*, EAU Guidelines on the management of Non-Neurogenice Male LUTS, in EAU Guidelines. Edn. published at the 33rd EAU Annual Congress, Copenhagen, E.G. Office, Editor. 2018, EAU Guidelines Office Arnhem, The Netherlands.
31. Buchsbaum, G.M., *et al.* Utility of urine reagent strip in screening women with incontinence for urinary tract infection. *Int Urogynecol J Pelvic Floor Dysfunct*, 2004. 15: 391.  
<https://www.ncbi.nlm.nih.gov/pubmed/15278254>
32. Arinzon, Z., *et al.* Clinical presentation of urinary tract infection (UTI) differs with aging in women. *Arch Gerontol Geriatr*, 2012. 55: 145.  
<https://www.ncbi.nlm.nih.gov/pubmed/21963175>
33. Moore, E.E., *et al.* Urinary incontinence and urinary tract infection: temporal relationships in postmenopausal women. *Obstet Gynecol*, 2008. 111: 317.  
<https://www.ncbi.nlm.nih.gov/pubmed/21963175>
34. Ouslander, J.G., *et al.* Does eradicating bacteriuria affect the severity of chronic urinary incontinence in nursing home residents? *Ann Intern Med*, 1995. 122: 749.  
<https://www.ncbi.nlm.nih.gov/pubmed/7717597>
35. Goode, P.S., *et al.* Measurement of postvoid residual urine with portable transabdominal bladder ultrasound scanner and urethral catheterization. *Int Urogynecol J Pelvic Floor Dysfunct*, 2000. 11: 296.  
<https://www.ncbi.nlm.nih.gov/pubmed/11052565>
36. Griffiths, D.J., *et al.* Variability of post-void residual urine volume in the elderly. *Urol Res*, 1996. 24: 23.  
<https://www.ncbi.nlm.nih.gov/pubmed/8966837>
37. Marks, L.S., *et al.* Three-dimensional ultrasound device for rapid determination of bladder volume. *Urology*, 1997. 50: 341.  
<https://www.ncbi.nlm.nih.gov/pubmed/9301695>
38. Nygaard, I.E. Postvoid residual volume cannot be accurately estimated by bimanual examination. *Int Urogynecol J Pelvic Floor Dysfunct*, 1996. 7: 74.  
<https://www.ncbi.nlm.nih.gov/pubmed/8798090>

39. Ouslander, J.G., *et al.* Use of a portable ultrasound device to measure post-void residual volume among incontinent nursing home residents. *J Am Geriatr Soc*, 1994. 42: 1189.  
<https://www.ncbi.nlm.nih.gov/pubmed/7963206>
40. Stoller, M.L., *et al.* The accuracy of a catheterized residual urine. *J Urol*, 1989. 141: 15.  
<https://www.ncbi.nlm.nih.gov/pubmed/2908944>
41. Gehrich, A., *et al.* Establishing a mean postvoid residual volume in asymptomatic perimenopausal and postmenopausal women. *Obstet Gynecol*, 2007. 110: 827.  
<https://www.ncbi.nlm.nih.gov/pubmed/17906016>
42. Tseng, L.H., *et al.* Postvoid residual urine in women with stress incontinence. *Neurourol Urodyn*, 2008. 27: 48.  
<https://www.ncbi.nlm.nih.gov/pubmed/17563112>
43. Haylen, B.T., *et al.* Immediate postvoid residual volumes in women with symptoms of pelvic floor dysfunction. *Obstet Gynecol*, 2008. 111: 1305.  
<https://www.ncbi.nlm.nih.gov/pubmed/18515513>
44. Lukacz, E.S., *et al.* Elevated postvoid residual in women with pelvic floor disorders: prevalence and associated risk factors. *Int Urogynecol J Pelvic Floor Dysfunct*, 2007. 18: 397.  
<https://www.ncbi.nlm.nih.gov/pubmed/16804634>
45. Milleman, M., *et al.* Post-void residual urine volume in women with overactive bladder symptoms. *J Urol*, 2004. 172: 1911.  
<https://www.ncbi.nlm.nih.gov/pubmed/15540753>
46. Brostrom, S., *et al.* Short-term reproducibility of cystometry and pressure-flow micturition studies in healthy women. *Neurourol Urodyn*, 2002. 21: 457.  
<https://www.ncbi.nlm.nih.gov/pubmed/12232880>
47. Broekhuis, S.R., *et al.* Reproducibility of same session repeated cystometry and pressure-flow studies in women with symptoms of urinary incontinence. *Neurourol Urodyn*, 2010. 29: 428.  
<https://www.ncbi.nlm.nih.gov/pubmed/19618451>
48. Schick, E., *et al.* Predictive value of maximum urethral closure pressure, urethral hypermobility and urethral incompetence in the diagnosis of clinically significant female genuine stress incontinence. *J Urol*, 2004. 171: 1871.  
<https://www.ncbi.nlm.nih.gov/pubmed/15076296>
49. Dorflinger, A., *et al.* Urethral pressure profile: is it affected by position? *Neurourol Urodyn*, 2002. 21: 553.  
<https://www.ncbi.nlm.nih.gov/pubmed/12382246>
50. Wang, A.C., *et al.* A comparison of urethral pressure profilometry using microtip and double-lumen perfusion catheters in women with genuine stress incontinence. *BJOG*, 2002. 109: 322.  
<https://www.ncbi.nlm.nih.gov/pubmed/11950188>
51. Zehnder, P., *et al.* Air charged and microtip catheters cannot be used interchangeably for urethral pressure measurement: a prospective, single-blind, randomized trial. *J Urol*, 2008. 180: 1013.  
<https://www.ncbi.nlm.nih.gov/pubmed/18639301>
52. Albo, M.E., *et al.* Burch colposuspension versus fascial sling to reduce urinary stress incontinence. *N Engl J Med*, 2007. 356: 2143.  
<https://www.ncbi.nlm.nih.gov/pubmed/17517855>
53. Urinary incontinence in women: management [CG171]. 2013, National Institute for Health and Care Excellence.  
<https://www.nice.org.uk/guidance/cg171?unlid=79956624201691465614>.
54. van Leijsen, S.A., *et al.* The correlation between clinical and urodynamic diagnosis in classifying the type of urinary incontinence in women. A systematic review of the literature. *Neurourol Urodyn*, 2011. 30: 495.  
<https://www.ncbi.nlm.nih.gov/pubmed/21298721>
55. Rosier, P., *et al.*, Committee 6: Urodynamic Testing, in 5th International Consultation on Incontinence, Paris February, 2012, P. Abrams, L. Cardozo, S. Khoury & A. Wein, Editors. 2013: Paris, France.
56. Klarskov, N. Urethral pressure reflectometry. A method for simultaneous measurements of pressure and cross-sectional area in the female urethra. *Dan Med J*, 2012. 59: B4412.  
<https://www.ncbi.nlm.nih.gov/pubmed/22381095>
57. Dokmeci, F., *et al.* Comparison of ambulatory versus conventional urodynamics in females with urinary incontinence. *Neurourol Urodyn*, 2010. 29: 518.  
<https://www.ncbi.nlm.nih.gov/pubmed/19731314>
58. Radley, S.C., *et al.* Conventional and ambulatory urodynamic findings in women with symptoms suggestive of bladder overactivity. *J Urol*, 2001. 166: 2253.  
<https://www.ncbi.nlm.nih.gov/pubmed/11696746>



59. Glazener, C.M., *et al.* Urodynamic studies for management of urinary incontinence in children and adults. *Cochrane Database Syst Rev*, 2012. 1: CD003195.  
<https://www.ncbi.nlm.nih.gov/pubmed/22258952>
60. Nitti, V.W., *et al.* Response to fesoterodine in patients with an overactive bladder and urgency urinary incontinence is independent of the urodynamic finding of detrusor overactivity. *BJU Int*, 2010. 105: 1268.  
<https://www.ncbi.nlm.nih.gov/pubmed/19889062>
61. Rovner, E., *et al.* Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxinA in a randomized, placebo-controlled dose-finding study in idiopathic overactive bladder. *Neurourol Urodyn*, 2011. 30: 556.  
<https://www.ncbi.nlm.nih.gov/pubmed/21351127>
62. Sirls, L.T., *et al.* The effect of urodynamic testing on clinical diagnosis, treatment plan and outcomes in women undergoing stress urinary incontinence surgery. *J Urol*, 2013. 189: 204.  
<https://www.ncbi.nlm.nih.gov/pubmed/22982425>
63. Nager, C.W., *et al.* A randomized trial of urodynamic testing before stress-incontinence surgery. *N Engl J Med*, 2012. 366: 1987.  
<https://www.ncbi.nlm.nih.gov/pubmed/22551104>
64. van Leijsen, S.A., *et al.* Can preoperative urodynamic investigation be omitted in women with stress urinary incontinence? A non-inferiority randomized controlled trial. *Neurourol Urodyn*, 2012. 31: 1118.  
<https://www.ncbi.nlm.nih.gov/pubmed/22488817>
65. van Leijsen, S.A., *et al.* Value of urodynamics before stress urinary incontinence surgery: a randomized controlled trial. *Obstet Gynecol*, 2013. 121: 999.  
<https://www.ncbi.nlm.nih.gov/pubmed/23635736>
66. Nager, C.W., *et al.* Baseline urodynamic predictors of treatment failure 1 year after mid urethral sling surgery. *J Urol*, 2011. 186: 597.  
<https://www.ncbi.nlm.nih.gov/pubmed/21683412>
67. Dawson, T., *et al.* Factors predictive of post-TVT voiding dysfunction. *Int Urogynecol J Pelvic Floor Dysfunct*, 2007. 18: 1297.  
<https://www.ncbi.nlm.nih.gov/pubmed/17347790>
68. Hong, B., *et al.* Factors predictive of urinary retention after a tension-free vaginal tape procedure for female stress urinary incontinence. *J Urol*, 2003. 170: 852.  
<https://www.ncbi.nlm.nih.gov/pubmed/12913715>
69. Abdel-Fattah, M., *et al.* Pelvicol pubovaginal sling versus tension-free vaginal tape for treatment of urodynamic stress incontinence: a prospective randomized three-year follow-up study. *Eur Urol*, 2004. 46: 629.  
<https://www.ncbi.nlm.nih.gov/pubmed/15474274>
70. Lemack, G.E., *et al.* Normal preoperative urodynamic testing does not predict voiding dysfunction after Burch colposuspension versus pubovaginal sling. *J Urol*, 2008. 180: 2076.  
<https://www.ncbi.nlm.nih.gov/pubmed/18804239>
71. Gomha, M.A., *et al.* Artificial urinary sphincter for post-prostatectomy incontinence in men who had prior radiotherapy: a risk and outcome analysis. *J Urol*, 2002. 167: 591.  
<https://www.ncbi.nlm.nih.gov/pubmed/11792924>
72. Thiel, D.D., *et al.* Do clinical or urodynamic parameters predict artificial urinary sphincter outcome in post-radical prostatectomy incontinence? *Urology*, 2007. 69: 315.  
<https://www.ncbi.nlm.nih.gov/pubmed/17320671>
73. Rosier, P., *et al.* International Continence Society Good Urodynamic Practices and Terms 2016: Urodynamics, uroflowmetry, cystometry, and pressure-flow study. *Neurourol Urodyn*, 2017. 36: 1243.  
<https://www.ncbi.nlm.nih.gov/pubmed/27917521>
74. Al Afraa, T., *et al.* Normal lower urinary tract assessment in women: I. Uroflowmetry and post-void residual, pad tests, and bladder diaries. *Int Urogynecol J*, 2012. 23: 681.  
<https://www.ncbi.nlm.nih.gov/pubmed/21935667>
75. Krhut, J., *et al.* Pad weight testing in the evaluation of urinary incontinence. *Neurourol Urodyn*, 2014. 33: 507.  
<https://www.ncbi.nlm.nih.gov/pubmed/23797972>
76. Painter, V., *et al.* Does patient activity level affect 24-hr pad test results in stress-incontinent women? *Neurourol Urodyn*, 2012. 31: 143.  
<https://www.ncbi.nlm.nih.gov/pubmed/21780173>
77. Rimstad, L., *et al.* Pad stress tests with increasing load for the diagnosis of stress urinary incontinence. *Neurourol Urodyn*, 2014. 33: 1135.  
<https://www.ncbi.nlm.nih.gov/pubmed/23913797>

78. Richter, H.E., *et al.* Demographic and clinical predictors of treatment failure one year after midurethral sling surgery. *Obstet Gynecol*, 2011. 117: 913.  
<https://www.ncbi.nlm.nih.gov/pubmed/21422865>
79. Sato, Y., *et al.* Simple and reliable predictor of urinary continence after radical prostatectomy: serial measurement of urine loss ratio after catheter removal. *Int J Urol*, 2014. 21: 647.  
<https://www.ncbi.nlm.nih.gov/pubmed/24612261>
80. Ward, K.L., *et al.* A prospective multicenter randomized trial of tension-free vaginal tape and colposuspension for primary urodynamic stress incontinence: two-year follow-up. *Am J Obstet Gynecol*, 2004. 190: 324.  
<https://www.ncbi.nlm.nih.gov/pubmed/14981369>
81. Lewicky-Gaupp, C., *et al.* "The cough game": are there characteristic urethrovesical movement patterns associated with stress incontinence? *Int Urogynecol J Pelvic Floor Dysfunct*, 2009. 20: 171.  
<https://www.ncbi.nlm.nih.gov/pubmed/18850057>
82. Shek, K.L., *et al.* The effect of childbirth on urethral mobility: a prospective observational study. *J Urol*, 2010. 184: 629.  
<https://www.ncbi.nlm.nih.gov/pubmed/20639028>
83. Woodfield, C.A., *et al.* Imaging pelvic floor disorders: trend toward comprehensive MRI. *AJR Am J Roentgenol*, 2010. 194: 1640.  
<https://www.ncbi.nlm.nih.gov/pubmed/20489108>
84. Lockhart, M.E., *et al.* Reproducibility of dynamic MR imaging pelvic measurements: a multi-institutional study. *Radiology*, 2008. 249: 534.  
<https://www.ncbi.nlm.nih.gov/pubmed/18796659>
85. Shek, K.L., *et al.* The urethral motion profile before and after suburethral sling placement. *J Urol*, 2010. 183: 1450.  
<https://www.ncbi.nlm.nih.gov/pubmed/20171657>
86. Chantarasorn, V., *et al.* Sonographic appearance of transobturator slings: implications for function and dysfunction. *Int Urogynecol J*, 2011. 22: 493.  
<https://www.ncbi.nlm.nih.gov/pubmed/20967418>
87. Morgan, D.M., *et al.* Urethral sphincter morphology and function with and without stress incontinence. *J Urol*, 2009. 182: 203.  
<https://www.ncbi.nlm.nih.gov/pubmed/19450822>
88. Digesu, G.A., *et al.* Three-dimensional ultrasound of the urethral sphincter predicts continence surgery outcome. *Neurourol Urodyn*, 2009. 28: 90.  
<https://www.ncbi.nlm.nih.gov/pubmed/18726938>
89. Nguyen, L., *et al.* Surgical technique to overcome anatomical shortcoming: balancing post-prostatectomy continence outcomes of urethral sphincter lengths on preoperative magnetic resonance imaging. *J Urol*, 2008. 179: 1907.  
<https://www.ncbi.nlm.nih.gov/pubmed/18353395>
90. Paparel, P., *et al.* Recovery of urinary continence after radical prostatectomy: association with urethral length and urethral fibrosis measured by preoperative and postoperative endorectal magnetic resonance imaging. *Eur Urol*, 2009. 55: 629.  
<https://www.ncbi.nlm.nih.gov/pubmed/18801612>
91. Antunes-Lopes, T., *et al.* Biomarkers in lower urinary tract symptoms/overactive bladder: a critical overview. *Curr Opin Urol*, 2014. 24: 352.  
<https://www.ncbi.nlm.nih.gov/pubmed/24841379>
92. Sarma, A.V., *et al.* Risk factors for urinary incontinence among women with type 1 diabetes: findings from the epidemiology of diabetes interventions and complications study. *Urology*, 2009. 73: 1203.  
<https://www.ncbi.nlm.nih.gov/pubmed/19362350>
93. Coyne, K.S., *et al.* The prevalence of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) by racial/ethnic group and age: results from OAB-POLL. *Neurourol Urodyn*, 2013. 32: 230.  
<https://www.ncbi.nlm.nih.gov/pubmed/22847394>
94. Diokno, A.C., *et al.* Medical correlates of urinary incontinence in the elderly. *Urology*, 1990. 36: 129.  
<https://www.ncbi.nlm.nih.gov/pubmed/2385880>
95. Alling Moller, L., *et al.* Risk factors for lower urinary tract symptoms in women 40 to 60 years of age. *Obstet Gynecol*, 2000. 96: 446.  
<https://www.ncbi.nlm.nih.gov/pubmed/10960640>
96. Byles, J., *et al.* Living with urinary incontinence: a longitudinal study of older women. *Age Ageing*, 2009. 38: 333.  
<https://www.ncbi.nlm.nih.gov/pubmed/19258398>



97. Kaplan, S.A., *et al.* Systematic review of the relationship between bladder and bowel function: implications for patient management. *Int J Clin Pract*, 2013. 67: 205.  
<https://www.ncbi.nlm.nih.gov/pubmed/23409689>
98. Schnelle, J.F., *et al.* A controlled trial of an intervention to improve urinary and fecal incontinence and constipation. *J Am Geriatr Soc*, 2010. 58: 1504.  
<https://www.ncbi.nlm.nih.gov/pubmed/20653804>
99. Geng, V., *et al.*, Catheterisation Indwelling catheters in adults – Urethral and Suprapubic - Evidence-based Guidelines for Best Practice in Urological Health Care. 2012 ed, ed. E.A.o.U. Nurses. 2012,  
<http://nurses.uroweb.org/guideline/catheterisation-indwelling-catheters-in-adults-urethral-and-suprapubic/>.
100. Geng, V., *et al.*, Male external catheters in adults – Urinary catheter management - Evidence-based Guidelines for Best Practice in Urological Health Care, ed. E.A.o.U. Nurses. Vol. Edn. presented at the 17th International EAUN Meeting, Munich. 2016. 2016, Arnhem, The Netherlands
101. Vahr, S., *et al.*, Catheterisation Urethral Intermittent in adults - Evidence-based Guidelines for Best Practice in Urological Health Care, ed. E.A.o.U. Nurses. Vol. Edn. presented at the 14th International EAUN Meeting, Milan. 2013, Arnhem, The Netherlands
102. McMurdo, M.E., *et al.* A cost-effectiveness study of the management of intractable urinary incontinence by urinary catheterisation or incontinence pads. *J Epidemiol Community Health*, 1992. 46: 222.  
<https://www.ncbi.nlm.nih.gov/pubmed/1645076>
103. Saint, S., *et al.* Condom versus indwelling urinary catheters: a randomized trial. *J Am Geriatr Soc*, 2006. 54: 1055.  
<https://www.ncbi.nlm.nih.gov/pubmed/16866675>
104. Chartier-Kastler, E., *et al.* Randomized, crossover study evaluating patient preference and the impact on quality of life of urisheaths vs absorbent products in incontinent men. *BJU Int*, 2011. 108: 241.  
<https://www.ncbi.nlm.nih.gov/pubmed/20950307>
105. Brazzelli, M., *et al.* Absorbent products for containing urinary and/or fecal incontinence in adults. *J Wound Ostomy Continence Nurs*, 2002. 29: 45.  
<https://www.ncbi.nlm.nih.gov/pubmed/11810074>
106. Fader, M., *et al.* A multi-centre evaluation of absorbent products for men with light urinary incontinence. *Neurourol Urodyn*, 2006. 25: 689.  
<https://www.ncbi.nlm.nih.gov/pubmed/17009303>
107. Fader, M., *et al.* Absorbent products for urinary/faecal incontinence: a comparative evaluation of key product designs. *Health Technol Assess*, 2008. 12: iii.  
<https://www.ncbi.nlm.nih.gov/pubmed/18547500>
108. Jahn, P., *et al.* Types of indwelling urinary catheters for long-term bladder drainage in adults. *Cochrane Database Syst Rev*, 2012. 10: CD004997.  
<https://www.ncbi.nlm.nih.gov/pubmed/23076911>
109. Hunter, K.F., *et al.* Long-term bladder drainage: Suprapubic catheter versus other methods: a scoping review. *Neurourol Urodyn*, 2013. 32: 944.  
<https://www.ncbi.nlm.nih.gov/pubmed/23192860>
110. Prieto, J., *et al.* Catheter designs, techniques and strategies for intermittent catheterisation: What is the evidence for preventing symptomatic UTI and other complications? A Cochrane systematic review. *Eur Urol Suppl*, 2014. 13: e762.  
[http://www.eusupplements.europanurology.com/article/S1569-9056\(14\)60751-X/pdf](http://www.eusupplements.europanurology.com/article/S1569-9056(14)60751-X/pdf)
111. Hakansson, M.A. Reuse versus single-use catheters for intermittent catheterization: what is safe and preferred? Review of current status. *Spinal Cord*, 2014. 52: 511.  
<https://www.ncbi.nlm.nih.gov/pubmed/24861702>
112. Hagen, S., *et al.* Washout policies in long-term indwelling urinary catheterisation in adults. *Cochrane Database Syst Rev*, 2010: CD004012.  
<https://www.ncbi.nlm.nih.gov/pubmed/20238325>
113. Niel-Weise, B.S., *et al.* Urinary catheter policies for long-term bladder drainage. *Cochrane Database Syst Rev*, 2012: CD004201.  
<https://www.ncbi.nlm.nih.gov/pubmed/22895939>
114. Moore, K.N., *et al.* Assessing comfort, safety, and patient satisfaction with three commonly used penile compression devices. *Urology*, 2004. 63: 150.  
<https://www.ncbi.nlm.nih.gov/pubmed/14751370>
115. Lipp, A., *et al.* Mechanical devices for urinary incontinence in women. *Cochrane Database Syst Rev*, 2014: CD001756.  
<https://www.ncbi.nlm.nih.gov/pubmed/25517397>

116. Hannestad, Y.S., *et al.* Are smoking and other lifestyle factors associated with female urinary incontinence? The Norwegian EPINCONT Study. *BJOG*, 2003. 110: 247.  
<https://www.ncbi.nlm.nih.gov/pubmed/12628262>
117. Arya, L.A., *et al.* Dietary caffeine intake and the risk for detrusor instability: a case-control study. *Obstet Gynecol*, 2000. 96: 85.  
<https://www.ncbi.nlm.nih.gov/pubmed/10862848>
118. Bryant, C.M., *et al.* Caffeine reduction education to improve urinary symptoms. *Br J Nurs*, 2002. 11: 560.  
<https://www.ncbi.nlm.nih.gov/pubmed/11979209>
119. Swithinbank, L., *et al.* The effect of fluid intake on urinary symptoms in women. *J Urol*, 2005. 174: 187.  
<https://www.ncbi.nlm.nih.gov/pubmed/15947624>
120. Tomlinson, B.U., *et al.* Dietary caffeine, fluid intake and urinary incontinence in older rural women. *Int Urogynecol J Pelvic Floor Dysfunct*, 1999. 10: 22.  
<https://www.ncbi.nlm.nih.gov/pubmed/10207763>
121. Townsend, M.K., *et al.* Caffeine intake and risk of urinary incontinence progression among women. *Obstet Gynecol*, 2012. 119: 950.  
<https://www.ncbi.nlm.nih.gov/pubmed/22525905>
122. Jorgensen, S., *et al.* Heavy lifting at work and risk of genital prolapse and herniated lumbar disc in assistant nurses. *Occup Med (Lond)*, 1994. 44: 47.  
<https://www.ncbi.nlm.nih.gov/pubmed/8167320>
123. Nygaard, I., *et al.* Exercise and incontinence. *Obstet Gynecol*, 1990. 75: 848.  
<https://www.ncbi.nlm.nih.gov/pubmed/2325968>
124. Nygaard, I.E., *et al.* Urinary incontinence in elite nulliparous athletes. *Obstet Gynecol*, 1994. 84: 183.  
<https://www.ncbi.nlm.nih.gov/pubmed/8041527>
125. Bo, K., *et al.* Prevalence of stress and urge urinary incontinence in elite athletes and controls. *Med Sci Sports Exerc*, 2001. 33: 1797.  
<https://www.ncbi.nlm.nih.gov/pubmed/11689727>
126. Bo, K., *et al.* Are former female elite athletes more likely to experience urinary incontinence later in life than non-athletes? *Scand J Med Sci Sports*, 2010. 20: 100.  
<https://www.ncbi.nlm.nih.gov/pubmed/19000097>
127. Bovell, K., *et al.* Prevalence of stress urinary incontinence among physically active and sedentary female students. *Scand J Med Sci Sports*, 1989. 11: 113.  
[https://www.researchgate.net/publication/279889192\\_Prevalence\\_of\\_stress\\_urinary\\_incontinence\\_among\\_physically\\_active\\_and\\_sedentary\\_female\\_students](https://www.researchgate.net/publication/279889192_Prevalence_of_stress_urinary_incontinence_among_physically_active_and_sedentary_female_students)
128. Caylet, N., *et al.* Prevalence and occurrence of stress urinary incontinence in elite women athletes. *Can J Urol*, 2006. 13: 3174.  
<https://www.ncbi.nlm.nih.gov/pubmed/16953954>
129. Kruger, J.A., *et al.* Pelvic floor function in elite nulliparous athletes. *Ultrasound Obstet Gynecol*, 2007. 30: 81.  
<https://www.ncbi.nlm.nih.gov/pubmed/17497753>
130. Thyssen, H.H., *et al.* Urinary incontinence in elite female athletes and dancers. *Int Urogynecol J Pelvic Floor Dysfunct*, 2002. 13: 15.  
<https://www.ncbi.nlm.nih.gov/pubmed/11999199>
131. Brown, W.J., *et al.* Too wet to exercise? Leaking urine as a barrier to physical activity in women. *J Sci Med Sport*, 2001. 4: 373.  
<https://www.ncbi.nlm.nih.gov/pubmed/11905931>
132. Nygaard, I.E. Does prolonged high-impact activity contribute to later urinary incontinence? A retrospective cohort study of female Olympians. *Obstet Gynecol*, 1997. 90: 718.  
<https://www.ncbi.nlm.nih.gov/pubmed/9351751>
133. Eliasson, K., *et al.* Influence of physical activity on urinary leakage in primiparous women. *Scand J Med Sci Sports*, 2005. 15: 87.  
<https://www.ncbi.nlm.nih.gov/pubmed/15773862>
134. Kikuchi, A., *et al.* Association between physical activity and urinary incontinence in a community-based elderly population aged 70 years and over. *Eur Urol*, 2007. 52: 868.  
<https://www.ncbi.nlm.nih.gov/pubmed/17412488>
135. Kim, H., *et al.* Effectiveness of multidimensional exercises for the treatment of stress urinary incontinence in elderly community-dwelling Japanese women: a randomized, controlled, crossover trial. *J Am Geriatr Soc*, 2007. 55: 1932.  
<https://www.ncbi.nlm.nih.gov/pubmed/17944890>

136. Kim, H., *et al.* The effects of multidimensional exercise treatment on community-dwelling elderly Japanese women with stress, urge, and mixed urinary incontinence: a randomized controlled trial. *Int J Nurs Stud*, 2011. 48: 1165.  
<https://www.ncbi.nlm.nih.gov/pubmed/21459381>
137. Dowd, T.T., *et al.* Fluid intake and urinary incontinence in older community-dwelling women. *J Community Health Nurs*, 1996. 13: 179.  
<https://www.ncbi.nlm.nih.gov/pubmed/8916607>
138. Hashim, H., *et al.* How should patients with an overactive bladder manipulate their fluid intake? *BJU Int*, 2008. 102: 62.  
<https://www.ncbi.nlm.nih.gov/pubmed/18284414>
139. Zimmern, P., *et al.* Effect of fluid management on fluid intake and urge incontinence in a trial for overactive bladder in women. *BJU Int*, 2010. 105: 1680.  
<https://www.ncbi.nlm.nih.gov/pubmed/19912207>
140. Hunskaar, S. A systematic review of overweight and obesity as risk factors and targets for clinical intervention for urinary incontinence in women. *Neurourol Urodyn*, 2008. 27: 749.  
<https://www.ncbi.nlm.nih.gov/pubmed/18951445>
141. Subak, L.L., *et al.* Weight loss to treat urinary incontinence in overweight and obese women. *N Engl J Med*, 2009. 360: 481.  
<https://www.ncbi.nlm.nih.gov/pubmed/11999205>
142. Nygaard, I., *et al.* Prevalence of symptomatic pelvic floor disorders in US women. *JAMA*, 2008. 300: 1311.  
<https://www.ncbi.nlm.nih.gov/pubmed/18799443>
143. Chen, C.C., *et al.* Obesity is associated with increased prevalence and severity of pelvic floor disorders in women considering bariatric surgery. *Surg Obes Relat Dis*, 2009. 5: 411.  
<https://www.ncbi.nlm.nih.gov/pubmed/19136310>
144. Gozukara, Y.M., *et al.* The improvement in pelvic floor symptoms with weight loss in obese women does not correlate with the changes in pelvic anatomy. *Int Urogynecol J*, 2014. 25: 1219.  
<https://www.ncbi.nlm.nih.gov/pubmed/24711149>
145. Brown, J.S., *et al.* Lifestyle intervention is associated with lower prevalence of urinary incontinence: the Diabetes Prevention Program. *Diabetes Care*, 2006. 29: 385.  
<https://www.ncbi.nlm.nih.gov/pubmed/16443892>
146. Bump, R.C., *et al.* Obesity and lower urinary tract function in women: effect of surgically induced weight loss. *Am J Obstet Gynecol*, 1992. 167: 392.  
<https://www.ncbi.nlm.nih.gov/pubmed/1497041>
147. Subak, L.L., *et al.* Does weight loss improve incontinence in moderately obese women? *Int Urogynecol J Pelvic Floor Dysfunct*, 2002. 13: 40.  
<https://www.ncbi.nlm.nih.gov/pubmed/11999205>
148. Wing, R.R., *et al.* Improving urinary incontinence in overweight and obese women through modest weight loss. *Obstet Gynecol*, 2010. 116: 284.  
<https://www.ncbi.nlm.nih.gov/pubmed/20664387>
149. Subak, L.L., *et al.* Weight loss: a novel and effective treatment for urinary incontinence. *J Urol*, 2005. 174: 190.  
<https://www.ncbi.nlm.nih.gov/pubmed/15947625>
150. Phelan, S., *et al.* Weight loss prevents urinary incontinence in women with type 2 diabetes: results from the Look AHEAD trial. *J Urol*, 2012. 187: 939.  
<https://www.ncbi.nlm.nih.gov/pubmed/15947625>
151. Burgio, K.L., *et al.* Changes in urinary and fecal incontinence symptoms with weight loss surgery in morbidly obese women. *Obstet Gynecol*, 2007. 110: 1034.  
<https://www.ncbi.nlm.nih.gov/pubmed/17978117>
152. Deitel, M., *et al.* Gynecologic-obstetric changes after loss of massive excess weight following bariatric surgery. *J Am Coll Nutr*, 1988. 7: 147.  
<https://www.ncbi.nlm.nih.gov/pubmed/3361039>
153. Laungani, R.G., *et al.* Effect of laparoscopic gastric bypass surgery on urinary incontinence in morbidly obese women. *Surg Obes Relat Dis*, 2009. 5: 334.  
<https://www.ncbi.nlm.nih.gov/pubmed/19342304>
154. Mishra, G.D., *et al.* Body weight through adult life and risk of urinary incontinence in middle-aged women: results from a British prospective cohort. *Int J Obes (Lond)*, 2008. 32: 1415.  
<https://www.ncbi.nlm.nih.gov/pubmed/18626483>

155. Richter, H.E., *et al.* The impact of obesity on urinary incontinence symptoms, severity, urodynamic characteristics and quality of life. *J Urol*, 2010. 183: 622.  
<https://www.ncbi.nlm.nih.gov/pubmed/20018326>
156. Danforth, K.N., *et al.* Risk factors for urinary incontinence among middle-aged women. *Am J Obstet Gynecol*, 2006. 194: 339.  
<https://www.ncbi.nlm.nih.gov/pubmed/16458626>
157. Imamura, M., *et al.* Systematic review and economic modelling of the effectiveness and cost-effectiveness of non-surgical treatments for women with stress urinary incontinence. *Health Technol Assess*, 2010. 14: 1.  
<https://www.ncbi.nlm.nih.gov/pubmed/20738930>
158. Bo, K., *et al.*, An International Urogynecological Association (IUGA) /International Continence Society (ICS) Joint report on the terminology for the conservative management of pelvic floor dysfunction (in Committee Review). *Int Urogynecol J*, 2017. 28: 191.  
<http://www.bethshelly.com/docs/IUGA-ICS-joint-report.pdf>
159. Eustice, S., *et al.* Prompted voiding for the management of urinary incontinence in adults. *Cochrane Database Syst Rev*, 2000: CD002113.  
<https://www.ncbi.nlm.nih.gov/pubmed/10796861>
160. Flanagan, L., *et al.* Systematic review of care intervention studies for the management of incontinence and promotion of continence in older people in care homes with urinary incontinence as the primary focus (1966-2010). *Geriatr Gerontol Int*, 2012. 12: 600.  
<https://www.ncbi.nlm.nih.gov/pubmed/22672329>
161. Ostaszkiwicz, J., *et al.* Habit retraining for the management of urinary incontinence in adults. *Cochrane Database Syst Rev*, 2004: CD002801.  
<https://www.ncbi.nlm.nih.gov/pubmed/15106179>
162. Shamliyan, T., *et al.*, Nonsurgical Treatments for Urinary Incontinence in Adult Women: Diagnosis and Comparative Effectiveness. 2012, IUGA-ICS Conservative Management for Female Pelvic Floor Dysfunction: Rockville (MD).  
<https://www.ncbi.nlm.nih.gov/pubmed/22624162>
163. Rai, B.P., *et al.* Anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adults. *Cochrane Database Syst Rev*, 2012. 12: CD003193.  
<https://www.ncbi.nlm.nih.gov/pubmed/23235594>
164. Sherburn, M., *et al.* Incontinence improves in older women after intensive pelvic floor muscle training: an assessor-blinded randomized controlled trial. *Neurourol Urodyn*, 2011. 30: 317.  
<https://www.ncbi.nlm.nih.gov/pubmed/21284022>
165. Berghmans, B., *et al.* Efficacy of physical therapeutic modalities in women with proven bladder overactivity. *Eur Urol*, 2002. 41: 581.  
<https://www.ncbi.nlm.nih.gov/pubmed/12074773>
166. Dumoulin, C., *et al.* Pelvic floor muscle training versus no treatment for urinary incontinence in women. A Cochrane systematic review. *Eur J Phys Rehabil Med*, 2008. 44: 47.  
<https://www.ncbi.nlm.nih.gov/pubmed/18385628>
167. Hay-Smith, E.J., *et al.* Comparisons of approaches to pelvic floor muscle training for urinary incontinence in women. *Cochrane Database Syst Rev*, 2011: CD009508.  
<https://www.ncbi.nlm.nih.gov/pubmed/22161451>
168. Bo, K., *et al.* Lower urinary tract symptoms and pelvic floor muscle exercise adherence after 15 years. *Obstet Gynecol*, 2005. 105: 999.  
<https://www.ncbi.nlm.nih.gov/pubmed/15863536>
169. Herderschee, R., *et al.* Feedback or biofeedback to augment pelvic floor muscle training for urinary incontinence in women. *Cochrane Database Syst Rev*, 2011: CD009252.  
<https://www.ncbi.nlm.nih.gov/pubmed/21735442>
170. Boyle, R., *et al.* Pelvic floor muscle training for prevention and treatment of urinary and faecal incontinence in antenatal and postnatal women. *Cochrane Database Syst Rev*, 2012. 10: CD007471.  
<https://www.ncbi.nlm.nih.gov/pubmed/23076935>
171. Haddow, G., *et al.* Effectiveness of a pelvic floor muscle exercise program on urinary incontinence following childbirth. *Int J Evid Based Healthc*, 2005. 3: 103.  
<https://www.ncbi.nlm.nih.gov/pubmed/21631746>
172. McFall, S.L., *et al.* Outcomes of a small group educational intervention for urinary incontinence: health-related quality of life. *J Aging Health*, 2000. 12: 301.  
<https://www.ncbi.nlm.nih.gov/pubmed/11067699>

173. Campbell, S.E., *et al.* Conservative management for postprostatectomy urinary incontinence. *Cochrane Database Syst Rev*, 2012. 1: CD001843.  
<https://www.ncbi.nlm.nih.gov/pubmed/22258946>
174. Geraerts, I., *et al.* Influence of preoperative and postoperative pelvic floor muscle training (PFMT) compared with postoperative PFMT on urinary incontinence after radical prostatectomy: a randomized controlled trial. *Eur Urol*, 2013. 64: 766.  
<https://www.ncbi.nlm.nih.gov/pubmed/23357349>
175. Dubbelman, Y., *et al.* The recovery of urinary continence after radical retropubic prostatectomy: a randomized trial comparing the effect of physiotherapist-guided pelvic floor muscle exercises with guidance by an instruction folder only. *BJU Int*, 2010. 106: 515.  
<https://www.ncbi.nlm.nih.gov/pubmed/20201841>
176. Moore, K.N., *et al.* Return to continence after radical retropubic prostatectomy: a randomized trial of verbal and written instructions versus therapist-directed pelvic floor muscle therapy. *Urology*, 2008. 72: 1280.  
<https://www.ncbi.nlm.nih.gov/pubmed/18384853>
177. Goode, P.S., *et al.* Behavioral therapy with or without biofeedback and pelvic floor electrical stimulation for persistent postprostatectomy incontinence: a randomized controlled trial. *JAMA*, 2011. 305: 151.  
<https://www.ncbi.nlm.nih.gov/pubmed/21224456>
178. Glazener, C., *et al.* Urinary incontinence in men after formal one-to-one pelvic-floor muscle training following radical prostatectomy or transurethral resection of the prostate (MAPS): two parallel randomised controlled trials. *Lancet*, 2011. 378: 328.  
<https://www.ncbi.nlm.nih.gov/pubmed/21741700>
179. Berghmans, L.C., *et al.* Conservative treatment of stress urinary incontinence in women: a systematic review of randomized clinical trials. *Br J Urol*, 1998. 82: 181.  
<https://www.ncbi.nlm.nih.gov/pubmed/9722751>
180. Berghmans, L.C., *et al.* Conservative treatment of urge urinary incontinence in women: a systematic review of randomized clinical trials. *BJU Int*, 2000. 85: 254.  
<https://www.ncbi.nlm.nih.gov/pubmed/10671878>
181. Hartmann, K.E., *et al.* Treatment of overactive bladder in women. *Evid Rep Technol Assess (Full Rep)*, 2009: 1.  
<https://www.ncbi.nlm.nih.gov/pubmed/19947666>
182. Berghmans, B., *et al.* Electrical stimulation with non-implanted electrodes for urinary incontinence in men. *Cochrane Database Syst Rev*, 2013: CD001202.  
<https://www.ncbi.nlm.nih.gov/pubmed/23740763>
183. Lim, R., *et al.* Efficacy of electromagnetic therapy for urinary incontinence: A systematic review. *Neurourol Urodyn*, 2015. 34: 713.  
<https://www.ncbi.nlm.nih.gov/pubmed/25251335>
184. Wallace, P.A., *et al.* Sacral nerve neuromodulation in patients with underlying neurologic disease. *Am J Obstet Gynecol*, 2007. 197: 96 e1.  
<https://www.ncbi.nlm.nih.gov/pubmed/17618775>
185. Finazzi-Agro, E., *et al.* Percutaneous tibial nerve stimulation effects on detrusor overactivity incontinence are not due to a placebo effect: a randomized, double-blind, placebo controlled trial. *J Urol*, 2010. 184: 2001.  
<https://www.ncbi.nlm.nih.gov/pubmed/20850833>
186. Peters, K.M., *et al.* Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmIT trial. *J Urol*, 2010. 183: 1438.  
<https://www.ncbi.nlm.nih.gov/pubmed/20171677>
187. Peters, K.M., *et al.* Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial. *J Urol*, 2009. 182: 1055.  
<https://www.ncbi.nlm.nih.gov/pubmed/19616802>
188. Peters, K.M., *et al.* Percutaneous tibial nerve stimulation for the long-term treatment of overactive bladder: 3-year results of the STEP study. *J Urol*, 2013. 189: 2194.  
<https://www.ncbi.nlm.nih.gov/pubmed/23219541>
189. Schreiner, L., *et al.* Randomized trial of transcutaneous tibial nerve stimulation to treat urge urinary incontinence in older women. *Int Urogynecol J*, 2010. 21: 1065.  
<https://www.ncbi.nlm.nih.gov/pubmed/20458465>
190. Nygaard, I.E., *et al.* Efficacy of pelvic floor muscle exercises in women with stress, urge, and mixed urinary incontinence. *Am J Obstet Gynecol*, 1996. 174: 120.  
<https://www.ncbi.nlm.nih.gov/pubmed/8571994>



191. Lagro-Janssen, T., *et al.* Long-term effect of treatment of female incontinence in general practice. *Br J Gen Pract*, 1998. 48: 1735.  
<https://www.ncbi.nlm.nih.gov/pubmed/10198479>
192. Chapple, C., *et al.* The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. *Eur Urol*, 2005. 48: 5.  
<https://www.ncbi.nlm.nih.gov/pubmed/15885877>
193. Chapple, C.R., *et al.* The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. *Eur Urol*, 2008. 54: 543.  
<https://www.ncbi.nlm.nih.gov/pubmed/18599186>
194. McDonagh, M.S., *et al.*, In: *Drug Class Review: Agents for Overactive Bladder: Final Report Update 4*. 2009: Portland (OR).
195. Shamliyan, T.A., *et al.* Systematic review: randomized, controlled trials of nonsurgical treatments for urinary incontinence in women. *Ann Intern Med*, 2008. 148: 459.  
<https://www.ncbi.nlm.nih.gov/pubmed/18268288>
196. Buser, N., *et al.* Efficacy and adverse events of antimuscarinics for treating overactive bladder: network meta-analyses. *Eur Urol*, 2012. 62: 1040.  
<https://www.ncbi.nlm.nih.gov/pubmed/22999811>
197. Reynolds, W.S., *et al.* Comparative Effectiveness of Anticholinergic Therapy for Overactive Bladder in Women: A Systematic Review and Meta-analysis. *Obstet Gynecol*, 2015. 125: 1423.  
<https://www.ncbi.nlm.nih.gov/pubmed/26000514>
198. Chapple, C., *et al.* Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial. *BJU Int*, 2014. 114: 418.  
<https://www.ncbi.nlm.nih.gov/pubmed/24552358>
199. Kaplan, S.A., *et al.* Efficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine ER. *Int J Clin Pract*, 2014. 68: 1065.  
<https://www.ncbi.nlm.nih.gov/pubmed/24898471>
200. Goldfischer, E.R., *et al.* Efficacy and safety of oxybutynin topical gel 3% in patients with urgency and/or mixed urinary incontinence: a randomized, double-blind, placebo-controlled study. *Neurourol Urodyn*, 2015. 34: 37.  
<https://www.ncbi.nlm.nih.gov/pubmed/24133005>
201. Novara, G., *et al.* A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder. *Eur Urol*, 2008. 54: 740.  
<https://www.ncbi.nlm.nih.gov/pubmed/18632201>
202. Gacci, M., *et al.* Tolterodine extended release in the treatment of male OAB/storage LUTS: a systematic review. *BMC Urol*, 2014. 14: 84.  
<https://www.ncbi.nlm.nih.gov/pubmed/25348235>
203. Madhuvrata, P., *et al.* Which anticholinergic drug for overactive bladder symptoms in adults. *Cochrane Database Syst Rev*, 2012. 1: CD005429.  
<https://www.ncbi.nlm.nih.gov/pubmed/22258963>
204. Chapple, C., *et al.* Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. *Eur Urol*, 2007. 52: 1204.  
<https://www.ncbi.nlm.nih.gov/pubmed/17651893>
205. Herschorn, S., *et al.* Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. *BJU Int*, 2010. 105: 58.  
<https://www.ncbi.nlm.nih.gov/pubmed/20132103>
206. DuBeau, C.E., *et al.* Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials. *Neurourol Urodyn*, 2012. 31: 1258.  
<https://www.ncbi.nlm.nih.gov/pubmed/22907761>
207. Goode, P.S., *et al.* Incontinence in older women. *JAMA*, 2010. 303: 2172.  
<https://www.ncbi.nlm.nih.gov/pubmed/20516418>
208. Gormley, E.A., *et al.* Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. *J Urol*, 2012. 188: 2455.  
<https://www.ncbi.nlm.nih.gov/pubmed/23098785>
209. Burgio, K.L., *et al.* Behavioral versus drug treatment for overactive bladder in men: the Male Overactive Bladder Treatment in Veterans (MOTIVE) Trial. *J Am Geriatr Soc*, 2011. 59: 2209.  
<https://www.ncbi.nlm.nih.gov/pubmed/21224456>

210. Mattiasson, A., *et al.* Efficacy of simplified bladder training in patients with overactive bladder receiving a solifenacin flexible-dose regimen: results from a randomized study. *BJU Int*, 2010. 105: 1126.  
<https://www.ncbi.nlm.nih.gov/pubmed/19818077>
211. Ayeleke, R.O., *et al.* Pelvic floor muscle training added to another active treatment versus the same active treatment alone for urinary incontinence in women. *Cochrane Database Syst Rev*, 2015: CD010551.  
<https://www.ncbi.nlm.nih.gov/pubmed/26526663>
212. Manriquez, V., *et al.* Transcutaneous posterior tibial nerve stimulation versus extended release oxybutynin in overactive bladder patients. A prospective randomized trial. *Eur J Obstet Gynecol Reprod Biol*, 2016. 196: 6.  
<https://www.ncbi.nlm.nih.gov/pubmed/26645117>
213. Franzen, K., *et al.* Electrical stimulation compared with tolterodine for treatment of urge/urge incontinence amongst women--a randomized controlled trial. *Int Urogynecol J*, 2010. 21: 1517.  
<https://www.ncbi.nlm.nih.gov/pubmed/20585755>
214. Kosilov, K.V., *et al.* Randomized controlled trial of cyclic and continuous therapy with tiroprium and solifenacin combination for severe overactive bladder in elderly patients with regard to patient compliance. *Ther Adv Urol*, 2014. 6: 215.  
<https://www.ncbi.nlm.nih.gov/pubmed/25435915>
215. Veenboer, P.W., *et al.* Long-term adherence to antimuscarinic therapy in everyday practice: a systematic review. *J Urol*, 2014. 191: 1003.  
<https://www.ncbi.nlm.nih.gov/pubmed/24140548>
216. Sand, P.K., *et al.* Long-term safety, tolerability and efficacy of fesoterodine in subjects with overactive bladder symptoms stratified by age: pooled analysis of two open-label extension studies. *Drugs Aging*, 2012. 29: 119.  
<https://www.ncbi.nlm.nih.gov/pubmed/22276958>
217. Scarpero, H., *et al.* Long-term safety, tolerability, and efficacy of fesoterodine treatment in men and women with overactive bladder symptoms. *Curr Med Res Opin*, 2011. 27: 921.  
<https://www.ncbi.nlm.nih.gov/pubmed/21355814>
218. D'Souza, A.O., *et al.* Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan. *J Manag Care Pharm*, 2008. 14: 291.  
<https://www.ncbi.nlm.nih.gov/pubmed/18439051>
219. Sears, C.L., *et al.* Overactive bladder medication adherence when medication is free to patients. *J Urol*, 2010. 183: 1077.  
<https://www.ncbi.nlm.nih.gov/pubmed/20092838>
220. Shaya, F.T., *et al.* Persistence with overactive bladder pharmacotherapy in a Medicaid population. *Am J Manag Care*, 2005. 11: S121.  
<https://www.ncbi.nlm.nih.gov/pubmed/16161385>
221. Yeaw, J., *et al.* Comparing adherence and persistence across 6 chronic medication classes. *J Manag Care Pharm*, 2009. 15: 728.  
<https://www.ncbi.nlm.nih.gov/pubmed/19954264>
222. Yu, Y.F., *et al.* Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the california medicaid program. *Value Health*, 2005. 8: 495.  
<https://www.ncbi.nlm.nih.gov/pubmed/16091027>
223. Kalder, M., *et al.* Discontinuation of treatment using anticholinergic medications in patients with urinary incontinence. *Obstet Gynecol*, 2014. 124: 794.  
<https://www.ncbi.nlm.nih.gov/pubmed/25198276>
224. Chapple, C.R., *et al.* Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability. *Neurourol Urodyn*, 2014. 33: 17.  
<https://www.ncbi.nlm.nih.gov/pubmed/24127366>
225. Cui, Y., *et al.* The efficacy and safety of mirabegron in treating OAB: a systematic review and meta-analysis of phase III trials. *Int Urol Nephrol*, 2014. 46: 275.  
<https://www.ncbi.nlm.nih.gov/pubmed/23896942>
226. Herschorn, S., *et al.* A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the beta(3) adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. *Urology*, 2013. 82: 313.  
<https://www.ncbi.nlm.nih.gov/pubmed/23896942>



227. Yamaguchi, O., *et al.* Phase III, randomised, double-blind, placebo-controlled study of the beta3-adrenoceptor agonist mirabegron, 50 mg once daily, in Japanese patients with overactive bladder. *BJU Int*, 2014. 113: 951.  
<https://www.ncbi.nlm.nih.gov/pubmed/24471907>
228. Wu, T., *et al.* The role of mirabegron in overactive bladder: a systematic review and meta-analysis. *Urol Int*, 2014. 93: 326.  
<https://www.ncbi.nlm.nih.gov/pubmed/25115445>
229. Maman, K., *et al.* Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison. *Eur Urol*, 2014. 65: 755.  
<https://www.ncbi.nlm.nih.gov/pubmed/24275310>
230. Chapple, C.R., *et al.* Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a beta(3)-adrenoceptor agonist, in overactive bladder. *Eur Urol*, 2013. 63: 296.  
<https://www.ncbi.nlm.nih.gov/pubmed/23195283>
231. Castro-Diaz, D., *et al.* The effect of mirabegron on patient-related outcomes in patients with overactive bladder: the results of post hoc correlation and responder analyses using pooled data from three randomized Phase III trials. *Qual Life Res*, 2015. 24: 1719.  
<https://www.ncbi.nlm.nih.gov/pubmed/25688038>
232. Chapple, C., *et al.* Efficacy of the beta3-adrenoceptor agonist mirabegron for the treatment of overactive bladder by severity of incontinence at baseline: a post hoc analysis of pooled data from three randomised phase 3 trials. *Eur Urol*, 2015. 67: 11.  
<https://www.ncbi.nlm.nih.gov/pubmed/25092537>
233. Malik, M., *et al.* Proarrhythmic safety of repeat doses of mirabegron in healthy subjects: a randomized, double-blind, placebo-, and active-controlled thorough QT study. *Clin Pharmacol Ther*, 2012. 92: 696.  
<https://www.ncbi.nlm.nih.gov/pubmed/23149929>
234. Martin, N., *et al.* Randomised, double-blind, placebo-controlled study to assess the ocular safety of mirabegron in normotensive IOP research subjects. *Eur Urol Suppl*, 2014. 13: e686.  
[http://www.eusupplements.europeanurology.com/article/S1569-9056\(12\)60683-6/fulltext](http://www.eusupplements.europeanurology.com/article/S1569-9056(12)60683-6/fulltext)
235. Wagg, A., *et al.* Persistence and adherence with the new beta-3 receptor agonist, mirabegron, versus antimuscarinics in overactive bladder: Early experience in Canada. *Can Urol Assoc J*, 2015. 9: 343.  
<https://www.ncbi.nlm.nih.gov/pubmed/26644809>
236. Nitti, V.W., *et al.* Urodynamics and safety of the beta(3)-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction. *J Urol*, 2013. 190: 1320.  
<https://www.ncbi.nlm.nih.gov/pubmed/23727415>
237. Kelleher, C., *et al.* A post-HOC analysis of pooled data from 3 randomised phase 3 trials of mirabegron in patients with overactive bladder (OAB): Correlations between objective and subjective outcome measures. . *Int Urogynecol J nPelvic Floor Dysfunct*, 2013. 24: S119. [No abstract available].
238. MacDiarmid, S., *et al.* Mirabegron as Add-On Treatment to Solifenacin in Patients with Incontinent Overactive Bladder and an Inadequate Response to Solifenacin Monotherapy. *J Urol*, 2016. 196: 809.  
<https://www.ncbi.nlm.nih.gov/pubmed/27063854>
239. DuBeau, C.E., *et al.* Incontinence in the frail elderly: report from the 4th International Consultation on Incontinence. *Neurourol Urodyn*, 2010. 29: 165.  
<https://www.ncbi.nlm.nih.gov/pubmed/20025027>
240. Fink, H.A., *et al.* Treatment interventions in nursing home residents with urinary incontinence: a systematic review of randomized trials. *Mayo Clin Proc*, 2008. 83: 1332.  
<https://www.ncbi.nlm.nih.gov/pubmed/19046552>
241. Ancelin, M.L., *et al.* Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study. *BMJ*, 2006. 332: 455.  
<https://www.ncbi.nlm.nih.gov/pubmed/16452102>
242. Tannenbaum, C., *et al.* A systematic review of amnestic and non-amnestic mild cognitive impairment induced by anticholinergic, antihistamine, GABAergic and opioid drugs. *Drugs Aging*, 2012. 29: 639.  
<https://www.ncbi.nlm.nih.gov/pubmed/22812538>
243. Gray, S.L., *et al.* Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. *JAMA Intern Med*, 2015. 175: 401.  
<https://www.ncbi.nlm.nih.gov/pubmed/25621434>

244. Risacher, S.L., *et al.* Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal older adults. *JAMA Neurol*, 2016. 73: 721.  
<https://www.ncbi.nlm.nih.gov/pubmed/27088965>
245. Kessler, T.M., *et al.* Adverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approach. *PLoS One*, 2011. 6: e16718.  
<https://www.ncbi.nlm.nih.gov/pubmed/21373193>
246. Paquette, A., *et al.* Systematic review and meta-analysis: do clinical trials testing antimuscarinic agents for overactive bladder adequately measure central nervous system adverse events? *J Am Geriatr Soc*, 2011. 59: 1332.  
<https://www.ncbi.nlm.nih.gov/pubmed/21718264>
247. Kay, G., *et al.* Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. *Eur Urol*, 2006. 50: 317.  
<https://www.ncbi.nlm.nih.gov/pubmed/16687205>
248. Isik, A.T., *et al.* Tropicium and cognition in patients with late onset Alzheimer disease. *J Nutr Health Aging*, 2009. 13: 672.  
<https://www.ncbi.nlm.nih.gov/pubmed/19657549>
249. Lackner, T.E., *et al.* Randomized, placebo-controlled trial of the cognitive effect, safety, and tolerability of oral extended-release oxybutynin in cognitively impaired nursing home residents with urge urinary incontinence. *J Am Geriatr Soc*, 2008. 56: 862.  
<https://www.ncbi.nlm.nih.gov/pubmed/18410326>
250. Lackner, T.E., *et al.* Efficacy of oral extended-release oxybutynin in cognitively impaired older nursing home residents with urge urinary incontinence: a randomized placebo-controlled trial. *J Am Med Dir Assoc*, 2011. 12: 639.  
<https://www.ncbi.nlm.nih.gov/pubmed/21450183>
251. Minassian, V.A., *et al.* Randomized trial of oxybutynin extended versus immediate release for women aged 65 and older with overactive bladder: lessons learned from conducting a trial. *J Obstet Gynaecol Can*, 2007. 29: 726.  
<https://www.ncbi.nlm.nih.gov/pubmed/17825137>
252. Wagg, A., *et al.* Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study. *Eur Urol*, 2013. 64: 74.  
<https://www.ncbi.nlm.nih.gov/pubmed/23332882>
253. Wesnes, K.A., *et al.* Exploratory pilot study assessing the risk of cognitive impairment or sedation in the elderly following single doses of solifenacin 10 mg. *Expert Opin Drug Saf*, 2009. 8: 615.  
<https://www.ncbi.nlm.nih.gov/pubmed/19747069>
254. Sink, K.M., *et al.* Dual use of bladder anticholinergics and cholinesterase inhibitors: long-term functional and cognitive outcomes. *J Am Geriatr Soc*, 2008. 56: 847.  
<https://www.ncbi.nlm.nih.gov/pubmed/18384584>
255. Wagg, A., *et al.* Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis. *Am J Geriatr Pharmacother*, 2006. 4: 14.  
<https://www.ncbi.nlm.nih.gov/pubmed/16730617>
256. Zinner, N., *et al.* Impact of solifenacin on quality of life, medical care use, work productivity, and health utility in the elderly: an exploratory subgroup analysis. *Am J Geriatr Pharmacother*, 2009. 7: 373.  
<https://www.ncbi.nlm.nih.gov/pubmed/20129258>
257. Herschorn, S., *et al.* Tolerability of solifenacin and oxybutynin immediate release in older (> 65 years) and younger (<= 65 years) patients with overactive bladder: sub-analysis from a Canadian, randomized, double-blind study. *Curr Med Res Opin*, 2011. 27: 375.  
<https://www.ncbi.nlm.nih.gov/pubmed/21175373>
258. Drutz, H.P., *et al.* Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. *Int Urogynecol J Pelvic Floor Dysfunct*, 1999. 10: 283.  
<https://www.ncbi.nlm.nih.gov/pubmed/10543335>
259. Michel, M.C., *et al.* Does gender or age affect the efficacy and safety of tolterodine? *J Urol*, 2002. 168: 1027.  
<https://www.ncbi.nlm.nih.gov/pubmed/12187215>
260. Millard, R., *et al.* Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity. *J Urol*, 1999. 161: 1551.  
<https://www.ncbi.nlm.nih.gov/pubmed/10210394>
261. Zinner, N.R., *et al.* Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. *J Am Geriatr Soc*, 2002. 50: 799.  
<https://www.ncbi.nlm.nih.gov/pubmed/12028164>

262. Jumadilova, Z., *et al.* Retrospective evaluation of outcomes in patients with overactive bladder receiving tolterodine versus oxybutynin. *Am J Health Syst Pharm*, 2006. 63: 2357.  
<https://www.ncbi.nlm.nih.gov/pubmed/17106009>
263. Chapple, C., *et al.* Darifenacin treatment of patients  $\geq$  65 years with overactive bladder: results of a randomized, controlled, 12-week trial. *Curr Med Res Opin*, 2007. 23: 2347.  
<https://www.ncbi.nlm.nih.gov/pubmed/17706004>
264. Lipton, R.B., *et al.* Assessment of cognitive function of the elderly population: effects of darifenacin. *J Urol*, 2005. 173: 493.  
<https://www.ncbi.nlm.nih.gov/pubmed/15643227>
265. Pietzko, A., *et al.* Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers. *Eur J Clin Pharmacol*, 1994. 47: 337.  
<https://www.ncbi.nlm.nih.gov/pubmed/7875185>
266. Todorova, A., *et al.* Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. *J Clin Pharmacol*, 2001. 41: 636.  
<https://www.ncbi.nlm.nih.gov/pubmed/11402632>
267. Staskin, D.R., *et al.* Trospium chloride once-daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised, phase III trials. *Int J Clin Pract*, 2009. 63: 1715.  
<https://www.ncbi.nlm.nih.gov/pubmed/19930332>
268. Sand, P.K., *et al.* Trospium chloride once-daily extended release is efficacious and tolerated in elderly subjects (aged  $\geq$  75 years) with overactive bladder syndrome. *BJU Int*, 2011. 107: 612.  
<https://www.ncbi.nlm.nih.gov/pubmed/20707790>
269. Kraus, S.R., *et al.* Efficacy and tolerability of fesoterodine in older and younger subjects with overactive bladder. *Urology*, 2010. 76: 1350.  
<https://www.ncbi.nlm.nih.gov/pubmed/20974482>
270. Dubeau, C.E., *et al.* Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial. *J Urol*, 2014. 191: 395.  
<https://www.ncbi.nlm.nih.gov/pubmed/23973522>
271. Mariappan, P., *et al.* Duloxetine, a serotonin and noradrenaline reuptake inhibitor (SNRI) for the treatment of stress urinary incontinence: a systematic review. *Eur Urol*, 2007. 51: 67.  
<https://www.ncbi.nlm.nih.gov/pubmed/17014950>
272. Li, J., *et al.* The role of duloxetine in stress urinary incontinence: a systematic review and meta-analysis. *Int Urol Nephrol*, 2013. 45: 679.  
<https://www.ncbi.nlm.nih.gov/pubmed/23504618>
273. Wagg, A., *et al.* Review of the efficacy and safety of fesoterodine for treating overactive bladder and urgency urinary incontinence in elderly patients. *Drugs Aging*, 2015. 32: 103.  
<https://www.ncbi.nlm.nih.gov/pubmed/25673122>
274. Wagg, A., *et al.* Review of cognitive impairment with antimuscarinic agents in elderly patients with overactive bladder. *Int J Clin Pract*, 2010. 64: 1279.  
<https://www.ncbi.nlm.nih.gov/pubmed/20529135>
275. Wagg, A., *et al.* Long-term safety, tolerability and efficacy of flexible-dose fesoterodine in elderly patients with overactive bladder: open-label extension of the SOFIA trial. *Neurourol Urodyn*, 2014. 33: 106.  
<https://www.ncbi.nlm.nih.gov/pubmed/23460503>
276. Karakoyunlu, N., *et al.* A comparison of standard PCNL and staged retrograde FURS in pelvis stones over 2 cm in diameter: a prospective randomized study. *Urolithiasis*, 2015. 43: 283.  
<https://www.ncbi.nlm.nih.gov/pubmed/25838180>
277. Boustani, M., *et al.* Impact of anticholinergics on the aging brain: a review and practical application. *Aging Health*, 2008. 4: 311.  
<https://www.futuremedicine.com/doi/abs/10.2217/1745509x.4.3.311>
278. Cai, X., *et al.* Long-term anticholinergic use and the aging brain. *Alzheimers Dement*, 2013. 9: 377.  
<https://www.ncbi.nlm.nih.gov/pubmed/23183138>
279. Campbell, N., *et al.* The cognitive impact of anticholinergics: a clinical review. *Clin Interv Aging*, 2009. 4: 225.  
<https://www.ncbi.nlm.nih.gov/pubmed/19554093>
280. Carriere, I., *et al.* Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: the 3-city study. *Arch Intern Med*, 2009. 169: 1317.  
<https://www.ncbi.nlm.nih.gov/pubmed/19636034>

281. Fox, C., *et al.* Anticholinergic medication use and cognitive impairment in the older population: the medical research council cognitive function and ageing study. *J Am Geriatr Soc*, 2011. 59: 1477.  
<https://www.ncbi.nlm.nih.gov/pubmed/21707557>
282. Ghoniem, G.M., *et al.* A randomized controlled trial of duloxetine alone, pelvic floor muscle training alone, combined treatment and no active treatment in women with stress urinary incontinence. *J Urol*, 2005. 173: 1647.  
<https://www.ncbi.nlm.nih.gov/pubmed/15821528>
283. Bump, R.C., *et al.* Long-term efficacy of duloxetine in women with stress urinary incontinence. *BJU Int*, 2008. 102: 214.  
<https://www.ncbi.nlm.nih.gov/pubmed/18422764>
284. Vella, M., *et al.* Duloxetine 1 year on: the long-term outcome of a cohort of women prescribed duloxetine. *Int Urogynecol J Pelvic Floor Dysfunct*, 2008. 19: 961.  
<https://www.ncbi.nlm.nih.gov/pubmed/18231697>
285. Cody, J.D., *et al.* Oestrogen therapy for urinary incontinence in post-menopausal women. *Cochrane Database Syst Rev*, 2012. 10: CD001405.  
<https://www.ncbi.nlm.nih.gov/pubmed/23076892>
286. Lytinen, H., *et al.* Breast cancer risk in postmenopausal women using estrogen-only therapy. *Obstet Gynecol*, 2006. 108: 1354.  
<https://www.ncbi.nlm.nih.gov/pubmed/17138766>
287. Yumru, A.E., *et al.* The use of local 17beta-oestradiol treatment for improving vaginal symptoms associated with post-menopausal oestrogen deficiency. *J Int Med Res*, 2009. 37: 198.  
<https://www.ncbi.nlm.nih.gov/pubmed/19215691>
288. Robinson, D., *et al.* Estrogens and the lower urinary tract. *Neurourol Urodyn*, 2011. 30: 754.  
<https://www.ncbi.nlm.nih.gov/pubmed/21661025>
289. Mettler, L., *et al.* Long-term treatment of atrophic vaginitis with low-dose oestradiol vaginal tablets. *Maturitas*, 1991. 14: 23.  
<https://www.ncbi.nlm.nih.gov/pubmed/1791769>
290. Weber, M.A., *et al.* Local Oestrogen for Pelvic Floor Disorders: A Systematic Review. *PLoS One*, 2015. 10: e0136265.  
<https://www.ncbi.nlm.nih.gov/pubmed/26383760>
291. Castellani, D., *et al.* Low-Dose Intravaginal Estriol and Pelvic Floor Rehabilitation in Post-Menopausal Stress Urinary Incontinence. *Urol Int*, 2015. 95: 417.  
<https://www.ncbi.nlm.nih.gov/pubmed/26043913>
292. Grady, D., *et al.* Postmenopausal hormones and incontinence: the Heart and Estrogen/Progestin Replacement Study. *Obstet Gynecol*, 2001. 97: 116.  
<https://www.ncbi.nlm.nih.gov/pubmed/16260510>
293. Hendrix, S.L., *et al.* Effects of estrogen with and without progestin on urinary incontinence. *JAMA*, 2005. 293: 935.  
<https://www.ncbi.nlm.nih.gov/pubmed/15728164>
294. Rossouw, J.E., *et al.* Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. *JAMA*, 2002. 288: 321.  
<https://www.ncbi.nlm.nih.gov/pubmed/12117397>
295. Steinauer, J.E., *et al.* Postmenopausal hormone therapy: does it cause incontinence? *Obstet Gynecol*, 2005. 106: 940.  
<https://www.ncbi.nlm.nih.gov/pubmed/16260510>
296. Goldstein, S.R., *et al.* Incidence of urinary incontinence in postmenopausal women treated with raloxifene or estrogen. *Menopause*, 2005. 12: 160.  
<https://www.ncbi.nlm.nih.gov/pubmed/15772563>
297. Molander, U., *et al.* Effect of oral oestriol on vaginal flora and cytology and urogenital symptoms in the post-menopause. *Maturitas*, 1990. 12: 113.  
<https://www.ncbi.nlm.nih.gov/pubmed/2255263>
298. Samsioe, G., *et al.* Occurrence, nature and treatment of urinary incontinence in a 70-year-old female population. *Maturitas*, 1985. 7: 335.  
<https://www.ncbi.nlm.nih.gov/pubmed/3908884>
299. Wang, C.J., *et al.* Low dose oral desmopressin for nocturnal polyuria in patients with benign prostatic hyperplasia: a double-blind, placebo controlled, randomized study. *J Urol*, 2011. 185: 219.  
<https://www.ncbi.nlm.nih.gov/pubmed/21074790>

300. Robinson, D., *et al.* Antidiuresis: a new concept in managing female daytime urinary incontinence. *BJU Int*, 2004. 93: 996.  
<https://www.ncbi.nlm.nih.gov/pubmed/15142150>
301. Khullar, V., *et al.* Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial. *Urology*, 2004. 64: 269.  
<https://www.ncbi.nlm.nih.gov/pubmed/15302476>
302. Kreder, K.J., Jr., *et al.* Tolterodine is equally effective in patients with mixed incontinence and those with urge incontinence alone. *BJU Int*, 2003. 92: 418.  
<https://www.ncbi.nlm.nih.gov/pubmed/12930432>
303. Kelleher, C., *et al.* Solifenacin: as effective in mixed urinary incontinence as in urge urinary incontinence. *Int Urogynecol J Pelvic Floor Dysfunct*, 2006. 17: 382.  
<https://www.ncbi.nlm.nih.gov/pubmed/16283422>
304. Staskin, D.R., *et al.* Short- and long-term efficacy of solifenacin treatment in patients with symptoms of mixed urinary incontinence. *BJU Int*, 2006. 97: 1256.  
<https://www.ncbi.nlm.nih.gov/pubmed/16686722>
305. Bent, A.E., *et al.* Duloxetine compared with placebo for the treatment of women with mixed urinary incontinence. *Neurourol Urodyn*, 2008. 27: 212.  
<https://www.ncbi.nlm.nih.gov/pubmed/17580357>
306. Bump, R.C., *et al.* Mixed urinary incontinence symptoms: urodynamic findings, incontinence severity, and treatment response. *Obstet Gynecol*, 2003. 102: 76.  
<https://www.ncbi.nlm.nih.gov/pubmed/12850610>
307. Morling, J.R., *et al.* Adverse events after first, single, mesh and non-mesh surgical procedures for stress urinary incontinence and pelvic organ prolapse in Scotland, 1997-2016: a population-based cohort study. *Lancet*, 2017. 389: 629.  
<https://www.ncbi.nlm.nih.gov/pubmed/28010993>
308. Lapitan, M.C., *et al.* Open retropubic colposuspension for urinary incontinence in women. *Cochrane Database Syst Rev*, 2016. 2: CD002912.  
<https://www.ncbi.nlm.nih.gov/pubmed/19821297>
309. Brubaker, L., *et al.* 5-year continence rates, satisfaction and adverse events of burch urethropexy and fascial sling surgery for urinary incontinence. *J Urol*, 2012. 187: 1324.  
<https://www.ncbi.nlm.nih.gov/pubmed/22341290>
310. Ford, A.A., *et al.* Mid-urethral sling operations for stress urinary incontinence in women. *Cochrane Database Syst Rev*, 2015: CD006375.  
<https://www.ncbi.nlm.nih.gov/pubmed/28756647>
311. Kenton, K., *et al.* 5-year longitudinal followup after retropubic and transobturator mid urethral slings. *J Urol*, 2015. 193: 203.  
<https://www.ncbi.nlm.nih.gov/pubmed/25158274>
312. Albo, M.E., *et al.* Treatment success of retropubic and transobturator mid urethral slings at 24 months. *J Urol*, 2012. 188: 2281.  
<https://www.ncbi.nlm.nih.gov/pubmed/17437826>
313. Lier, D., *et al.* Surgical treatment of stress urinary incontinence-trans-obturator tape compared with tension-free vaginal tape-5-year follow up: an economic evaluation. *BJOG*, 2017. 124: 1431.  
<https://www.ncbi.nlm.nih.gov/pubmed/27506185>
314. Khan, Z.A., *et al.* Long-term follow-up of a multicentre randomised controlled trial comparing tension-free vaginal tape, xenograft and autologous fascial slings for the treatment of stress urinary incontinence in women. *BJU Int*, 2015. 115: 968.  
<https://www.ncbi.nlm.nih.gov/pubmed/24961647>
315. Zhang, Z., *et al.* Retropubic tension-free vaginal tape and inside-out transobturator tape: a long-term randomized trial. *Int Urogynecol J*, 2016. 27: 103.  
<https://www.ncbi.nlm.nih.gov/pubmed/26264474>
316. Brennand, E.A., *et al.* Twelve-month outcomes following midurethral sling procedures for stress incontinence: impact of obesity. *BJOG*, 2015. 122: 1705.  
<https://www.ncbi.nlm.nih.gov/pubmed/25316484>
317. Brennand, E.A., *et al.* Five years after midurethral sling surgery for stress incontinence: obesity continues to have an impact on outcomes. *Int Urogynecol J*, 2017. 28: 621.  
<https://www.ncbi.nlm.nih.gov/pubmed/27686569>
318. Moore, R.D., *et al.* Two-year evaluation of the MiniArc in obese versus non-obese patients for treatment of stress urinary incontinence. *Int J Urol*, 2013. 20: 434.  
<https://www.ncbi.nlm.nih.gov/pubmed/22989174>



319. Karmakar, D., *et al.* Long-term outcomes of transobturator tapes in women with stress urinary incontinence: E-TOT randomised controlled trial. *BJOG*, 2017. 124: 973.  
<https://www.ncbi.nlm.nih.gov/pubmed/28094468>
320. Serati, M., *et al.* Tension-free Vaginal Tape-Obturator for Treatment of Pure Urodynamic Stress Urinary Incontinence: Efficacy and Adverse Effects at 10-year Follow-up. *Eur Urol*, 2017. 71: 674.  
<https://www.ncbi.nlm.nih.gov/pubmed/27597239>
321. Nilsson, C.G., *et al.* Seventeen years' follow-up of the tension-free vaginal tape procedure for female stress urinary incontinence. *Int Urogynecol J*, 2013. 24: 1265.  
<https://www.ncbi.nlm.nih.gov/pubmed/23563892>
322. Svenningsen, R., *et al.* Long-term follow-up of the retropubic tension-free vaginal tape procedure. *Int Urogynecol J*, 2013. 24: 1271.  
<https://www.ncbi.nlm.nih.gov/pubmed/23417313>
323. Fusco, F., *et al.* Updated Systematic Review and Meta-analysis of the Comparative Data on Colposuspensions, Pubovaginal Slings, and Midurethral Tapes in the Surgical Treatment of Female Stress Urinary Incontinence. *Eur Urol*, 2017. 72: 567.  
<https://www.ncbi.nlm.nih.gov/pubmed/28479203>
324. Cheung, R.Y., *et al.* Inside-out versus outside-in transobturator tension-free vaginal tape: a 5-year prospective comparative study. *Int J Urol*, 2014. 21: 74.  
<https://www.ncbi.nlm.nih.gov/pubmed/23675961>
325. Abdel-Fattah, M., *et al.* Long-term outcomes for transobturator tension-free vaginal tapes in women with urodynamic mixed urinary incontinence. *Neurourol Urodyn*, 2017. 36: 902.  
<https://www.ncbi.nlm.nih.gov/pubmed/28028822>
326. Mostafa, A., *et al.* Single-incision mini-slings versus standard midurethral slings in surgical management of female stress urinary incontinence: an updated systematic review and meta-analysis of effectiveness and complications. *Eur Urol*, 2014. 65: 402.  
<https://www.ncbi.nlm.nih.gov/pubmed/24055431>
327. Zhang, P., *et al.* Meta-analysis of female stress urinary incontinence treatments with adjustable single-incision mini-slings and transobturator tension-free vaginal tape surgeries. *BMC Urol*, 2015. 15: 64.  
<https://www.ncbi.nlm.nih.gov/pubmed/26148987>
328. Ogah, J., *et al.* Minimally invasive synthetic suburethral sling operations for stress urinary incontinence in women. *Cochrane Database Syst Rev*, 2009: CD006375.  
<https://www.ncbi.nlm.nih.gov/pubmed/19821363>
329. Groutz, A., *et al.* The safety and efficacy of the "inside-out" trans-obturator TVT in elderly versus younger stress-incontinent women: a prospective study of 353 consecutive patients. *Neurourol Urodyn*, 2011. 30: 380.  
<https://www.ncbi.nlm.nih.gov/pubmed/20665549>
330. Alwaal, A., *et al.* Female sexual function following mid-urethral slings for the treatment of stress urinary incontinence. *Int J Impot Res*, 2016. 28: 121.  
<https://www.ncbi.nlm.nih.gov/pubmed/27146350>
331. Fan, Y., *et al.* Incontinence-specific quality of life measures used in trials of sling procedures for female stress urinary incontinence: a meta-analysis. *Int Urol Nephrol*, 2015. 47: 1277.  
<https://www.ncbi.nlm.nih.gov/pubmed/26093584>
332. Rechberger, T., *et al.* The clinical effectiveness of retropubic (IVS-02) and transobturator (IVS-04) midurethral slings: randomized trial. *Eur Urol*, 2009. 56: 24.  
<https://www.ncbi.nlm.nih.gov/pubmed/19285788>
333. Barber, M.D., *et al.* Risk factors associated with failure 1 year after retropubic or transobturator midurethral slings. *Am J Obstet Gynecol*, 2008. 199: 666 e1.  
<https://www.ncbi.nlm.nih.gov/pubmed/19084098>
334. Richter, H.E., *et al.* Predictors of treatment failure 24 months after surgery for stress urinary incontinence. *J Urol*, 2008. 179: 1024.  
<https://www.ncbi.nlm.nih.gov/pubmed/18206917>
335. Campeau, L., *et al.* A multicenter, prospective, randomized clinical trial comparing tension-free vaginal tape surgery and no treatment for the management of stress urinary incontinence in elderly women. *Neurourol Urodyn*, 2007. 26: 990.  
<https://www.ncbi.nlm.nih.gov/pubmed/17638307>
336. Serati, M., *et al.* Transobturator vaginal tape for the treatment of stress urinary incontinence in elderly women without concomitant pelvic organ prolapse: is it effective and safe? *Eur J Obstet Gynecol Reprod Biol*, 2013. 166: 107.  
<https://www.ncbi.nlm.nih.gov/pubmed/23164504>

337. Franzen, K., *et al.* Surgery for urinary incontinence in women 65 years and older: a systematic review. *Int Urogynecol J*, 2015. 26: 1095.  
<https://www.ncbi.nlm.nih.gov/pubmed/25477140>
338. Dean, N.M., *et al.* Laparoscopic colposuspension for urinary incontinence in women. *Cochrane Database Syst Rev*, 2006: CD002239.  
<https://www.ncbi.nlm.nih.gov/pubmed/16855989>
339. Glazener, C.M., *et al.* Anterior vaginal repair for urinary incontinence in women. *Cochrane Database Syst Rev*, 2001: CD001755.  
<https://www.ncbi.nlm.nih.gov/pubmed/11279728>
340. Lapitan, M.C., *et al.* Open retropubic colposuspension for urinary incontinence in women. *Cochrane Database Syst Rev*, 2009: CD002912.  
<https://www.ncbi.nlm.nih.gov/pubmed/19821297>
341. Foss Hansen, M., *et al.* Reoperation for urinary incontinence: a nationwide cohort study, 1998-2007. *Am J Obstet Gynecol*, 2016. 214: 263.e1.  
<https://www.ncbi.nlm.nih.gov/pubmed/26344752>
342. Jonsson Funk, M., *et al.* Long-term outcomes after stress urinary incontinence surgery. *Obstet Gynecol*, 2012. 120: 83.  
<https://www.ncbi.nlm.nih.gov/pubmed/22914395>
343. Rehman, H., *et al.* Traditional suburethral sling operations for urinary incontinence in women. *Cochrane Database Syst Rev*, 2011: CD001754.  
<https://www.ncbi.nlm.nih.gov/pubmed/21249648>
344. Rehman, H., *et al.* Traditional suburethral sling operations for urinary incontinence in women. *Cochrane Database Syst Rev*, 2017. 7: CD001754.  
<https://www.ncbi.nlm.nih.gov/pubmed/28743177>
345. Gumus, Il, *et al.* Laparoscopic single-port Burch colposuspension with an extraperitoneal approach and standard instruments for stress urinary incontinence: early results from a series of 15 patients. *Minim Invasive Ther Allied Technol*, 2013. 22: 116.  
<https://www.ncbi.nlm.nih.gov/pubmed/22909022>
346. Kirchin, V., *et al.* Urethral injection therapy for urinary incontinence in women. *Cochrane Database Syst Rev*, 2012: CD003881.  
<https://www.ncbi.nlm.nih.gov/pubmed/22336797>
347. Davis, N.F., *et al.* Injectable biomaterials for the treatment of stress urinary incontinence: their potential and pitfalls as urethral bulking agents. *Int Urogynecol J*, 2013. 24: 913.  
<https://www.ncbi.nlm.nih.gov/pubmed/23224022>
348. Ghoniem, G.M., *et al.* A systematic review and meta-analysis of Macroplastique for treating female stress urinary incontinence. *Int Urogynecol J*, 2013. 24: 27.  
<https://www.ncbi.nlm.nih.gov/pubmed/15821528>
349. Kasi, A.D., *et al.* Polyacrylamide hydrogel (Bulkamid(R)) for stress urinary incontinence in women: a systematic review of the literature. *Int Urogynecol J*, 2016. 27: 367.  
<https://www.ncbi.nlm.nih.gov/pubmed/26209952>
350. Siddiqui, Z.A., *et al.* Intraurethral bulking agents for the management of female stress urinary incontinence: a systematic review. *Int Urogynecol J*, 2017.  
<https://www.ncbi.nlm.nih.gov/pubmed/28220200>
351. Matsuoka, P.K., *et al.* The efficacy and safety of urethral injection therapy for urinary incontinence in women: a systematic review. *Clinics (Sao Paulo)*, 2016. 71: 94.  
<https://www.ncbi.nlm.nih.gov/pubmed/26934239>
352. Lee, P.E., *et al.* Periurethral autologous fat injection as treatment for female stress urinary incontinence: a randomized double-blind controlled trial. *J Urol*, 2001. 165: 153.  
<https://www.ncbi.nlm.nih.gov/pubmed/11125386>
353. Zhao, Y., *et al.*, Bulking agents - An analysis of 500 cases and review of the literature. *Clin Exp Obstet Gynecol*, 2016. 43: 666. [No abstract available].
354. Hegde, A., *et al.* Three-dimensional endovaginal ultrasound examination following injection of Macroplastique for stress urinary incontinence: outcomes based on location and periurethral distribution of the bulking agent. *Int Urogynecol J*, 2013. 24: 1151.  
<https://www.ncbi.nlm.nih.gov/pubmed/23229417>
355. Krhut, J., *et al.* Treatment of stress urinary incontinence using polyacrylamide hydrogel in women after radiotherapy: 1-year follow-up. *Int Urogynecol J*, 2016. 27: 301.  
<https://www.ncbi.nlm.nih.gov/pubmed/26342812>



356. Carr, L.K., *et al.* Autologous muscle derived cell therapy for stress urinary incontinence: a prospective, dose ranging study. *J Urol*, 2013. 189: 595.  
<https://www.ncbi.nlm.nih.gov/pubmed/28220200>
357. Maher, C.F., *et al.* Pubovaginal sling versus transurethral Macroplastique for stress urinary incontinence and intrinsic sphincter deficiency: a prospective randomised controlled trial. *BJOG*, 2005. 112: 797.  
<https://www.ncbi.nlm.nih.gov/pubmed/15924540>
358. Kuhn, A., *et al.* Where should bulking agents for female urodynamic stress incontinence be injected? *Int Urogynecol J Pelvic Floor Dysfunct*, 2008. 19: 817.  
<https://www.ncbi.nlm.nih.gov/pubmed/18157642>
359. Ashok, K., *et al.* Recurrent urinary stress incontinence: an overview. *J Obstet Gynaecol Res*, 2010. 36: 467.  
<https://www.ncbi.nlm.nih.gov/pubmed/20598022>
360. Lovatsis, D., *et al.* Guidelines for the evaluation and treatment of recurrent urinary incontinence following pelvic floor surgery. *J Obstet Gynaecol Can*, 2010. 32: 893.  
<https://www.ncbi.nlm.nih.gov/pubmed/21050525>
361. Bakali, E., *et al.* Treatment of recurrent stress urinary incontinence after failed minimally invasive synthetic suburethral tape surgery in women. *Cochrane Database Syst Rev*, 2013: CD009407.  
<https://www.ncbi.nlm.nih.gov/pubmed/23450602>
362. Maher, C., *et al.* Laparoscopic colposuspension or tension-free vaginal tape for recurrent stress urinary incontinence and/or urethral sphincter deficiency-a randomised controlled trial. *Neurourology Urodyn.*, 2004. 23: 433.  
<https://www.ics.org/Abstracts/Publish/42/000025.pdf>
363. Abdel-Fattah, M., *et al.* Evaluation of transobturator tension-free vaginal tapes in management of women with recurrent stress urinary incontinence. *Urology*, 2011. 77: 1070.  
<https://www.ncbi.nlm.nih.gov/pubmed/21414653>
364. Richter, H.E., *et al.* . Baseline predictors of one year treatment failure of retropubic and transobturator midurethral sling procedures for stress urinary incontinence. *Female Pelvic Med Reconstr Surg* 2010. 16: S62. [No abstract available].
365. Amaye-Obu, F.A., *et al.* Surgical management of recurrent stress urinary incontinence: A 12-year experience. *Am J Obstet Gynecol*, 1999. 181: 1296.  
<https://www.ncbi.nlm.nih.gov/pubmed/10601904>
366. Rardin, C.R., *et al.* Tension-free vaginal tape: outcomes among women with primary versus recurrent stress urinary incontinence. *Obstet Gynecol*, 2002. 100: 893.  
<https://www.ncbi.nlm.nih.gov/pubmed/12423849>
367. Rezapour, M., *et al.* Tension-Free vaginal tape (TVT) in women with mixed urinary incontinence--a long-term follow-up. *Int Urogynecol J Pelvic Floor Dysfunct*, 2001. 12 Suppl 2: S15.  
<https://www.ncbi.nlm.nih.gov/pubmed/11450974>
368. Lee, K.S., *et al.* Outcomes following repeat mid urethral synthetic sling after failure of the initial sling procedure: rediscovery of the tension-free vaginal tape procedure. *J Urol*, 2007. 178: 1370.  
<https://www.ncbi.nlm.nih.gov/pubmed/17706716>
369. Stav, K., *et al.* Repeat synthetic mid urethral sling procedure for women with recurrent stress urinary incontinence. *J Urol*, 2010. 183: 241.  
<https://www.ncbi.nlm.nih.gov/pubmed/19913831>
370. Jarvis, G.J. Surgery for genuine stress incontinence. *Br J Obstet Gynaecol*, 1994. 101: 371.  
<https://www.ncbi.nlm.nih.gov/pubmed/8018606>
371. Agur, W., *et al.* Surgical treatment of recurrent stress urinary incontinence in women: a systematic review and meta-analysis of randomised controlled trials. *Eur Urol*, 2013. 64: 323.  
<https://www.ncbi.nlm.nih.gov/pubmed/23680414>
372. Meyer, F., *et al.* Repeat mid-urethral sling for recurrent female stress urinary incontinence. *Int Urogynecol J*, 2013. 24: 817.  
<https://www.ncbi.nlm.nih.gov/pubmed/22976532>
373. Shaikh, S., *et al.* Mechanical devices for urinary incontinence in women. *Cochrane Database Syst Rev*, 2006: CD001756.  
<https://www.ncbi.nlm.nih.gov/pubmed/16855977>
374. Chung, E., *et al.* 25-year experience in the outcome of artificial urinary sphincter in the treatment of female urinary incontinence. *BJU Int*, 2010. 106: 1664.  
<https://www.ncbi.nlm.nih.gov/pubmed/20500509>

375. Costa, P., *et al.* The use of an artificial urinary sphincter in women with type III incontinence and a negative Marshall test. *J Urol*, 2001. 165: 1172.  
<https://www.ncbi.nlm.nih.gov/pubmed/11257664>
376. Heitz, M., *et al.* [Therapy of female urinary incontinence with the AMS 800 artificial sphincter. Indications, outcome, complications and risk factors]. *Urologe A*, 1997. 36: 426.  
<https://www.ncbi.nlm.nih.gov/pubmed/9424794>
377. Vayleux, B., *et al.* Female urinary incontinence and artificial urinary sphincter: study of efficacy and risk factors for failure and complications. *Eur Urol*, 2011. 59: 1048.  
<https://www.ncbi.nlm.nih.gov/pubmed/21420781>
378. Alonso Rodriguez, D., *et al.* Four years experience with the flowsecure artificial urinary sphincter. Problems and solutions. *Neurourol Urodyn* 2011. 30: #250.  
<https://www.ics.org/Abstracts/Publish/106/000250.pdf>
379. Mandron, E., *et al.* Laparoscopic artificial urinary sphincter implantation for female genuine stress urinary incontinence: technique and 4-year experience in 25 patients. *BJU Int*, 2010. 106: 1194.  
<https://www.ncbi.nlm.nih.gov/pubmed/20132197>
380. Roupret, M., *et al.* Laparoscopic approach for artificial urinary sphincter implantation in women with intrinsic sphincter deficiency incontinence: a single-centre preliminary experience. *Eur Urol*, 2010. 57: 499.  
<https://www.ncbi.nlm.nih.gov/pubmed/19346059>
381. Aboseif, S.R., *et al.* The adjustable continence therapy system for recurrent female stress urinary incontinence: 1-year results of the North America Clinical Study Group. *J Urol*, 2009. 181: 2187.  
<https://www.ncbi.nlm.nih.gov/pubmed/19296967>
382. Aboseif, S.R., *et al.* Treatment of moderate to severe female stress urinary incontinence with the adjustable continence therapy (ACT) device after failed surgical repair. *World J Urol*, 2011. 29: 249.  
<https://www.ncbi.nlm.nih.gov/pubmed/20959993>
383. Kocjancic, E., *et al.* Adjustable continence therapy for severe intrinsic sphincter deficiency and recurrent female stress urinary incontinence: long-term experience. *J Urol*, 2010. 184: 1017.  
<https://www.ncbi.nlm.nih.gov/pubmed/18761534>
384. Wachter, J., *et al.* Adjustable continence therapy for female urinary incontinence: a minimally invasive option for difficult cases. *Urol Int*, 2008. 81: 160.  
<https://www.ncbi.nlm.nih.gov/pubmed/18758213>
385. Maher, C., *et al.* Surgical management of pelvic organ prolapse in women. *Cochrane Database Syst Rev*, 2013: CD004014.  
<https://www.ncbi.nlm.nih.gov/pubmed/23633316>
386. van der Ploeg, J.M., *et al.* Prolapse surgery with or without stress incontinence surgery for pelvic organ prolapse: a systematic review and meta-analysis of randomised trials. *BJOG*, 2014. 121: 537.  
<https://www.ncbi.nlm.nih.gov/pubmed/24382099>
387. Borstad, E., *et al.* Surgical strategies for women with pelvic organ prolapse and urinary stress incontinence. *Int Urogynecol J*, 2010. 21: 179.  
<https://www.ncbi.nlm.nih.gov/pubmed/19940978>
388. Costantini, E., *et al.* Pelvic organ prolapse repair with and without prophylactic concomitant Burch colposuspension in continent women: a randomized, controlled trial with 8-year followup. *J Urol*, 2011. 185: 2236.  
<https://www.ncbi.nlm.nih.gov/pubmed/21497843>
389. van der Ploeg, J.M., *et al.* Transvaginal prolapse repair with or without the addition of a midurethral sling in women with genital prolapse and stress urinary incontinence: a randomised trial. *BJOG*, 2015. 122: 1022.  
<https://www.ncbi.nlm.nih.gov/pubmed/25754458>
390. van der Ploeg, J.M., *et al.* Vaginal prolapse repair with or without a midurethral sling in women with genital prolapse and occult stress urinary incontinence: a randomized trial. *Int Urogynecol J*, 2016. 27: 1029.  
<https://www.ncbi.nlm.nih.gov/pubmed/26740197>
391. Costantini, E., *et al.* Urgency, detrusor overactivity and posterior vault prolapse in women who underwent pelvic organ prolapse repair. *Urol Int*, 2013. 90: 168.  
<https://www.ncbi.nlm.nih.gov/pubmed/23327990>
392. Kummeling, M.T., *et al.* Sequential urodynamic assessment before and after laparoscopic sacrocolpopexy. *Acta Obstet Gynecol Scand*, 2013. 92: 172.  
<https://www.ncbi.nlm.nih.gov/pubmed/23157606>

393. Lee, D.M., *et al.* A predictive factor in overactive bladder symptoms improvement after combined anterior vaginal wall prolapse repair: a pilot study. *Korean J Urol*, 2012. 53: 405.  
<https://www.ncbi.nlm.nih.gov/pubmed/22741049>
394. Visco, A.G., *et al.* The role of preoperative urodynamic testing in stress-continent women undergoing sacrocolpopexy: the Colpopexy and Urinary Reduction Efforts (CARE) randomized surgical trial. *Int Urogynecol J Pelvic Floor Dysfunct*, 2008. 19: 607.  
<https://www.ncbi.nlm.nih.gov/pubmed/18185903>
395. Duecy, E.E., *et al.* Urodynamic prediction of occult stress urinary incontinence before vaginal surgery for advanced pelvic organ prolapse: evaluation of postoperative outcomes. *Female Pelvic Med Reconstr Surg*, 2010. 16: 215.  
<https://www.ncbi.nlm.nih.gov/pubmed/22453344>
396. Chughtai, B., *et al.* Ambulatory pessary trial unmasks occult stress urinary incontinence. *Obstet Gynecol Int*, 2012. 2012: 392027.  
<https://www.ncbi.nlm.nih.gov/pubmed/21949665>
397. Blander, D.S., *et al.* Endoluminal magnetic resonance imaging in the evaluation of urethral diverticula in women. *Urology*, 2001. 57: 660.  
<https://www.ncbi.nlm.nih.gov/pubmed/11306374>
398. Pathi, S.D., *et al.* Utility of clinical parameters, cystourethroscopy, and magnetic resonance imaging in the preoperative diagnosis of urethral diverticula. *Int Urogynecol J*, 2013. 24: 319.  
<https://www.ncbi.nlm.nih.gov/pubmed/22707007>
399. Dwarkasing, R.S., *et al.* MRI evaluation of urethral diverticula and differential diagnosis in symptomatic women. *AJR Am J Roentgenol*, 2011. 197: 676.  
<https://www.ncbi.nlm.nih.gov/pubmed/21862811>
400. Chung, D.E., *et al.* Urethral diverticula in women: discrepancies between magnetic resonance imaging and surgical findings. *J Urol*, 2010. 183: 2265.  
<https://www.ncbi.nlm.nih.gov/pubmed/20400161>
401. Han, D.H., *et al.* Outcomes of surgery of female urethral diverticula classified using magnetic resonance imaging. *Eur Urol*, 2007. 51: 1664.  
<https://www.ncbi.nlm.nih.gov/pubmed/17335961>
402. Ingber, M.S., *et al.* Surgically corrected urethral diverticula: long-term voiding dysfunction and reoperation rates. *Urology*, 2011. 77: 65.  
<https://www.ncbi.nlm.nih.gov/pubmed/20800882>
403. Lee, U.J., *et al.* Rate of de novo stress urinary incontinence after urethral diverticulum repair. *Urology*, 2008. 71: 849.  
<https://www.ncbi.nlm.nih.gov/pubmed/18355904>
404. Ljungqvist, L., *et al.* Female urethral diverticulum: 26-year followup of a large series. *J Urol*, 2007. 177: 219.  
<https://www.ncbi.nlm.nih.gov/pubmed/17162049>
405. Migliari, R., *et al.* Recurrent pseudodiverticula of female urethra: five-year experience. *Urology*, 2009. 73: 1218.  
<https://www.ncbi.nlm.nih.gov/pubmed/19375782>
406. Stav, K., *et al.* Urinary symptoms before and after female urethral diverticulectomy--can we predict de novo stress urinary incontinence? *J Urol*, 2008. 180: 2088.  
<https://www.ncbi.nlm.nih.gov/pubmed/18804229>
407. Thomas, A.A., *et al.* Urethral diverticula in 90 female patients: a study with emphasis on neoplastic alterations. *J Urol*, 2008. 180: 2463.  
<https://www.ncbi.nlm.nih.gov/pubmed/18930487>
408. Cornu, J.N., *et al.* Duloxetine for mild to moderate postprostatectomy incontinence: preliminary results of a randomised, placebo-controlled trial. *Eur Urol*, 2011. 59: 148.  
<https://www.ncbi.nlm.nih.gov/pubmed/21030144>
409. Filocamo, M.T., *et al.* Pharmacologic treatment in postprostatectomy stress urinary incontinence. *Eur Urol*, 2007. 51: 1559.  
<https://www.ncbi.nlm.nih.gov/pubmed/16942833>
410. Alan, C., *et al.* Efficacy of Duloxetine in the Early Management of Urinary Continence after Radical Prostatectomy. *Curr Urol*, 2015. 8: 43.  
<https://www.ncbi.nlm.nih.gov/pubmed/26195963>
411. Imamoglu, M.A., *et al.* The comparison of artificial urinary sphincter implantation and endourethral macroplastique injection for the treatment of postprostatectomy incontinence. *Eur Urol*, 2005. 47: 209.  
<https://www.ncbi.nlm.nih.gov/pubmed/15661416>

412. Secin, F.P., *et al.* [Limited efficacy of permanent injectable agents in the treatment of stress urinary incontinence after radical prostatectomy]. *Arch Esp Urol*, 2005. 58: 431.  
<https://www.ncbi.nlm.nih.gov/pubmed/16078785>
413. Mantovani, F., *et al.* VID-2.02: Bulkamide hydrogel: limits of a new bulking agent in the mini-invasive therapy of incontinence after prostatectomy. *Urology*. 76: S50.  
<https://www.researchgate.net/publication/241078170> VID-202 Bulkamide hydrogel limits of a new bulking agent in the mini-invasive therapy of incontinence after prostatectomy
414. Werther, M., *et al.* Stress urinary incontinence after radical prostatectomy: long term effects of endoscopic injection with dextranomer/hyaluronic acid copolymer. *Neurourol Urodyn*, 2009. 8.  
<https://www.ics.org/Abstracts/Publish/47/000643.pdf>
415. Silva, L.A., *et al.* Surgery for stress urinary incontinence due to presumed sphincter deficiency after prostate surgery. *Cochrane Database Syst Rev*, 2011: CD008306.  
<https://www.ncbi.nlm.nih.gov/pubmed/21491408>
416. Zeif, H.-J., *et al.* The male sling for post-radical prostatectomy urinary incontinence: urethral compression versus urethral relocation or what is next? *British Journal of Medical and Surgical Urology*, 2010. 3: 134.  
<http://www.sciencedirect.com/science/article/pii/S1875974210000248>
417. Cornel, E.B., *et al.* Can advance transobturator sling suspension cure male urinary postoperative stress incontinence? *J Urol*, 2010. 183: 1459.  
<https://www.ncbi.nlm.nih.gov/pubmed/20172561>
418. Abrams, P., *et al.* Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: Evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. *Neurourol Urodyn*, 2010. 29: 213.  
<https://www.ncbi.nlm.nih.gov/pubmed/20025020>
419. Bauer, R.M., *et al.* Contemporary management of postprostatectomy incontinence. *Eur Urol*, 2011. 59: 985.  
<https://www.ncbi.nlm.nih.gov/pubmed/21458914>
420. Herschorn, S., *et al.* Surgical treatment of stress incontinence in men. *Neurourol Urodyn*, 2010. 29: 179.  
<https://www.ncbi.nlm.nih.gov/pubmed/20025026>
421. Bauer, R.M., *et al.* Results of the AdVance transobturator male sling after radical prostatectomy and adjuvant radiotherapy. *Urology*, 2011. 77: 474.  
<https://www.ncbi.nlm.nih.gov/pubmed/21167563>
422. Bauer, R.M., *et al.* Mid-term results for the retroluminal transobturator sling suspension for stress urinary incontinence after prostatectomy. *BJU Int*, 2011. 108: 94.  
<https://www.ncbi.nlm.nih.gov/pubmed/20883489>
423. Cornu, J.N., *et al.* Mid-term evaluation of the transobturator male sling for post-prostatectomy incontinence: focus on prognostic factors. *BJU Int*, 2011. 108: 236.  
<https://www.ncbi.nlm.nih.gov/pubmed/20955265>
424. Gill, B.C., *et al.* Patient perceived effectiveness of a new male sling as treatment for post-prostatectomy incontinence. *J Urol*, 2010. 183: 247.  
<https://www.ncbi.nlm.nih.gov/pubmed/19913826>
425. Rehder, P., *et al.* The 1 year outcome of the transobturator retroluminal repositioning sling in the treatment of male stress urinary incontinence. *BJU Int*, 2010. 106: 1668.  
<https://www.ncbi.nlm.nih.gov/pubmed/20518761>
426. Cestari, A., *et al.* Retropubic Intracorporeal Placement of a Suburethral Autologous Sling During Robot-Assisted Radical Prostatectomy to Improve Early Urinary Continence Recovery: Preliminary Data. *J Endourol*, 2015. 29: 1379.  
<https://www.ncbi.nlm.nih.gov/pubmed/26131781>
427. Kojima, Y., *et al.* Bladder neck sling suspension during robot-assisted radical prostatectomy to improve early return of urinary continence: a comparative analysis. *Urology*, 2014. 83: 632.  
<https://www.ncbi.nlm.nih.gov/pubmed/24387929>
428. Cestari, A., *et al.* Simple vs six-branches autologous suburethral sling during robot-assisted radical prostatectomy to improve early urinary continence recovery: prospective randomized study. *J Robot Surg*, 2017.  
<https://www.ncbi.nlm.nih.gov/pubmed/28078523>
429. Nguyen, H.G., *et al.* A Randomized Study of Intraoperative Autologous Retropubic Urethral Sling on Urinary Control after Robotic Assisted Radical Prostatectomy. *J Urol*, 2017. 197: 369.  
<https://www.ncbi.nlm.nih.gov/pubmed/27693447>

430. Kim, J. Long term follow-up of readjustable urethral sling procedure (Remeex System) for male stress urinary incontinence. *Neurourol Urodyn*, 2011. 30: #209.  
[https://www.researchgate.net/publication/295670618\\_long\\_term\\_follow-up\\_of\\_readjustable\\_urethral\\_sling\\_procedure\\_remeex\\_system\\_r\\_for\\_male\\_stress\\_urinary\\_incontinence](https://www.researchgate.net/publication/295670618_long_term_follow-up_of_readjustable_urethral_sling_procedure_remeex_system_r_for_male_stress_urinary_incontinence)
431. Bochove-Overgaauw, D.M., *et al.* An adjustable sling for the treatment of all degrees of male stress urinary incontinence: retrospective evaluation of efficacy and complications after a minimal followup of 14 months. *J Urol*, 2011. 185: 1363.  
<https://www.ncbi.nlm.nih.gov/pubmed/21334683>
432. Hubner, W.A., *et al.* Adjustable bulbourethral sling: experience after 101 cases of moderate-to-severe male stress urinary incontinence. *BJU Int*, 2011. 107: 777.  
<https://www.ncbi.nlm.nih.gov/pubmed/20964801>
433. Dalpiaz, O., *et al.* Mid-term complications after placement of the male adjustable suburethral sling: a single center experience. *J Urol*, 2011. 186: 604.  
<https://www.ncbi.nlm.nih.gov/pubmed/21684559>
434. Hoda, M.R., *et al.* Early results of a European multicentre experience with a new self-anchoring adjustable transobturator system for treatment of stress urinary incontinence in men. *BJU Int*, 2013. 111: 296.  
<https://www.ncbi.nlm.nih.gov/pubmed/23186285>
435. Seweryn, J., *et al.* Initial experience and results with a new adjustable transobturator male system for the treatment of stress urinary incontinence. *J Urol*, 2012. 187: 956.  
<https://www.ncbi.nlm.nih.gov/pubmed/22264469>
436. Van der Aa, F., *et al.* The artificial urinary sphincter after a quarter of a century: a critical systematic review of its use in male non-neurogenic incontinence. *Eur Urol*, 2013. 63: 681.  
<https://www.ncbi.nlm.nih.gov/pubmed/23219375>
437. Trigo Rocha, F., *et al.* A prospective study evaluating the efficacy of the artificial sphincter AMS 800 for the treatment of postradical prostatectomy urinary incontinence and the correlation between preoperative urodynamic and surgical outcomes. *Urology*, 2008. 71: 85.  
<https://www.ncbi.nlm.nih.gov/pubmed/18242371>
438. Lai, H.H., *et al.* Urodynamic testing in evaluation of postradical prostatectomy incontinence before artificial urinary sphincter implantation. *Urology*, 2009. 73: 1264.  
<https://www.ncbi.nlm.nih.gov/pubmed/19371935>
439. Aaronson, D.S., *et al.* Transcortical artificial urinary sphincter placement for incontinence in high-risk patients after treatment of prostate cancer. *Urology*, 2008. 72: 825.  
<https://www.ncbi.nlm.nih.gov/pubmed/18752838>
440. Hudak, S.J., *et al.* Impact of 3.5 cm artificial urinary sphincter cuff on primary and revision surgery for male stress urinary incontinence. *J Urol*, 2011. 186: 1962.  
<https://www.ncbi.nlm.nih.gov/pubmed/21944140>
441. O'Connor, R.C., *et al.* Long-term follow-up of single versus double cuff artificial urinary sphincter insertion for the treatment of severe postprostatectomy stress urinary incontinence. *Urology*, 2008. 71: 90.  
<https://www.ncbi.nlm.nih.gov/pubmed/18242372>
442. Smith, P., *et al.* 1348 Hypercontinence and cuff erosion after artificial sphincter insertion: A comparison of cuff sizes and placement techniques. *The Journal of Urology*, 2011. 185: e538.  
<http://www.sciencedirect.com/science/article/pii/S0022534711014170>
443. Lentz, A.C., *et al.* Outcomes following artificial sphincter implantation after prior unsuccessful male sling. *J Urol*, 2012. 187: 2149.  
<https://www.ncbi.nlm.nih.gov/pubmed/22503016>
444. Roupret, M., *et al.* Management of stress urinary incontinence following prostate surgery with minimally invasive adjustable continence balloon implants: functional results from a single center prospective study. *J Urol*, 2011. 186: 198.  
<https://www.ncbi.nlm.nih.gov/pubmed/21575974>
445. Crivellaro, S., *et al.* Adjustable continence therapy (ProACT) and bone anchored male sling: Comparison of two new treatments of post prostatectomy incontinence. *Int J Urol*, 2008. 15: 910.  
<https://www.ncbi.nlm.nih.gov/pubmed/18761534>
446. Gilling, P.J., *et al.* An adjustable continence therapy device for treating incontinence after prostatectomy: a minimum 2-year follow-up. *BJU Int*, 2008. 102: 1426.  
<https://www.ncbi.nlm.nih.gov/pubmed/18564132>



447. Gregori, A., *et al.* Transrectal ultrasound-guided implantation of Adjustable Continence Therapy (ProACT): surgical technique and clinical results after a mean follow-up of 2 years. *Eur Urol*, 2010. 57: 430.  
<https://www.ncbi.nlm.nih.gov/pubmed/19942340>
448. Hubner, W.A., *et al.* Treatment of incontinence after prostatectomy using a new minimally invasive device: adjustable continence therapy. *BJU Int*, 2005. 96: 587.  
<https://www.ncbi.nlm.nih.gov/pubmed/16104915>
449. Martens, F.M., *et al.* ProACT for stress urinary incontinence after radical prostatectomy. *Urol Int*, 2009. 82: 394.  
<https://www.ncbi.nlm.nih.gov/pubmed/19506404>
450. Kjaer, L., *et al.* Adjustable continence balloons: clinical results of a new minimally invasive treatment for male urinary incontinence. *Scand J Urol Nephrol*, 2012. 46: 196.  
<https://www.ncbi.nlm.nih.gov/pubmed/22364390>
451. Duthie, J.B., *et al.* Botulinum toxin injections for adults with overactive bladder syndrome. *Cochrane Database Syst Rev*, 2011: CD005493.  
<https://www.ncbi.nlm.nih.gov/pubmed/22161392>
452. Mangera, A., *et al.* Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA). *Eur Urol*, 2011. 60: 784.  
<https://www.ncbi.nlm.nih.gov/pubmed/21782318>
453. Chapple, C., *et al.* OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. *Eur Urol*, 2013. 64: 249.  
<https://www.ncbi.nlm.nih.gov/pubmed/23608668>
454. Nitti, V.W., *et al.* OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. *J Urol*, 2013. 189: 2186.  
<https://www.ncbi.nlm.nih.gov/pubmed/23246476>
455. White, W.M., *et al.* Short-term efficacy of botulinum toxin a for refractory overactive bladder in the elderly population. *J Urol*, 2008. 180: 2522.  
<https://www.ncbi.nlm.nih.gov/pubmed/18930481>
456. Nitti, V.W., *et al.* Durable Efficacy and Safety of Long-Term OnabotulinumtoxinA Treatment in Patients with Overactive Bladder Syndrome: Final Results of a 3.5-Year Study. *J Urol*, 2016. 196: 791.  
<https://www.ncbi.nlm.nih.gov/pubmed/27038769>
457. Visco, A.G., *et al.* Anticholinergic therapy vs. onabotulinumtoxinA for urgency urinary incontinence. *N Engl J Med*, 2012. 367: 1803.  
<https://www.ncbi.nlm.nih.gov/pubmed/23036134>
458. Herbison, G.P., *et al.* Sacral neuromodulation with implanted devices for urinary storage and voiding dysfunction in adults. *Cochrane Database Syst Rev*, 2009: CD004202.  
<https://www.ncbi.nlm.nih.gov/pubmed/19370596>
459. Schmidt, R.A., *et al.* Sacral nerve stimulation for treatment of refractory urinary urge incontinence. Sacral Nerve Stimulation Study Group. *J Urol*, 1999. 162: 352.  
<https://www.ncbi.nlm.nih.gov/pubmed/10411037>
460. Weil, E.H., *et al.* Sacral root neuromodulation in the treatment of refractory urinary urge incontinence: a prospective randomized clinical trial. *Eur Urol*, 2000. 37: 161.  
<https://www.ncbi.nlm.nih.gov/pubmed/10705194>
461. Brazzelli, M., *et al.* Efficacy and safety of sacral nerve stimulation for urinary urge incontinence: a systematic review. *J Urol*, 2006. 175: 835.  
<https://www.ncbi.nlm.nih.gov/pubmed/16469561>
462. Groen, J., *et al.* Sacral neuromodulation as treatment for refractory idiopathic urge urinary incontinence: 5-year results of a longitudinal study in 60 women. *J Urol*, 2011. 186: 954.  
<https://www.ncbi.nlm.nih.gov/pubmed/21791355>
463. van Kerrebroeck, P.E., *et al.* Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study. *J Urol*, 2007. 178: 2029.  
<https://www.ncbi.nlm.nih.gov/pubmed/17869298>
464. Amundsen, C.L., *et al.* OnabotulinumtoxinA vs Sacral Neuromodulation on Refractory Urgency Urinary Incontinence in Women: A Randomized Clinical Trial. *JAMA*, 2016. 316: 1366.  
<https://www.ncbi.nlm.nih.gov/pubmed/27701661>

465. Siegel, S., *et al.* Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder. *Neurourol Urodyn*, 2015. 34: 224.  
<https://www.ncbi.nlm.nih.gov/pubmed/24415559>
466. Groenendijk, P.M., *et al.* Urodynamic evaluation of sacral neuromodulation for urge urinary incontinence. *BJU Int*, 2008. 101: 325.  
<https://www.ncbi.nlm.nih.gov/pubmed/18070199>
467. Cody, J.D., *et al.* Urinary diversion and bladder reconstruction/replacement using intestinal segments for intractable incontinence or following cystectomy. *Cochrane Database Syst Rev*, 2012: CD003306.  
<https://www.ncbi.nlm.nih.gov/pubmed/22336788>
468. Kockelbergh, R.C., *et al.* Clam enterocystoplasty in general urological practice. *Br J Urol*, 1991. 68: 38.  
<https://www.ncbi.nlm.nih.gov/pubmed/1873689>
469. Cohen, A.J., *et al.* Comparative Outcomes and Perioperative Complications of Robotic Vs Open Cystoplasty and Complex Reconstructions. *Urology*, 2016. 97: 172.  
<https://www.ncbi.nlm.nih.gov/pubmed/27443464>
470. Awad, S.A., *et al.* Long-term results and complications of augmentation ileocystoplasty for idiopathic urge incontinence in women. *Br J Urol*, 1998. 81: 569.  
<https://www.ncbi.nlm.nih.gov/pubmed/9598629>
471. Greenwell, T.J., *et al.* Augmentation cystoplasty. *BJU Int*, 2001. 88: 511.  
<https://www.ncbi.nlm.nih.gov/pubmed/11678743>
472. Covert, W.M., *et al.* The role of mucoregulatory agents after continence-preserving urinary diversion surgery. *Am J Health Syst Pharm*, 2012. 69: 483.  
<https://www.ncbi.nlm.nih.gov/pubmed/22382478>
473. Padmanabhan, P., *et al.* Five-year cost analysis of intra-detrusor injection of botulinum toxin type A and augmentation cystoplasty for refractory neurogenic detrusor overactivity. *World J Urol*, 2011. 29: 51.  
<https://www.ncbi.nlm.nih.gov/pubmed/21110030>
474. Cartwright, P.C., *et al.* Bladder autoaugmentation: partial detrusor excision to augment the bladder without use of bowel. *J Urol*, 1989. 142: 1050.  
<https://www.ncbi.nlm.nih.gov/pubmed/2795729>
475. Leng, W.W., *et al.* Enterocystoplasty or detrusor myectomy? Comparison of indications and outcomes for bladder augmentation. *J Urol*, 1999. 161: 758.  
<https://www.ncbi.nlm.nih.gov/pubmed/10022679>
476. ter Meulen, P.H., *et al.* A study on the feasibility of vesicomatomy in patients with motor urge incontinence. *Eur Urol*, 1997. 32: 166.  
<https://www.ncbi.nlm.nih.gov/pubmed/9286647>
477. Shirvan, M.K., *et al.* Tension-Free Vaginal Tape Plus Intradetrusor BOTOX® Injection Versus Tension-Free Vaginal Tape Versus Intradetrusor BOTOX Injection in Equal-Weight Mixed Urinary Incontinence: A Prospective Randomized Study *J Gynecol Surg*, 2013. 29: 235.  
<http://online.liebertpub.com/doi/abs/10.1089/gyn.2012.0134?journalCode=gyn>
478. Kuo, H.C. Effect of detrusor function on the therapeutic outcome of a suburethral sling procedure using a polypropylene sling for stress urinary incontinence in women. *Scand J Urol Nephrol*, 2007. 41: 138.  
<https://www.ncbi.nlm.nih.gov/pubmed/17454953>
479. Colombo, M., *et al.* The Burch colposuspension for women with and without detrusor overactivity. *Br J Obstet Gynaecol*, 1996. 103: 255.  
<https://www.ncbi.nlm.nih.gov/pubmed/8630311>
480. Kulseng-Hanssen, S., *et al.* The tension free vaginal tape operation for women with mixed incontinence: Do preoperative variables predict the outcome? *Neurourol Urodyn*, 2007. 26: 115.  
<https://www.ncbi.nlm.nih.gov/pubmed/16894616>
481. Kulseng-Hanssen, S., *et al.* Follow-up of TVT operations in 1,113 women with mixed urinary incontinence at 7 and 38 months. *Int Urogynecol J Pelvic Floor Dysfunct*, 2008. 19: 391.  
<https://www.ncbi.nlm.nih.gov/pubmed/17891326>
482. Han, J.Y., *et al.* Effectiveness of retropubic tension-free vaginal tape and transobturator inside-out tape procedures in women with overactive bladder and stress urinary incontinence. *Int Neurourol J*, 2013. 17: 145.  
<https://www.ncbi.nlm.nih.gov/pubmed/24143294>



483. Liao, C.H., *et al.* Increased risk of large post-void residual urine and decreased long-term success rate after intravesical onabotulinumtoxinA injection for refractory idiopathic detrusor overactivity. *J Urol*, 2013. 189: 1804.  
<https://www.ncbi.nlm.nih.gov/pubmed/23178902>
484. De Ridder, D., *et al.*, Fistula (Committee 18), in: 5th International Consultation on Incontinence, Paris, February 2012, 2013: Paris, France.
485. De Ridder, D., *et al.*, Fistula - Surgical management of obstetric fistula, in: 5th International Consultation on Incontinence, Paris, February 2012, 2013: Paris, France
486. Ostrzenski, A., *et al.* Bladder injury during laparoscopic surgery. *Obstet Gynecol Surv*, 1998. 53: 175.  
<https://www.ncbi.nlm.nih.gov/pubmed/9513988>
487. Hadzi-Djokic, J., *et al.* Vesico-vaginal fistula: report of 220 cases. *Int Urol Nephrol*, 2009. 41: 299.  
<https://www.ncbi.nlm.nih.gov/pubmed/18810652>
488. Narayanan, P., *et al.* Fistulas in malignant gynecologic disease: etiology, imaging, and management. *Radiographics*, 2009. 29: 1073.  
<https://www.ncbi.nlm.nih.gov/pubmed/19605657>
489. Lumen, N., *et al.* Review of the current management of lower urinary tract injuries by the EAU Trauma Guidelines Panel. *Eur Urol*, 2015. 67: 925.  
<https://www.ncbi.nlm.nih.gov/pubmed/25576009>
490. Latzko, W. Postoperative vesicovaginal fistulas. *The American Journal of Surgery*, 1942. 58: 211.  
<http://www.sciencedirect.com/science/article/pii/S0002961042900096>
491. Wall, L.L. Dr. George Hayward (1791-1863): a forgotten pioneer of reconstructive pelvic surgery. *Int Urogynecol J Pelvic Floor Dysfunct*, 2005. 16: 330.  
<https://www.ncbi.nlm.nih.gov/pubmed/15976986>
492. Hilton, P., *et al.* Epidemiological and surgical aspects of urogenital fistulae: a review of 25 years' experience in southeast Nigeria. *Int Urogynecol J Pelvic Floor Dysfunct*, 1998. 9: 189.  
<https://www.ncbi.nlm.nih.gov/pubmed/9795822>
493. Shaker, H., *et al.* Obstetric vesico-vaginal fistula repair: should we trim the fistula edges? A randomized prospective study. *Neurourol Urodyn*, 2011. 30: 302.  
<https://www.ncbi.nlm.nih.gov/pubmed/21308748>
494. Jovanovic, M., *et al.* Efficiency of urinary fistulas surgical treatment. *Eur Urol Suppl*, 2010. 9: S54.  
[http://www.europeanurology.com/article/S1569-9056\(10\)61340-1/abstract/](http://www.europeanurology.com/article/S1569-9056(10)61340-1/abstract/)
495. Krause, S., *et al.* Surgery for urologic complications following radiotherapy for gynecologic cancer. *Scand J Urol Nephrol*, 1987. 21: 115.  
<https://www.ncbi.nlm.nih.gov/pubmed/3616502>
496. Langkilde, N.C., *et al.* Surgical repair of vesicovaginal fistulae--a ten-year retrospective study. *Scand J Urol Nephrol*, 1999. 33: 100.  
<https://www.ncbi.nlm.nih.gov/pubmed/10360449>
497. Brandes, S., *et al.* Diagnosis and management of ureteric injury: an evidence-based analysis. *BJU Int*, 2004. 94: 277.  
<https://www.ncbi.nlm.nih.gov/pubmed/15291852>
498. Morton, H.C., *et al.* Urethral injury associated with minimally invasive mid-urethral sling procedures for the treatment of stress urinary incontinence: a case series and systematic literature search. *BJOG*, 2009. 116: 1120.  
<https://www.ncbi.nlm.nih.gov/pubmed/19438488>
499. Shaw, M.B., *et al.* The management of bilateral ureteric injury following radical hysterectomy. *Adv Urol*, 2008: 524919.  
<https://www.ncbi.nlm.nih.gov/pubmed/18604294>
500. Narang, V., *et al.* Uteroscopy: savior to the gynecologist? Uteroscopic management of post laparoscopic-assisted vaginal hysterectomy ureterovaginal fistulas. *J Minim Invasive Gynecol*, 2007. 14: 345.  
<https://www.ncbi.nlm.nih.gov/pubmed/17478367>
501. Abou-El-Ghar, M.E., *et al.* Radiological diagnosis of vesicouterine fistula: role of magnetic resonance imaging. *J Magn Reson Imaging*, 2012. 36: 438.  
<https://www.ncbi.nlm.nih.gov/pubmed/22535687>
502. Quiroz, L.H., *et al.* Three-dimensional ultrasound imaging for diagnosis of urethrovaginal fistula. *Int Urogynecol J*, 2010. 21: 1031.  
<https://www.ncbi.nlm.nih.gov/pubmed/20069418>
503. Pushkar, D.Y., *et al.* Management of urethrovaginal fistulas. *Eur Urol*, 2006. 50: 1000.  
<https://www.ncbi.nlm.nih.gov/pubmed/16945476>

504. Pushkar, D. Editorial comment on: Transpubic access using pedicle tubularized labial urethroplasty for the treatment of female urethral strictures associated with urethrovaginal fistulas secondary to pelvic fracture. *Eur Urol*, 2009. 56: 200.  
<https://www.ncbi.nlm.nih.gov/pubmed/18468776>
505. Xu, Y.M., *et al.* Transpubic access using pedicle tubularized labial urethroplasty for the treatment of female urethral strictures associated with urethrovaginal fistulas secondary to pelvic fracture. *Eur Urol*, 2009. 56: 193.  
<https://www.ncbi.nlm.nih.gov/pubmed/18468778>
506. Huang, C.R., *et al.* The management of old urethral injury in young girls: analysis of 44 cases. *J Pediatr Surg*, 2003. 38: 1329.  
<https://www.ncbi.nlm.nih.gov/pubmed/14523814>
507. Candiani, P., *et al.* Repair of a recurrent urethrovaginal fistula with an island bulbocavernous musculocutaneous flap. *Plast Reconstr Surg*, 1993. 92: 1393.  
<https://www.ncbi.nlm.nih.gov/pubmed/8248420>
508. McKinney, D.E. Use of full thickness patch graft in urethrovaginal fistula. *J Urol*, 1979. 122: 416.  
<https://www.ncbi.nlm.nih.gov/pubmed/381691>
509. Browning, A. Lack of value of the Martius fibrofatty graft in obstetric fistula repair. *Int J Gynaecol Obstet*, 2006. 93: 33.  
<https://www.ncbi.nlm.nih.gov/pubmed/16530766>
510. Baskin, D., *et al.* Martius repair in urethrovaginal defects. *J Pediatr Surg*, 2005. 40: 1489.  
<https://www.ncbi.nlm.nih.gov/pubmed/16150356>
511. Atan, A., *et al.* Treatment of refractory urethrovaginal fistula using rectus abdominis muscle flap in a six-year-old girl. *Urology*, 2007. 69: 384 e11.  
<https://www.ncbi.nlm.nih.gov/pubmed/17320687>
512. Bruce, R.G., *et al.* Use of rectus abdominis muscle flap for the treatment of complex and refractory urethrovaginal fistulas. *J Urol*, 2000. 163: 1212.  
<https://www.ncbi.nlm.nih.gov/pubmed/10737499>
513. Koraitim, M. A new retropubic retrourethral approach for large vesico-urethrovaginal fistulas. *J Urol*, 1985. 134: 1122.  
<https://www.ncbi.nlm.nih.gov/pubmed/4057401>

## 6. CONFLICT OF INTEREST

All members of the Urinary Incontinence Guidelines Panel have provided disclosure statements on all relationships that they have and that might be perceived to be a potential source of conflict of interest. This information is publically accessible through the European Association of Urology website: <http://uroweb.org/guideline/urinary-incontinence/>.

This guidelines document was developed with the financial support of the European Association of Urology. No external sources of funding and support have been involved. The EAU is a non-profit organisation and funding is limited to administrative assistance and travel and meeting expenses. No honoraria or other reimbursements have been provided.

## 7. CITATION INFORMATION

The format in which to cite the EAU Guidelines will vary depending on the style guide of the journal in which the citation appears. Accordingly, the number of authors or whether, for instance, to include the publisher, location, or an ISBN number may vary.

The compilation of the complete Guidelines should be referenced as:

*EAU Guidelines. Edn. presented at the EAU Annual Congress Copenhagen 2018. ISBN 978-94-92671-01-1.*

If a publisher and/or location is required, include:

*EAU Guidelines Office, Arnhem, The Netherlands. <http://uroweb.org/guidelines/compilations-of-all-guidelines/>*

References to individual guidelines should be structured in the following way:

*Contributors' names. Title of resource. Publication type. ISBN. Publisher and publisher location, year.*